Certain chemical entities, compositions, and methods

ABSTRACT

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

CROSS REFERENCE

This application is a continuation application of U.S. patentapplication Ser. No. 15/044,966, filed on Feb. 16, 2016, which claimsthe benefit of U.S. Provisional Application No. 62/117,442, filed Feb.17, 2015 and U.S. Provisional Application No. 62/117,773, filed Feb. 18,2015, each of which applications are incorporated herein in theirentirety by reference.

BACKGROUND OF THE INVENTION

There are at least 400 enzymes identified as protein kinases. Theseenzymes catalyze the phosphorylation of target protein substrates. Thephosphorylation is usually a transfer reaction of a phosphate group fromATP to the protein substrate. The specific structure in the targetsubstrate to which the phosphate is transferred is a tyrosine, serine orthreonine residue. Since these amino acid residues are the targetstructures for the phosphoryl transfer, these protein kinase enzymes arecommonly referred to as tyrosine kinases or serine/threonine kinases.

The phosphorylation reactions, and counteracting phosphatase reactions,at the tyrosine, serine and threonine residues are involved in countlesscellular processes that underlie responses to diverse intracellularsignals (typically mediated through cellular receptors), regulation ofcellular functions, and activation or deactivation of cellularprocesses. A cascade of protein kinases often participate inintracellular signal transduction and are necessary for the realizationof these cellular processes. Because of their ubiquity in theseprocesses, the protein kinases can be found as an integral part of theplasma membrane or as cytoplasmic enzymes or localized in the nucleus,often as components of enzyme complexes. In many instances, theseprotein kinases are an essential element of enzyme and structuralprotein complexes that determine where and when a cellular processoccurs within a cell.

The identification of effective small compounds which specificallyinhibit signal transduction and cellular proliferation by modulating theactivity of tyrosine and serine/threonine kinases to regulate andmodulate abnormal or inappropriate cell proliferation, differentiation,or metabolism is therefore desirable. In particular, the identificationof compounds that specifically inhibit the function of a kinase which isessential for processes leading to cancer would be beneficial.

SUMMARY OF THE INVENTION

In one aspect, the present disclosure provides a compound of Formula I

or a pharmaceutically acceptable salt thereof, wherein

is aryl or heteroaryl;

is selected from a group consisting of:

wherein

a is point of attachment for Land

b is point of attachment for G;

X₃ is C—R₃, or N; X₄ is C—R₄, or N; X₅ is C—R₅, or N; X₆ is C—R₁₉, or N;X₇ is C—R₂₀, or N; X₈ is C—R₂₁, or N; Y is O, S, or N—R₂₂;

L is —[(CR₃₀R₃₁)_(x)—O—(CR₃₂R₃₃)_(y)]_(z)—, —[(CR₃₀R₃₁)_(x)]_(z)—,—[(CR₃₀R₃₁)_(x)—S—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—NR₂₉—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CO—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—SO₂—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CO₂—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CONR₂₉—(CR₃₀R₃₁)_(y)]_(z)—, or—[(CR₃₀R₃₁)_(x)—SO₂NR₂₉—(CR₃₀R₃₁)_(y)]_(z)—;

each of R₃, R₄, R₅, R₆, R₁₅, R₁₆, R₁₉, R₂₀, R₂₁, R₃₀, R₃₁, R₃₂, R₃₃, andG is independently hydrogen, cyano, halo, hydroxy, azido, nitro,carboxy, oxo, sulfinyl, sulfanyl, sulfonyl, optionally substitutedalkoxy, optionally substituted cycloalkyloxy, optionally substitutedaryloxy, optionally substituted heteroaryloxy, optionally substitutedheterocycloalkyloxy, optionally substituted alkyl, optionallysubstituted cycloalkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted aryl, optionally substitutedheteroaryl, optionally substituted heterocycloalkyl, optionallysubstituted amino, optionally substituted acyl, optionally substitutedalkoxycarbonyl, optionally substituted aminocarbonyl, optionallysubstituted aminosulfonyl, or optionally substituted carbamimidoyl;

R₁₇, R₁₈, R₂₂, and R₂₉ are independently is independently hydrogen,sulfonyl, optionally substituted alkyl, optionally substitutedcycloalkyl, optionally substituted alkenyl, optionally substitutedalkynyl, optionally substituted aryl, optionally substituted heteroaryl,optionally substituted heterocycloalkyl, optionally substituted acyl,optionally substituted alkoxycarbonyl, optionally substitutedaminocarbonyl, optionally substituted aminosulfonyl, or optionallysubstituted carbamimidoyl;

or R₃ and R₄, R₄ and R₅, R₁₅ and R₁₆, R₁₅ and R₁₇, R₂₀ and R₂₁, R₂₀ andR₂₂, or R₂₁ and R₂₂ may optionally be joined together with anyintervening atoms to form an optionally substituted aryl, heteroaryl,cycloalkyl, or heterocycloalkyl ring;

each Z is independently hydrogen, cyano, halo, hydroxy, azido, nitro,carboxy, oxo, sulfinyl, sulfanyl, sulfonyl, optionally substitutedalkoxy, optionally substituted cycloalkyloxy, optionally substitutedaryloxy, optionally substituted heteroaryloxy, optionally substitutedheterocycloalkyloxy, optionally substituted alkyl, optionallysubstituted cycloalkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted aryl, optionally substitutedheteroaryl, optionally substituted heterocycloalkyl, optionallysubstituted amino, optionally substituted acyl, optionally substitutedalkoxycarbonyl, optionally substituted aminocarbonyl, optionallysubstituted aminosulfonyl, optionally substituted carbamimidoyl, or E;wherein each E is independently an electrophilic group capable offorming a covalent bond with a nucleophile;

n is 0, 1, 2, 3, 4 or 5; and x, y, or z, is independently 0, 1, 2, 3, or4;

provided that when

G is

wherein

is aryl, heteroaryl, or heterocycloalkyl; m is 0, 1, 2, 3, 4, or 5 andeach Q is independently hydrogen, cyano, halo, hydroxy, azido, nitro,carboxy, oxo, sulfinyl, sulfanyl, sulfonyl, optionally substitutedalkoxy, optionally substituted cycloalkyloxy, optionally substitutedaryloxy, optionally substituted heteroaryloxy, optionally substitutedheterocycloalkyloxy, optionally substituted alkyl, optionallysubstituted cycloalkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted aryl, optionally substitutedheteroaryl, optionally substituted heterocycloalkyl, optionallysubstituted amino, optionally substituted acyl, optionally substitutedalkoxycarbonyl, optionally substituted aminocarbonyl, optionallysubstituted aminosulfonyl, optionally substituted carbamimidoyl, or E;and L is —NH—; then n is 12, 3, 4, or 5, and at least one Z is E.

In some embodiments, G is cyano, halo, optionally substituted alkoxy,optionally substituted cycloalkyloxy, optionally substituted aryloxy,optionally substituted heteroaryloxy, optionally substitutedheterocycloalkyloxy, optionally substituted alkyl, optionallysubstituted cycloalkyl, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted heterocycloalkyl,optionally substituted amino, optionally substituted acyl, optionallysubstituted alkoxycarbonyl, optionally substituted aminocarbonyl,optionally substituted aminosulfonyl. In some embodiments, G is halo oroptionally substituted alkoxy. In some embodiments, G is optionallysubstituted aryl, optionally substituted heteroaryl, or optionallysubstituted heterocycloalkyl.

In some embodiments,

is selected from the group consisting of: pyrrolyl, furanyl, thienyl,imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,1,2,3-triazolyl, 1,2,4-triazolyl, furazanyl, 1,2,3-oxadiazolyl,1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, thiadiazolyl,dithiazolyl, tetrazolyl, pyridinyl, pyranyl, thiopyranyl, diazinyl,pyrazinyl, pyrimidinyl, pyridazinyl, oxazinyl, thiazinyl, dioxinyl,dithiinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl,tetrazinyl, and phenyl; For example

is selected from the group consisting of: phenyl, pyridinyl,pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl, pyrazolyl,isoxazolyl, and thienyl. In some embodiments,

is phenyl or pyridinyl.

In some embodiments, L is NH.

In some embodiments, Z is hydrogen, cyano, halo, optionally substitutedamino, optionally substituted alkoxy, optionally substitutedcycloalkyloxy, optionally substituted aryloxy, optionally substitutedheteroaryloxy, optionally substituted heterocycloalkyloxy, optionallysubstituted alkyl, optionally substituted cycloalkyl, optionallysubstituted aryloxy, optionally substituted heterocycloalkyl, optionallysubstituted aminocarbonyl, or E.

In some embodiments, Z is hydrogen, cyano, halo, optionally substitutedalkoxy, optionally substituted heterocycloalkyloxy, optionallysubstituted heterocycloalkyl, or optionally substituted amino,optionally substituted aminocarbonyl, or E.

In some embodiments, n is 1, 2, 3, 4, or 5; and at least one Z is cyano,fluoro, chloro, methoxy, —CONH₂, 2-methoxyethoxy,2-(dimethylamino)ethoxy, (1-methylpyrrolidin-3-yl)oxy,(1-methylpiperidin-4-yl)oxy, (1-methylpiperidin-3-yl)oxy,(1-methylazetidin-3-yl)oxy (2-(dimethylamino)ethyl)(methyl)amino,dimethylamino, methyl(1-methylazetidin-3-yl)amino,methyl(1-methylpyrrolidin-3-yl)amino,methyl(1-methylpiperidin-4-yl)amino, optionally substituted morpholinyl,optionally substituted piperazinyl, optionally substituted pyrrolidinyl,optionally substituted piperidinyl, optionally substituted azetidinyl.

In some embodiments, n is 1, 2, 3, 4, or 5; and at least one Z is E.

In some embodiments, each E is independently an electrophilic groupcapable of forming a covalent bond with a cysteine residue of a protein.

In some embodiments, each E is independently selected from a groupconsisting of

In some embodiments, at least one E is

In some embodiments, at least one E is

In some embodiments, at least one E is

In another aspect, the present disclosure provides the compound orpharmaceutically acceptable salt of Formula I wherein

X₁₀ is C—R₃₅, or N; and R₃₄, R₃₅, R₃₆, R₃₇, and R₃₈ are independentlyhydrogen, cyano, halo, hydroxy, azido, nitro, carboxy, sulfinyl,sulfanyl, sulfonyl, optionally substituted alkoxy, optionallysubstituted cycloalkyloxy, optionally substituted aryloxy, optionallysubstituted heteroaryloxy, optionally substituted heterocycloalkyloxy,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted aryl, optionally substituted heteroaryl,optionally substituted heterocycloalkyl, optionally substituted amino,optionally substituted acyl, optionally substituted alkoxycarbonyl,optionally substituted aminocarbonyl, optionally substitutedaminosulfonyl, optionally substituted carbamimidoyl, or E.

In some embodiments, the compound or pharmaceutically acceptable salthas the Formula Ia:

wherein

Z, L, and n are as defined for Formula I;

is optionally substituted aryl, optionally substituted heteroaryl, oroptionally substituted heterocycloalkyl;

each Q is independently hydrogen, cyano, halo, hydroxy, azido, nitro,carboxy, oxo, sulfinyl, sulfanyl, sulfonyl, optionally substitutedalkoxy, optionally substituted cycloalkyloxy, optionally substitutedaryloxy, optionally substituted heteroaryloxy, optionally substitutedheterocycloalkyloxy, optionally substituted alkyl, optionallysubstituted cycloalkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted aryl, optionally substitutedheteroaryl, optionally substituted heterocycloalkyl, optionallysubstituted amino, optionally substituted acyl, optionally substitutedalkoxycarbonyl, optionally substituted aminocarbonyl, optionallysubstituted aminosulfonyl, optionally substituted carbamimidoyl, or E;wherein each E is independently an electrophilic group capable offorming a covalent bond with a nucleophile; and m is 0, 1, 2, 3, 4, or5.

In some embodiments,

is selected from the group consisting of: piperazinyl, morpholinyl,piperidinyl, thiomorpholinyl, pyrrolidinyl, tetrahydrofuranyl,diazepanyl, azetidinyl, oxetanyl, oxiranyl, aziridinyl, pyrrolyl,furanyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl,thiazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, furazanyl,1,2,3-oxadiazolyl, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole,thiadiazolyl, dithiazolyl, tetrazolyl, pyridinyl, pyranyl, thiopyranyl,diazinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazinyl, thiazinyl,dioxinyl, dithiinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl,tetrazinyl, and phenyl. For example,

is selected from the group consisting of: phenyl, pyridinyl,pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl, pyrazolyl,isoxazolyl, and thienyl. In other embodiments,

is phenyl or pyridinyl. In some embodiments,

is selected from the group consisting of: piperazinyl, morpholinyl,piperidinyl, thiomorpholinyl, pyrrolidinyl, tetrahydrofuranyl,diazepanyl, azetidinyl, oxetanyl, oxiranyl, and aziridinyl. In someembodiments,

is selected from the group consisting of: piperazinyl, morpholinyl,piperidinyl, pyrrolidinyl, tetrahydrofuranyl, and diazepanyl. In someembodiments,

is selected from the group consisting of: piperazinyl, morpholinyl,piperidinyl, and pyrrolidinyl.

In some embodiments,

-   -   X₁₁ is C—R₂₇, or N; and    -   R₂₃, R₂₄, R₂₅, R₂₆, and R₂₇ are independently, hydrogen, cyano,        halo, hydroxy, azido, nitro, carboxy, oxo, sulfinyl, sulfanyl,        sulfonyl, optionally substituted alkoxy, optionally substituted        cycloalkyloxy, optionally substituted aryloxy, optionally        substituted heteroaryloxy, optionally substituted        heterocycloalkyloxy, optionally substituted alkyl, optionally        substituted cycloalkyl, optionally substituted alkenyl,        optionally substituted alkynyl, optionally substituted aryl,        optionally substituted heteroaryl, optionally substituted        heterocycloalkyl, optionally substituted amino, optionally        substituted acyl, optionally substituted alkoxycarbonyl,        optionally substituted aminocarbonyl, optionally substituted        aminosulfonyl, or optionally substituted carbamimidoyl or E;

In some embodiments, the compound or pharmaceutically acceptable salthas the Formula Ib:

-   -   wherein

-   -   Z, L, R₆, X₆, X₅, X₄, X₃, G and n are as defined for Formula I.

In some embodiments, X₃, X₄ and X₅ are respectively C—R₃, C—R₄, andC—R₅. In some embodiments, X₅, X₄ and X₃ are respectively N, C—R₄, andC—R₃. In some embodiments, X₅, X₄ and X₃ are respectively C—R₅, N, andC—R₃. In some embodiments, X₅, X₄ and X₃ are respectively C—R₅, C—R₄,and N. In some embodiments, X₅, X₄ and X₃ are respectively N, C—R4, andN.

In some embodiments, n is 1, 2, 3, 4, or 5; and at least one Z is E.

In some embodiments, the compound or pharmaceutically acceptable salthas the Formula Ic:

wherein

E, R₃₄, R₃₆, R₃₇, R₃₈, R₃, R₄, R₅, R₆ and G are as described above forFormula I.

In some embodiments, R₃, R₄, and R₅ are independently hydrogen, cyano,halo, optionally substituted alkoxy, optionally substitutedheterocycloalkyloxy, optionally substituted heterocycloalkyl, optionallysubstituted amino, or optionally substituted aminocarbonyl. In someembodiments, R₃, R₄, and R₅ are independently hydrogen, cyano, fluoro,chloro, methyl, hydroxymethyl, —CH₂F, —CONH₂, or methoxy.

In some embodiments, G is halo or optionally substituted alkoxy,optionally substituted aryl, optionally substituted heteroaryl, oroptionally substituted heterocycloalkyl. In some embodiments, G isoptionally substituted aryl. In some embodiments, G is optionallysubstituted phenyl or pyridinyl.

In some embodiments, R₃₄, R₃₇, and R₃₈ are independently hydrogen,cyano, halo, optionally substituted alkoxy, optionally substitutedheterocycloalkyloxy, optionally substituted heterocycloalkyl, optionallysubstituted amino, or optionally substituted aminocarbonyl. In someembodiments, R₃₄, R₃₇, and R₃₈ are independently hydrogen, cyano,fluoro, chloro, methoxy, or —CONH₂.

In some embodiments, R₃₆ is optionally substituted alkoxy, optionallysubstituted heterocycloalkyloxy, optionally substitutedheterocycloalkyl, or optionally substituted amino. In some embodiments,R₃₆ is methoxy, 2-methoxyethoxy, 2-(dimethylamino)ethoxy,(1-methylpyrrolidin-3-yl)oxy, (1-methylpiperidin-4-yl)oxy,(1-methylpiperidin-3-yl)oxy, (1-methylazetidin-3-yl)oxy(2-(dimethylamino)ethyl)(methyl)amino, dimethylamino,methyl(1-methylazetidin-3-yl)amino,methyl(1-methylpyrrolidin-3-yl)amino,methyl(1-methylpiperidin-4-yl)amino, optionally substituted morpholinyl,optionally substituted piperazinyl, optionally substituted pyrrolidinyl,optionally substituted piperidinyl, or optionally substitutedazetidinyl.

In some embodiments, E is

In some embodiments, wherein E is

In some embodiments, at least one E is

In some embodiments, the compound or pharmaceutically acceptable salthas the Formula Id:

wherein

X₁₀, X₁₁, R₂₃, R₂₅, R₂₆, R₃₄, R₃₆, R₃₇, R₃₈ and E are as defined abovefor Formula I.

In some embodiments, X₁₀ is C—R₂₅, or N. In some embodiments, X₁₁ isC—R₂₇, or N.

In some embodiments, X₁₀ is C—R₂₅, or N. In some embodiments, X₁₁ isC—R₂₇, or N.

In some embodiments, R₃₄, R₃₇, and R₃₈ are independently hydrogen,cyano, fluoro, chloro, methoxy, or —CONH₂, and R₃₆ is optionallysubstituted morpholinyl, optionally substituted piperazinyl, optionallysubstituted pyrrolidinyl, optionally substituted piperidinyl, optionallysubstituted azetidinyl, or substituted amino.

In some embodiments, R₃₆ is

wherein R₂₈ is hydrogen, sulfonyl, optionally substituted alkyl,optionally substituted cycloalkyl, optionally substituted alkenyl,optionally substituted alkynyl, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted heterocycloalkyl,optionally substituted amino, optionally substituted acyl, optionallysubstituted alkoxycarbonyl, optionally substituted aminocarbonyl,optionally substituted aminosulfonyl, or optionally substitutedcarbamimidoyl. In some embodiments, R₂₈ is —C(O)C₁-C₄ alkyl or C₁-C₆alkyl optionally substituted with —OH, halo, C₁-C₄ alkyl, or —OC₁-C₄alkyl. In some embodiments, R₂₈ is —CH₃, —COCH₃, —CH₂CH₂OH, —CH₂CH₂F,—CH₂CH₂OMe, —CH₂C(CH₃)₂OH, or —CH₂CH(CH₃)OH.

In some embodiments, E is selected from a group consisting of

In some embodiments, E is

In some embodiments, E is

In some embodiments, E is

In another aspect, the present disclosure provides a pharmaceuticalcomposition comprising a pharmaceutically acceptable carrier and acompound or pharmaceutically acceptable salt of any one of compoundsdescribed herein. The pharmaceutical composition may be formulated in aform which is a tablet, capsule, powder, liquid, suspension,suppository, or aerosol. The pharmaceutical composition may be packagedwith instructions for using the composition to treat a subject sufferingfrom cancer.

In another aspect, the present disclosure provides a method of treatingcancer in a subject which comprises administering to a subject in needthereof a therapeutically effective amount of a compound orpharmaceutically acceptable salt of any one of the compounds describedherein. The cancer may be colon carcinoma, pancreatic cancer, breastcancer, ovarian cancer, prostate cancer, thyroid cancer, fibrosarcoma,myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chondroma,angiosarcoma, endotheliosarcoma, lymphangiosarcoma,lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor,leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cellcarcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous glandcarcinoma, papillary carcinoma, papillary adenocarcinomas,cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renalcell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma,seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testiculartumor, lung carcinoma, small cell lung carcinoma, non-small cell lungcancer, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma,medulloblastoma, craniopharyngioma, ependymoma, pinealoma,hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma,melanoma, neuroblastoma, retinoblastoma, leukemia, acute lymphocyticleukemia and acute myelocytic leukemia (myeloblastic, promyelocytic,myelomonocytic, monocytic and erythroleukemia); chronic leukemia(chronic myelocytic (granulocytic) leukemia and chronic lymphocyticleukemia); and polycythemia vera, lymphoma (Hodgkin's disease andnon-Hodgkin's disease), multiple myeloma, Waldenstrom'smacroglobulinemia, or heavy chain disease. In a further embodiment, thecancer is melanoma, non-small cell lung cancer, thyroid cancer, ovariancancer, or colon cancer. The melanoma may be unresectable or metastaticmelanoma.

In another aspect, the present disclosure provides a method of treatinga disorder mediated by EGFR kinase or EGFR mutants in a subject in needthereof, comprising administering to the subject a therapeuticallyeffective amount of a compound or pharmaceutically acceptable salt ofany one of the compounds described herein.

In another aspect, the present disclosure provides a method of treatinga disorder in a subject in need thereof, comprising: a) determining thepresence or absence of a EGFR mutation in a biological sample isolatedfrom the subject; and b) if a EGFR mutation is determined to be presentin the subject, administering to the subject a therapeutically effectiveamount of a compound or pharmaceutically acceptable salt of any one ofthe compounds described herein.

Somatic activating mutations of the EGFR gene, increased gene copynumber and certain clinical and pathological features have been found incertain types of cancer. The specific types of activating mutations maybe Exon 19 deletion (del E746-A750) mutations, the single-pointsubstitution mutation L858R in exon 21 and the point mutation T790M. Aspecific type of activating mutation may also be the double mutations ofL858R and T790M. In some embodiments, determining the presence orabsence of the EGFR mutation comprises amplifying EGFR nucleic acid froma biological sample and sequencing the amplified nucleic acid. In someother embodiments, determining the presence or absence of the EGFRmutation comprises detecting a mutant EGFR polypeptide in a biologicalsample using a binding agent to a mutant EGFR polypeptide. The bindingagent may be an antibody. The biological sample may be isolated from atumor of the subject. In some embodiments, determining the presence orabsence of the both L858R and T790M EGFR mutations comprises amplifyingEGFR nucleic acid from the biological sample and sequencing theamplified nucleic acid, or detecting a double mutant EGFR polypeptidefrom the biological sample.

In some embodiments, the disorder is cancer. The cancer may be coloncarcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostatecancer, thyroid cancer, fibrosarcoma, myxosarcoma, liposarcoma,chondrosarcoma, osteogenic sarcoma, chondroma, angiosarcoma,endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma,synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma,rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma,adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma,papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma,medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma,hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonalcarcinoma, Wilms' tumor, cervical cancer, testicular tumor, lungcarcinoma, small cell lung carcinoma, non-small cell lung cancer,bladder carcinoma, epithelial carcinoma, glioma, astrocytoma,medulloblastoma, craniopharyngioma, ependymoma, pinealoma,hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma,melanoma, neuroblastoma, retinoblastoma, leukemia, acute lymphocyticleukemia and acute myelocytic leukemia (myeloblastic, promyelocytic,myelomonocytic, monocytic and erythroleukemia); chronic leukemia(chronic myelocytic (granulocytic) leukemia and chronic lymphocyticleukemia); and polycythemia vera, lymphoma (Hodgkin's disease andnon-Hodgkin's disease), multiple myeloma, Waldenstrom'smacroglobulinemia, or heavy chain disease. In a further embodiment, thecancer is melanoma, non-small cell lung cancer, thyroid cancer, ovariancancer, or colon cancer. The melanoma may be unresectable or metastaticmelanoma.

The treatment method described herein may further comprise administeringan additional anti-cancer and/or cytotoxic agent.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in thisspecification are herein incorporated by reference in their entiretiesto the same extent as if each individual publication, patent, or patentapplication was specifically and individually indicated to beincorporated by reference.

DETAILED DESCRIPTION OF THE INVENTION

As used herein, the following words and phrases are generally intendedto have the meanings as set forth below, except to the extent that thecontext in which they are used indicates otherwise.

The following abbreviations and terms have the indicated meaningsthroughout:

-   AcOH=acetic acid-   Boc=tert-butoxycarbonyl-   c-=cyclo-   DCC=dicyclohexylcarbodiimide-   DIEA=N,N-diisopropylethylamine-   DMAP=4-dimethylaminopyridine-   EDC=1-ethyl-3-(3-dimethylaminopropyl)carbodiimide-   eq=equivalent(s)-   Et=ethyl-   EtOAc or EA=ethyl acetate-   EtOH=ethanol-   g=gram-   horhr=hour-   HBTU=O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium    hexafluorophosphate-   HOBt=hydroxybenzotriazole-   HPLC=high pressure liquid chromatography-   i-=iso-   kg or Kg=kilogram-   L or l=liter-   LC/MS=LCMS=liquid chromatography-mass spectrometry-   LRMS=low resolution mass spectrometry-   m/z=mass-to-charge ratio-   Me=methyl-   MeOH=methanol-   mg=milligram-   min=minute-   mL=milliliter-   mmol=millimole-   n-=normal-   NaOAc=sodium acetate-   PE=petroleum ether-   Ph=phenyl-   Prep=preparative-   quant.=quantitative-   RP-HPLC=reverse phase-high pressure liquid chromatography-   rt, r.t., or RT=room temperature-   s-=sec-=secondary-   t-=tert-=tertiary-   THF=tetrahydrofuran-   TLC=thin layer chromatography-   UV=ultraviolet

As used herein, when any variable occurs more than one time in achemical formula, its definition on each occurrence is independent ofits definition at every other occurrence.

As used herein, a dash (“-”) that is not between two letters or symbolsis used to indicate a point of attachment for a substituent. Forexample, —CONH₂ is attached through the carbon atom.

As used herein, “optional” or “optionally” is meant that thesubsequently described event or circumstance may or may not occur, andthat the description includes instances wherein the event orcircumstance occurs and instances in which it does not. For example,“optionally substituted alkyl” encompasses both “alkyl” and “substitutedalkyl” as defined below. It will be understood by those skilled in theart, with respect to any group containing one or more substituents, thatsuch groups are not intended to introduce any substitution orsubstitution patterns that are sterically impractical, syntheticallynon-feasible and/or inherently unstable.

As used herein, “alkyl” refers to straight chain and branched chainhaving the indicated number of carbon atoms, usually from 1 to 20 carbonatoms, for example 1 to 8 carbon atoms, such as 1 to 6 carbon atoms. Forexample C₁-C₆ alkyl encompasses both straight and branched chain alkylof from 1 to 6 carbon atoms. When an alkyl residue having a specificnumber of carbons is named, all branched and straight chain versionshaving that number of carbons are intended to be encompassed; thus, forexample, “butyl” is meant to include n-butyl, sec-butyl, isobutyl andt-butyl; “propyl” includes n-propyl and isopropyl. “Lower alkyl” refersto alkyl groups having one to six carbons. Examples of alkyl groupsinclude methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl,tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl,3-hexyl, 3-methylpentyl, and the like. Alkylene is a subset of alkyl,referring to the same residues as alkyl, but having two points ofattachment. Alkylene groups will usually have from 2 to 20 carbon atoms,for example 2 to 8 carbon atoms, such as from 2 to 6 carbon atoms. Forexample, C₀ alkylene indicates a covalent bond and C₁ alkylene is amethylene group.

As used herein, “alkenyl” refers to an unsaturated branched orstraight-chain alkyl group having at least one carbon-carbon double bondderived by the removal of one molecule of hydrogen from adjacent carbonatoms of the parent alkyl. The group may be in either the cis or transconfiguration about the double bond(s). Typical alkenyl groups include,but are not limited to, ethenyl; propenyls such as prop-1-en-1-yl,prop-1-en-2-yl, prop-2-en-1-yl (allyl), prop-2-en-2-yl; butenyls such asbut-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl,but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl;and the like. In certain embodiments, an alkenyl group has from 2 to 20carbon atoms and in other embodiments, from 2 to 6 carbon atoms. “Loweralkenyl” refers to alkenyl groups having two to six carbons.

As used herein, “alkynyl” refers to an unsaturated branched orstraight-chain alkyl group having at least one carbon-carbon triple bondderived by the removal of two molecules of hydrogen from adjacent carbonatoms of the parent alkyl. Typical alkynyl groups include, but are notlimited to, ethynyl; propynyls such as prop-1-yn-1-yl, prop-2-yn-1-yl;butynyls such as but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl; and thelike. In certain embodiments, an alkynyl group has from 2 to 20 carbonatoms and in other embodiments, from 3 to 6 carbon atoms. “Loweralkynyl” refers to alkynyl groups having two to six carbons.

As used herein, “cycloalkyl” refers to a non-aromatic carbocyclic ring,usually having from 3 to 7 ring carbon atoms. The ring may be saturatedor have one or more carbon-carbon double bonds. Examples of cycloalkylgroups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl,cyclohexyl, and cyclohexenyl, as well as bridged and caged ring groupssuch as norbornane.

As used herein, “alkoxy” refers to an alkyl group of the indicatednumber of carbon atoms attached through an oxygen bridge such as, forexample, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy,tert-butoxy, pentyloxy, 2-pentyloxy, isopentyloxy, neopentyloxy,hexyloxy, 2-hexyloxy, 3-hexyloxy, 3-methylpentyloxy, and the like.Alkoxy groups will usually have from 1 to 7 carbon atoms attachedthrough the oxygen bridge. “Lower alkoxy” refers to alkoxy groups havingone to six carbons.

As used herein, “acyl” refers to the groups H—C(O)—; (alkyl)-C(O)—;(cycloalkyl)-C(O)—; (aryl)-C(O)—; (heteroaryl)-C(O)—; and(heterocycloalkyl)-C(O)—, wherein the group is attached to the parentstructure through the carbonyl functionality and wherein alkyl,cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are as describedherein. Acyl groups have the indicated number of carbon atoms, with thecarbon of the keto group being included in the numbered carbon atoms.For example a C₂ acyl group is an acetyl group having the formulaCH₃(C═O)—.

As used herein, “formyl” refers to the group —C(O)H.

As used herein, “alkoxycarbonyl” refers to a group of the formula(alkoxy)(C═O)— attached through the carbonyl carbon wherein the alkoxygroup has the indicated number of carbon atoms. Thus a C₁-C₆alkoxycarbonyl group is an alkoxy group having from 1 to 6 carbon atomsattached through its oxygen to a carbonyl linker.

As used herein, “azido” refers to the group —N₃.

As used herein, “amino” refers to the group —NH₂.

As used herein, “mono- and di-(alkyl)amino” refers to secondary andtertiary alkyl amino groups, wherein the alkyl groups are as definedabove and have the indicated number of carbon atoms. The point ofattachment of the alkylamino group is on the nitrogen. Examples of mono-and di-alkylamino groups include ethylamino, dimethylamino, andmethyl-propyl-amino.

As used herein, “aminocarbonyl” refers to the group —CONR^(b)R^(c),where

R^(b) is H, optionally substituted C₁-C₆ alkyl, optionally substitutedcycloalkyl, optionally substituted heterocycloalkyl, optionallysubstituted aryl, optionally substituted heteroaryl, or optionallysubstituted alkoxy; and

R^(c) is hydrogen or optionally substituted C₁-C₄ alkyl; or

R^(b) and R^(c) taken together with the nitrogen to which they arebound, form an optionally substituted 4- to 8-memberednitrogen-containing heterocycloalkyl which optionally includes 1 or 2additional heteroatoms chosen from O, N, and S in the heterocycloalkylring;

where each substituted group is independently substituted with one ormore substituents independently C₁-C₄ alkyl, aryl, heteroaryl,aryl-C₁-C₄ alkyl-, heteroaryl-C₁-C₄ alkyl-, C₁-C₄ haloalkyl, —OC₁-C₄alkyl, —OC₁-C₄ alkylphenyl, —C₁-C₄ alkyl-OH, —OC₁-C₄ haloalkyl, halo,—OH, —NH₂, —C₁-C₄ alkyl-NH₂, —N(C₁-C₄ alkyl)(C₁-C₄ alkyl), —NH(C₁-C₄alkyl), —N(C₁-C₄ alkyl)(C₁-C₄ alkylphenyl), —NH(C₁-C₄ alkylphenyl),cyano, nitro, oxo (as a substituent for cycloalkyl, heterocycloalkyl, orheteroaryl), —CO₂H, —C(O)OC₁-C₄ alkyl, —CON(C₁-C₄ alkyl)(C₁-C₄ alkyl),—CONH(C₁-C₄ alkyl), —CONH₂, —NHC(O)(C₁-C₄ alkyl), —NHC(O)(phenyl),—N(C₁-C₄ alkyl)C(O)(C₁-C₄ alkyl), —N(C₁-C₄ alkyl)C(O)(phenyl),—C(O)C₁-C₄ alkyl, —C(O)C₁-C₄ alkylphenyl, —C(O)C₁-C₄ haloalkyl,—OC(O)C₁-C₄ alkyl, —SO₂(C₁-C₄ alkyl), —SO₂(phenyl), —S₂(C₁-C₄haloalkyl), —SO₂NH₂, —SO₂NH(C₁-C₄ alkyl), —SO₂NH(phenyl), —NHSO₂(C₁-C₄alkyl), —NHSO₂(phenyl), or —NHSO₂(C₁-C₄ haloalkyl).

As used herein, “aryl” refers to: 6-membered carbocyclic aromatic rings,for example, benzene; bicyclic ring systems wherein at least one ring iscarbocyclic and aromatic, for example, naphthalene, indane, andtetralin; and tricyclic ring systems wherein at least one ring iscarbocyclic and aromatic, for example, fluorene.

For example, aryl includes 6-membered carbocyclic aromatic rings fusedto a 4- to 8-membered heterocycloalkyl ring containing 1 or moreheteroatoms chosen from N, O, and S. For such fused, bicyclic ringsystems wherein only one of the rings is a carbocyclic aromatic ring,the point of attachment may be at the carbocyclic aromatic ring or theheterocycloalkyl ring. Bivalent radicals formed from substituted benzenederivatives and having the free valences at ring atoms are named assubstituted phenylene radicals. Bivalent radicals derived from univalentpolycyclic hydrocarbon radicals whose names end in “-yl” by removal ofone hydrogen atom from the carbon atom with the free valence are namedby adding “-idene” to the name of the corresponding univalent radical,e.g. a naphthyl group with two points of attachment is termednaphthylidene. Aryl, however, does not encompass or overlap in any waywith heteroaryl, separately defined below. Hence, if one or morecarbocyclic aromatic rings is fused with a heterocycloalkyl aromaticring, the resulting ring system is heteroaryl, not aryl, as definedherein.

As used herein, “aryloxy” refers to the group —O-aryl.

As used herein, “aralkyl” refers to the group -alkyl-aryl.

As used herein, “carbamimidoyl” refers to the group —C(═NH)—NH2.

As used herein, “substituted carbamimidoyl” refers to the group—C(═NR^(e))—NR^(f)R^(g) where

R^(e) is hydrogen, cyano, optionally substituted alkyl, optionallysubstituted cycloalkyl, optionally substituted aryl, optionallysubstituted heteroaryl, or optionally substituted heterocycloalkyl; and

R^(f) and R^(g) are independently hydrogen optionally substituted alkyl,optionally substituted cycloalkyl, optionally substituted aryl,optionally substituted heteroaryl, or optionally substitutedheterocycloalkyl,

provided that at least one of R^(e), R^(f), and R^(g) is not hydrogenand wherein substituted alkyl, cycloalkyl, aryl, heterocycloalkyl, andheteroaryl refer respectively to alkyl, cycloalkyl, aryl,heterocycloalkyl, and heteroaryl wherein one or more (such as up to 5,for example, up to 3) hydrogen atoms are replaced by a substituentindependently —R^(a), —OR^(b), optionally substituted amino (including—NR^(c)COR^(b), —NR^(c)CO₂R^(a), —NR^(c)CONR^(b)R^(c),—NR^(b)C(NR^(c))NR^(b)R^(c), —NR^(b)C(NCN)NR^(b)R^(c), and—NR^(c)SO₂R^(a)), halo, cyano, nitro, oxo (as a substituent forcycloalkyl, heterocycloalkyl, and heteroaryl), optionally substitutedacyl (such as —COR^(b)), optionally substituted alkoxycarbonyl (such as—CO₂R^(b)), aminocarbonyl (such as —CONR^(b)R^(c)), —OCOR^(b),—OCO₂R^(a), —OCONR^(b)R^(c), —OP(O)(OR^(b))OR^(c), sulfanyl (such asSR^(b)), sulfinyl (such as —SOR^(a)), or sulfonyl (such as —SO₂R^(a) and—SO₂NR^(b)R^(c)),

where R^(a) is optionally substituted C1-C6 alkyl, optionallysubstituted aryl, or optionally substituted heteroaryl;

R^(b) is H, optionally substituted C1-C6 alkyl, optionally substitutedaryl, or optionally substituted heteroaryl; and

R^(c) is hydrogen or optionally substituted C1-C4 alkyl; or

R^(b) and R^(c), and the nitrogen to which they are attached, form anoptionally substituted heterocycloalkyl group; and

where each optionally substituted group is unsubstituted orindependently substituted with one or more, such as one, two, or three,substituents independently C₁-C₄ alkyl, aryl, heteroaryl, aryl-C₁-C₄alkyl-, heteroaryl-C₁-C₄ alkyl-, C₁-C₄ haloalkyl, —OC₁-C₄ alkyl, —OC₁-C₄alkylphenyl, —C₁-C₄ alkyl-OH, —OC₁-C₄ haloalkyl, halo, —OH, —NH₂, —C₁-C₄alkyl-NH₂, —N(C₁-C₄ alkyl)(C₁-C₄ alkyl), —NH(C₁-C₄ alkyl), —N(C₁-C₄alkyl)(C₁-C₄ alkylphenyl), —NH(C₁-C₄ alkylphenyl), cyano, nitro, oxo (asa substituent for cycloalkyl, heterocycloalkyl, or heteroaryl), —CO₂H,—C(O)OC₁-C₄ alkyl, —CON(C₁-C₄ alkyl)(C₁-C₄ alkyl), —CONH(C₁-C₄ alkyl),—CONH₂, —NHC(O)(C₁-C₄ alkyl), —NHC(O)(phenyl), —N(C₁-C₄ alkyl)C(O)(C₁-C₄alkyl), —N(C₁-C₄ alkyl)C(O)(phenyl), —C(O)C₁-C₄ alkyl, —C(O)C₁-C₄phenyl, —C(O)C₁-C₄ haloalkyl, —OC(O)C₁-C₄ alkyl, —SO₂(C₁-C₄ alkyl),—SO₂(phenyl), —SO₂(C₁-C₄ haloalkyl), —SO₂NH₂, —SO₂NH(C₁-C₄ alkyl),—SO₂NH(phenyl), —NHSO₂(C₁-C₄ alkyl), —NHSO₂(phenyl), or —NHSO₂(C₁-C₄haloalkyl).

As used herein, E refers to the electrophilic group capable of forming acovalent bond with a nucleophile. In some embodiments, compoundscomprising E can undergo a spontaneous reaction with a protein. In someembodiments, compounds comprising E can undergo a spontaneous reactionwith a protein to form a new covalent bond under moderate reactionconditions. In some embodiments, compounds comprising E can undergo aspontaneous reaction with a protein to form a new covalent bond whereinthe new covalent bond forms between the compound and the nitrogen orsulfur of an amino acid residue sidechain. Some non-limiting examples ofthe amino acid can be lysine or cysteine, for example. In someembodiments, moderate reaction conditions can be at a temperature belowabout 50° C., 45° C., 40° C., 39° C., 38° C., 37° C., 36° C., 35° C.,34° C., 33° C., 30° C., 27° C., 25° C., 20° C., or 5° C. in an aqueoussolution at a concentration of protein and compound below about 1M forexample. In some embodiments, E is an electrophilic group capable offorming a covalent bond with a cysteine residue of a protein. In someembodiments, compounds comprising E are capable of forming a covalentbond with a cysteine residue of a protein. Examples of E include, butare not limited to, the following groups:

As used herein, “halo” refers to fluoro, chloro, bromo, and iodo, andthe term “halogen” includes fluorine, chlorine, bromine, and iodine.

As used herein, “haloalkyl” refers to alkyl as defined above having thespecified number of carbon atoms, substituted with 1 or more halogenatoms, up to the maximum allowable number of halogen atoms. Examples ofhaloalkyl include, but are not limited to, trifluoromethyl,difluoromethyl, 2-fluoroethyl, and penta-fluoroethyl.

As used herein, “heteroaryl” refers to:

5- to 7-membered aromatic, monocyclic rings containing one or more, forexample, from 1 to 4, or in certain embodiments, from 1 to 3,heteroatoms chosen from N, O, and S, with the remaining ring atoms beingcarbon;

bicyclic heterocycloalkyl rings containing one or more, for example,from 1 to 4, or in certain embodiments, from 1 to 3, heteroatoms chosenfrom N, O, and S, with the remaining ring atoms being carbon and whereinat least one heteroatom is present in an aromatic ring; and

tricyclic heterocycloalkyl rings containing one or more, for example,from 1 to 5, or in certain embodiments, from 1 to 4, heteroatoms chosenfrom N, O, and S, with the remaining ring atoms being carbon and whereinat least one heteroatom is present in an aromatic ring.

For example, heteroaryl includes a 5- to 7-membered heterocycloalkyl,aromatic ring fused to a 4- to 8-membered cycloalkyl or heterocycloalkylring. For such fused, bicyclic heteroaryl ring systems wherein only oneof the rings contains one or more heteroatoms, the point of attachmentmay be at either ring. When the total number of S and O atoms in theheteroaryl group exceeds 1, those heteroatoms are not adjacent to oneanother. In certain embodiments, the total number of S and O atoms inthe heteroaryl group is not more than 2. In certain embodiments, thetotal number of S and O atoms in the aromatic heterocycle is not morethan 1. Examples of heteroaryl groups include, but are not limited to,pyridyl, pyrazinyl, pyrimidinyl, pyrazolinyl, imidazolyl, isoxazolyl,oxazolyl, thiazolyl, thiadiazolyl, tetrazolyl, thienyl, benzothiophenyl,furanyl, pyrrolyl, benzofuranyl, benzoimidazolyl, indolyl, pyridazinyl,triazolyl, quinolinyl, quinoxalinyl, pyrazolyl, and5,6,7,8-tetrahydroisoquinolinyl. Bivalent radicals derived fromunivalent heteroaryl radicals whose names end in “-yl” by removal of onehydrogen atom from the atom with the free valence are named by adding“-idene” to the name of the corresponding univalent radical, e.g. apyridyl group with two points of attachment is a pyridylidene.Heteroaryl does not encompass or overlap with aryl, cycloalkyl, orheterocycloalkyl, as defined herein.

Substituted heteroaryl also includes ring systems substituted with oneor more oxide (—O—) substituents, such as pyridinyl N-oxides.

As used herein, “heterocycloalkyl” refers to a single, non-aromaticring, usually with 3 to 8 ring atoms, containing at least 2 carbon atomsin addition to 1-3 heteroatoms independently chosen from oxygen, sulfur,and nitrogen, as well as combinations comprising at least one of theforegoing heteroatoms. The ring may be saturated or have one or morecarbon-carbon double bonds. Suitable heterocycloalkyl groups include butare not limited to, for example, pyrrolidinyl, morpholinyl, piperidinyl,piperazinyl, azetidinyl, diazepanyl, diazocanyl, pyrrolidinyl,morpholinyl, piperidinyl, piperazinyl, imidazolidinyl, pyrazolidinyl,dihydrofuranyl, and tetrahydrofuranyl. Substituted heterocycloalkyl canalso include ring systems substituted with one or more oxo (═O) or oxide(—O—) substituents, such as piperidinyl N-oxide, morpholinyl-N-oxide,1-oxo-1-thiomorpholinyl and 1,1-dioxo-1-thiomorpholinyl.

“Heterocycloalkyl” also includes bicyclic ring systems wherein onenon-aromatic ring, usually with 3 to 7 ring atoms, contains at least 2carbon atoms in addition to 1-3 heteroatoms independently chosen fromoxygen, sulfur, and nitrogen, as well as combinations comprising atleast one of the foregoing heteroatoms; and the other ring, usually with3 to 7 ring atoms, optionally contains 1-3 heteroatoms independentlychosen from oxygen, sulfur, and nitrogen and is not aromatic.

As used herein, “sulfanyl” refers to the groups: —S-(optionallysubstituted (C₁-C₆)alkyl), —S-(optionally substituted cycloalkyl),—S-(optionally substituted aryl), —S-(optionally substitutedheteroaryl), and —S-(optionally substituted heterocycloalkyl). Hence,sulfanyl includes the group C₁-C₆ alkylsulfanyl.

As used herein, “sulfinyl” refers to the groups: —S(O)-(optionallysubstituted (C₁-C₆)alkyl), —S(O)-(optionally substituted cycloalkyl),—S(O)-(optionally substituted aryl), —S(O)-optionally substitutedheteroaryl), —S(O)-(optionally substituted heterocycloalkyl); and—S(O)-(optionally substituted amino).

As used herein, “sulfonyl” refers to the groups: —S(O₂)-(optionallysubstituted (C₁-C₆)alkyl), —S(O₂)-(optionally substituted cycloalkyl),—S(O₂)-(optionally substituted aryl), —S(O₂)-(optionally substitutedheteroaryl), —S(O₂)-(optionally substituted heterocycloalkyl), and—S(O₂)-(optionally substituted amino).

As used herein, “substituted” refers to anyone or more hydrogens on thedesignated atom or group is replaced with a selection from the indicatedgroup, provided that the designated atom's normal valence is notexceeded. When a substituent is oxo (i.e. ═O) then 2 hydrogens on theatom are replaced. Combinations of substituents and/or variables arepermissible only if such combinations result in stable compounds oruseful synthetic intermediates. A stable compound or stable structure ismeant to imply a compound that is sufficiently robust to surviveisolation from a reaction mixture, and subsequent formulation as anagent having at least practical utility. Unless otherwise specified,substituents are named into the core structure. For example, it is to beunderstood that when (cycloalkyl)alkyl is listed as a possiblesubstituent, the point of attachment of this substituent to the corestructure is in the alkyl portion.

As used herein, the terms “substituted” alkyl, cycloalkyl, aryl,heterocycloalkyl, and heteroaryl, unless otherwise expressly defined,refer respectively to alkyl, cycloalkyl, aryl, heterocycloalkyl, andheteroaryl wherein one or more (such as up to 5, for example, up to 3)hydrogen atoms are replaced by a substituent independently —R^(a),—OR^(b), optionally substituted amino (including —NR^(c)COR^(b),—NR^(c)CO₂R^(a), —NR^(c)CONR^(b)R^(c), —NR^(b)C(NR^(c))NR^(b)R^(c),—NR^(b)C(NCN)NR^(b)R^(c), and —NR^(c)SO₂R^(a)), halo, cyano, azido,nitro, oxo (as a substituent for cycloalkyl or heterocycloalkyl),optionally substituted acyl (such as —COR^(b)), optionally substitutedalkoxycarbonyl (such as —CO₂R^(b)), aminocarbonyl (such as—CONR^(b)R^(c)), —OCOR^(b), —OCO₂R^(a), —OCONR^(b)R^(c),—OP(O)(OR^(b))OR^(c), sulfanyl (such as SR^(b)), sulfinyl (such as—SOR^(a)), or sulfonyl (such as —SO₂R^(a) and —SO₂NR^(b)R^(c)),

where R^(a) is optionally substituted C₁-C₆ alkyl, optionallysubstituted cycloalkyl, optionally substituted heterocycloalkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted aryl, or optionally substituted heteroaryl; R^(b)is hydrogen, optionally substituted C₁-C₆ alkyl, optionally substitutedcycloalkyl, optionally substituted heterocycloalkyl, optionallysubstituted aryl, or optionally substituted heteroaryl; and

R^(c) is hydrogen or optionally substituted C₁-C₄ alkyl; or

R^(b) and R^(c), and the nitrogen to which they are attached, form anoptionally substituted heterocycloalkyl group; and

where each optionally substituted group is unsubstituted orindependently substituted with one or more, such as one, two, or three,substituents independently C₁-C₄ alkyl, aryl, heteroaryl, aryl-C₁-C₄alkyl-, heteroaryl-C₁-C₄ alkyl-, C₁-C₄ haloalkyl, —OC₁-C₄ alkyl, —OC₁-C₄alkylphenyl, —C₁-C₄ alkyl-OH, —OC₁-C₄ haloalkyl, halo, —OH, —NH₂, —C₁-C₄alkyl-NH₂, —N(C₁-C₄ alkyl)(C₁-C₄ alkyl), —NH(C₁-C₄ alkyl), —N(C₁-C₄alkyl)(C₁-C₄ alkylphenyl), —NH(C₁-C₄ alkylphenyl), cyano, nitro, oxo (asa substituent for cycloalkyl or heterocycloalkyl), —CO₂H, —C(O)OC₁-C₄alkyl, —CON(C₁-C₄ alkyl)(C₁-C₄ alkyl), —CONH(C₁-C₄ alkyl), —CONH₂,—NHC(O)(C₁-C₄ alkyl), —NHC(O)(phenyl), —N(C₁-C₄ alkyl)C(O)(C₁-C₄ alkyl),—N(C₁-C₄ alkyl)C(O)(phenyl), —C(O)C₁-C₄ alkyl, —C(O)C₁-C₄ alkylphenyl,—C(O)C₁-C₄ haloalkyl, —OC(O)C₁-C₄ alkyl, —SO₂(C₁-C₄ alkyl),—SO₂(phenyl), —SO₂(C₁-C₄ haloalkyl), —SO₂NH₂, —SO₂NH(C₁-C₄ alkyl),—SO₂NH(phenyl), —NHSO₂(C₁-C₄ alkyl), —NHSO₂(phenyl), or —NHSO₂(C₁-C₄haloalkyl).

As used herein, “substituted acyl” refers to the groups (substitutedalkyl)-C(O)—; (substituted cycloalkyl)-C(O)—; (substituted aryl)-C(O)—;(substituted heteroaryl)-C(O)—; and (substitutedheterocycloalkyl)-C(O)—, wherein the group is attached to the parentstructure through the carbonyl functionality and wherein substitutedalkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl, referrespectively to alkyl, cycloalkyl, aryl, heteroaryl, andheterocycloalkyl wherein one or more (such as up to 5, for example, upto 3) hydrogen atoms are replaced by a substituent independently —R^(a),—OR^(b), optionally substituted amino (including —NR^(c)COR^(b),—NR^(c)CO₂R^(a), —NR^(c)CONR^(b)R^(c), —NR^(b)C(NR^(c))NR^(b)R^(c),—NR^(b)C(NCN)NR^(b)R^(c), and —NR^(c)SO₂R^(a)), halo, cyano, nitro, oxo(as a substituent for cycloalkyl or heterocycloalkyl), optionallysubstituted acyl (such as —COR^(b)), optionally substitutedalkoxycarbonyl (such as —CO₂R^(b)), aminocarbonyl (such as—CONR^(b)R^(c)), —OCOR^(b), —OCO₂R^(a), —OCONR^(b)R^(c),—OP(O)(OR^(b))OR^(c), sulfanyl (such as SR^(b)), sulfinyl (such as—SOR^(a)), or sulfonyl (such as —SO₂R^(a) and —SO₂NR^(b)R^(c)),

where R^(a) is optionally substituted C₁-C₆ alkyl, optionallysubstituted alkenyl, optionally substituted alkynyl, optionallysubstituted aryl, or optionally substituted heteroaryl;

R^(b) is H, optionally substituted C₁-C₆ alkyl, optionally substitutedcycloalkyl, optionally substituted heterocycloalkyl, optionallysubstituted aryl, or optionally substituted heteroaryl; and

R^(c) is hydrogen or optionally substituted C₁-C₄ alkyl; or

R^(b) and R^(c), and the nitrogen to which they are attached, form anoptionally substituted heterocycloalkyl group; and

where each optionally substituted group is unsubstituted orindependently substituted with one or more, such as one, two, or three,substituents independently C₁-C₄ alkyl, aryl, heteroaryl, aryl-C₁-C₄alkyl-, heteroaryl-C₁-C₄ alkyl-, C₁-C₄ haloalkyl, —OC₁-C₄ alkyl, —OC₁-C₄alkylphenyl, —C₁-C₄ alkyl-OH, —OC₁-C₄ haloalkyl, halo, —OH, —NH₂, —C₁-C₄alkyl-NH₂, —N(C₁-C₄ alkyl)(C₁-C₄ alkyl), —NH(C₁-C₄ alkyl), —N(C₁-C₄alkyl)(C₁-C₄ alkylphenyl), —NH(C₁-C₄ alkylphenyl), cyano, nitro, oxo (asa substituent for cycloalkyl or heterocycloalkyl), —CO₂H, —C(O)OC₁-C₄alkyl, —CON(C₁-C₄ alkyl)(C₁-C₄ alkyl), —CONH(C₁-C₄ alkyl), —CONH₂,—NHC(O)(C₁-C₄ alkyl), —NHC(O)(phenyl), —N(C₁-C₄ alkyl)C(O)(C₁-C₄ alkyl),—N(C₁-C₄ alkyl)C(O)(phenyl), —C(O)C₁-C₄ alkyl, —C(O)C₁-C₄ alkylphenyl,—C(O)C₁-C₄ haloalkyl, —OC(O)C₁-C₄ alkyl, —SO₂(C₁-C₄ alkyl),—SO₂(phenyl), —SO₂(C₁-C₄ haloalkyl), —SO₂NH₂, —S₂NH(C₁-C₄ alkyl),—SO₂NH(phenyl), —NHSO₂(C₁-C₄ alkyl), —NHSO₂(phenyl), or —NHSO₂(C₁-C₄haloalkyl).

As used herein, “substituted alkoxy” refers to alkoxy wherein the alkylconstituent is substituted (i.e. —O-(substituted alkyl)) wherein“substituted alkyl” refers to alkyl wherein one or more (such as up to5, for example, up to 3) hydrogen atoms are replaced by a substituentindependently —R^(a), —OR^(b), optionally substituted amino (including—NR^(c)COR^(b), —NR^(c)CO₂R^(a), —NR^(c)CONR^(b)R^(c),—NR^(b)C(NR^(c))NR^(b)R^(c), —NR^(b)C(NCN)NR^(b)R^(c), and—NR^(c)SO₂R^(a)), halo, cyano, nitro, oxo (as a substituent forcycloalkyl or heterocycloalkyl), optionally substituted acyl (such as—COR^(b)), optionally substituted alkoxycarbonyl (such as —CO₂R^(b)),aminocarbonyl (such as —CONR^(b)R^(c)), —OCOR^(b), —OCO₂R^(a),—OCONR^(b)R^(c), —OP(O)(OR^(b))OR^(c), sulfanyl (such as SR^(b)),sulfinyl (such as —SOR^(a)), and sulfonyl (such as —SO₂R^(a) and—SO₂NR^(b)R^(c)),

where R^(a) is optionally substituted C₁-C₆ alkyl, optionallysubstituted alkenyl, optionally substituted alkynyl, optionallysubstituted aryl, or optionally substituted heteroaryl;

R^(b) is H, optionally substituted C₁-C₆ alkyl, optionally substitutedcycloalkyl, optionally substituted heterocycloalkyl, optionallysubstituted aryl, or optionally substituted heteroaryl; and

R^(c) is hydrogen or optionally substituted C₁-C₄ alkyl; or

R^(b) and R^(c), and the nitrogen to which they are attached, form anoptionally substituted heterocycloalkyl group; and

where each optionally substituted group is unsubstituted orindependently substituted with one or more, such as one, two, or three,substituents independently C₁-C₄ alkyl, aryl, heteroaryl, aryl-C₁-C₄alkyl-, heteroaryl-C₁-C₄ alkyl-, C₁-C₄ haloalkyl, —OC₁-C₄ alkyl, —OC₁-C₄alkylphenyl, —C₁-C₄ alkyl-OH, —OC₁-C₄ haloalkyl, halo, —OH, —NH₂, —C₁-C₄alkyl-NH₂, —N(C₁-C₄ alkyl)(C₁-C₄ alkyl), —NH(C₁-C₄ alkyl), —N(C₁-C₄alkyl)(C₁-C₄ alkylphenyl), —NH(C₁-C₄ alkylphenyl), cyano, nitro, oxo (asa substituent for cycloalkyl or heterocycloalkyl), —CO₂H, —C(O)OC₁-C₄alkyl, —CON(C₁-C₄ alkyl)(C₁-C₄ alkyl), —CONH(C₁-C₄ alkyl), —CONH₂,—NHC(O)(C₁-C₄ alkyl), —NHC(O)(phenyl), —N(C₁-C₄ alkyl)C(O)(C₁-C₄ alkyl),—N(C₁-C₄ alkyl)C(O)(phenyl), —C(O)C₁-C₄ alkyl, —C(O)C₁-C₄ alkylphenyl,—C(O)C₁-C₄ haloalkyl, —OC(O)C₁-C₄ alkyl, —SO₂(C₁-C₄ alkyl),—SO₂(phenyl), —SO₂(C₁-C₄ haloalkyl), —SO₂NH₂, —SO₂NH(C₁-C₄ alkyl),—SO₂NH(phenyl), —NHSO₂(C₁-C₄ alkyl), —NHSO₂(phenyl), or —NHSO₂(C₁-C₄haloalkyl).

In some embodiments, a substituted alkoxy group is “polyalkoxy” or—O-(optionally substituted alkylene)-(optionally substituted alkoxy),and includes groups such as —OCH₂CH₂OCH₃, and residues of glycol etherssuch as polyethyleneglycol, and —O(CH₂CH₂O)_(x)CH₃, where x is aninteger of 2-20, such as 2-10, and for example, 2-5. Another substitutedalkoxy group is hydroxyalkoxy or —OCH₂(CH₂)_(y)OH, where y is an integerof 1-10, such as 1-4.

As used herein, “substituted alkoxycarbonyl” refers to the group(substituted alkyl)-O—C(O)— wherein the group is attached to the parentstructure through the carbonyl functionality and wherein substitutedrefers to alkyl wherein one or more (such as up to 5, for example, up to3) hydrogen atoms are replaced by a substituent independently —R^(a),—OR^(b), optionally substituted amino (including —NR^(c)COR^(b),—NR^(c)CO₂R^(a), —NR^(c)CONR^(b)R^(c), —NR^(b)C(NR^(c))NR^(b)R^(c),—NR^(b)C(NCN)NR^(b)R^(c), and —NR^(c)SO₂R^(a)), halo, cyano, nitro, oxo(as a substituent for cycloalkyl or heterocycloalkyl), optionallysubstituted acyl (such as —COR^(b)), optionally substitutedalkoxycarbonyl (such as —CO₂R^(b)), aminocarbonyl (such as—CONR^(b)R^(c)), —OCOR^(b), —OCO₂R^(a), —OCONR^(b)R^(c),—OP(O)(OR^(b))OR^(c), sulfanyl (such as SR^(b)), sulfinyl (such as—SOR^(a)), and sulfonyl (such as —SO₂R^(a) and —SO₂NR^(b)R^(c)),

where R^(a) is optionally substituted C₁-C₆ alkyl, optionallysubstituted alkenyl, optionally substituted alkynyl, optionallysubstituted aryl, or optionally substituted heteroaryl;

R^(b) is H, optionally substituted C₁-C₆ alkyl, optionally substitutedcycloalkyl, optionally substituted heterocycloalkyl, optionallysubstituted aryl, or optionally substituted heteroaryl; and

R^(c) is hydrogen or optionally substituted C₁-C₄ alkyl; or

R^(b) and R^(c), and the nitrogen to which they are attached, form anoptionally substituted heterocycloalkyl group; and

where each optionally substituted group is unsubstituted orindependently substituted with one or more, such as one, two, or three,substituents independently C₁-C₄ alkyl, aryl, heteroaryl, aryl-C₁-C₄alkyl-, heteroaryl-C₁-C₄ alkyl-, C₁-C₄ haloalkyl, —OC₁-C₄ alkyl, —OC₁-C₄alkylphenyl, —C₁-C₄ alkyl-OH, —OC₁-C₄ haloalkyl, halo, —OH, —NH₂, —C₁-C₄alkyl-NH₂, —N(C₁-C₄ alkyl)(C₁-C₄ alkyl), —NH(C₁-C₄ alkyl), —N(C₁-C₄alkyl)(C₁-C₄ alkylphenyl), —NH(C₁-C₄ alkylphenyl), cyano, nitro, oxo (asa substituent for cycloalkyl or heterocycloalkyl), —CO₂H, —C(O)OC₁-C₄alkyl, —CON(C₁-C₄ alkyl)(C₁-C₄ alkyl), —CONH(C₁-C₄ alkyl), —CONH₂,—NHC(O)(C₁-C₄ alkyl), —NHC(O)(phenyl), —N(C₁-C₄ alkyl)C(O)(C₁-C₄ alkyl),—N(C₁-C₄ alkyl)C(O)(phenyl), —C(O)C₁-C₄ alkyl, —C(O)C₁-C₄ alkylphenyl,—C(O)C₁-C₄ haloalkyl, —OC(O)C₁-C₄ alkyl, —SO₂(C₁-C₄ alkyl),—SO₂(phenyl), —SO₂(C₁-C₄ haloalkyl), —SO₂NH₂, —S₂NH(C₁-C₄ alkyl),—SO₂NH(phenyl), —NHSO₂(C₁-C₄ alkyl), —NHSO₂(phenyl), or —NHSO₂(C₁-C₄haloalkyl).

As used herein, “substituted amino” refers to the group —NHR^(d) or—NR^(d)R^(e) wherein R^(d) is hydroxyl, formyl, optionally substitutedalkoxy, optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted acyl, optionally substituted carbamimidoyl,aminocarbonyl, optionally substituted aryl, optionally substitutedheteroaryl, optionally substituted heterocycloalkyl, optionallysubstituted alkoxycarbonyl, sulfinyl and sulfonyl, and wherein R^(e) ischosen from optionally substituted alkyl, optionally substitutedcycloalkyl, optionally substituted aryl, optionally substitutedheteroaryl, or optionally substituted heterocycloalkyl, and whereinsubstituted alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroarylrefer respectively to alkyl, cycloalkyl, aryl, heterocycloalkyl, andheteroaryl wherein one or more (such as up to 5, for example, up to 3)hydrogen atoms are replaced by a substituent independently —R^(a),—OR^(b), optionally substituted amino (including —NR^(c)COR^(b),—NR^(c)CO₂R^(a), —NR^(c)CONR^(b)R^(c), —NR^(b)C(NR^(c))NR^(b)R^(c),—NR^(b)C(NCN)NR^(b)R^(c), and —NR^(c)SO₂R^(a)), halo, cyano, nitro, oxo(as a substituent for cycloalkyl or heterocycloalkyl), optionallysubstituted acyl (such as —COR^(b)), optionally substitutedalkoxycarbonyl (such as —CO₂R^(b)), aminocarbonyl (such as—CONR^(b)R^(c)), —OCOR^(b), —OCO₂R^(a), —OCONR^(b)R^(c),—OP(O)(OR^(b))OR^(c), sulfanyl (such as SR^(b)), sulfinyl (such as—SOR^(a)), or sulfonyl (such as —SO₂R^(a) and —SO₂NR^(b)R^(c)),

wherein R^(a) is optionally substituted C₁-C₆ alkyl, optionallysubstituted alkenyl, optionally substituted alkynyl, optionallysubstituted aryl, or optionally substituted heteroaryl;

R^(b) is H, optionally substituted C₁-C₆ alkyl, optionally substitutedcycloalkyl, optionally substituted heterocycloalkyl, optionallysubstituted aryl, or optionally substituted heteroaryl; and

R^(c) is hydrogen or optionally substituted C₁-C₄ alkyl; or R^(b) andR^(c), and the nitrogen to which they are attached, form an optionallysubstituted heterocycloalkyl group; and wherein each optionallysubstituted group is unsubstituted or independently substituted with oneor more, such as one, two, or three, substituents independently chosenfrom C₁-C₄ alkyl, aryl, heteroaryl, aryl-C₁-C₄ alkyl-, heteroaryl-C₁-C₄alkyl-, C₁-C₄ haloalkyl, —OC₁-C₄ alkyl, —OC₁-C₄ alkylphenyl, —C₁-C₄alkyl-OH, —OC₁-C₄ haloalkyl, halo, —OH, —NH₂, —C₁-C₄ alkyl-NH₂, —N(C₁-C₄alkyl)(C₁-C₄ alkyl), —NH(C₁-C₄ alkyl), —N(C₁-C₄ alkyl)(C₁-C₄alkylphenyl), —NH(C₁-C₄ alkylphenyl), cyano, nitro, oxo (as asubstituent for cycloalkyl or heterocycloalkyl), —CO₂H, —C(O)OC₁-C₄alkyl, —CON(C₁-C₄ alkyl)(C₁-C₄ alkyl), —CONH(C₁-C₄ alkyl), —CONH₂,—NHC(O)(C₁-C₄ alkyl), —NHC(O)(phenyl), —N(C₁-C₄ alkyl)C(O)(C₁-C₄ alkyl),—N(C₁-C₄ alkyl)C(O)(phenyl), —C(O)C₁-C₄ alkyl, —C(O)C₁-C₄ alkylphenyl,—C(O)C₁-C₄ haloalkyl, —OC(O)C₁-C₄ alkyl, —SO₂(C₁-C₄ alkyl),—SO₂(phenyl), —SO₂(C₁-C₄ haloalkyl), —SO₂NH₂, —SO₂NH(C₁-C₄ alkyl),—SO₂NH(phenyl), —NHSO₂(C₁-C₄ alkyl), —NHSO₂(phenyl), or —NHSO₂(C₁-C₄haloalkyl); and

wherein optionally substituted acyl, optionally substitutedalkoxycarbonyl, sulfinyl and sulfonyl are as defined herein.

The term “substituted amino” also refers to N-oxides of the groups—NHR^(d), and NR^(d)R^(d) each as described above. N-oxides can beprepared by treatment of the corresponding amino group with, forexample, hydrogen peroxide or m-chloroperoxybenzoic acid. The personskilled in the art is familiar with reaction conditions for carrying outthe N-oxidation.

Compounds described herein include, but are not limited to, theiroptical isomers, racemates, and other mixtures thereof. In thosesituations, the single enantiomers or diastereomers, i.e., opticallyactive forms, can be obtained by asymmetric synthesis or by resolutionof the racemates. Resolution of the racemates can be accomplished, forexample, by conventional methods such as crystallization in the presenceof a resolving agent, or chromatography, using, for example a chiralhigh-pressure liquid chromatography (HPLC) column. In addition,compounds include Z- and E-forms (or cis- and trans-forms) of compoundswith carbon-carbon double bonds. Where compounds described herein existin various tautomeric forms, the term “compound” is intended to includeall tautomeric forms of the compound.

Compounds of Formula I also include crystalline and amorphous forms ofthose compounds, including, for example, polymorphs, pseudopolymorphs,solvates (including hydrates), unsolvated polymorphs (includinganhydrates), conformational polymorphs, and amorphous forms of thecompounds, as well as mixtures thereof “Crystalline form,” “polymorph,”and “novel form” may be used interchangeably herein, and are meant toinclude all crystalline and amorphous forms of the compound, including,for example, polymorphs, pseudopolymorphs, solvates (includinghydrates), unsolvated polymorphs (including anhydrates), conformationalpolymorphs, and amorphous forms, as well as mixtures thereof, unless aparticular crystalline or amorphous form is referred to. Similarly,“pharmaceutically acceptable forms” of compounds of Formula I alsoinclude crystalline and amorphous forms of those compounds, including,for example, polymorphs, pseudopolymorphs, solvates (includinghydrates), unsolvated polymorphs (including anhydrates), conformationalpolymorphs, and amorphous forms of the pharmaceutically acceptablesalts, as well as mixtures thereof.

A “solvate” is formed by the interaction of a solvent and a compound.The term “compound” is intended to include solvates of compounds.Similarly, “pharmaceutically acceptable salts” includes solvates ofpharmaceutically acceptable salts. Suitable solvates arepharmaceutically acceptable solvates, such as hydrates, includingmonohydrates and hemi-hydrates.

Compounds of Formula I also include other pharmaceutically acceptableforms of the recited compounds, including chelates, non-covalentcomplexes, prodrugs, and mixtures thereof.

A “chelate” is formed by the coordination of a compound to a metal ionat two (or more) points. The term “compound” is intended to includechelates of compounds. Similarly, “pharmaceutically acceptable salts”includes chelates of pharmaceutically acceptable salts.

A “non-covalent complex” is formed by the interaction of a compound andanother molecule wherein a covalent bond is not formed between thecompound and the molecule. For example, complexation can occur throughvan der Waals interactions, hydrogen bonding, and electrostaticinteractions (also called ionic bonding). Such non-covalent complexesare included in the term “compound”. Similarly, pharmaceuticallyacceptable salts include “non-covalent complexes” of pharmaceuticallyacceptable salts.

The term “hydrogen bond” refers to a form of association between anelectronegative atom (also known as a hydrogen bond acceptor) and ahydrogen atom attached to a second, relatively electronegative atom(also known as a hydrogen bond donor). Suitable hydrogen bond donor andacceptors are well understood in medicinal chemistry.

“Hydrogen bond acceptor” refers to a group comprising an oxygen ornitrogen, such as an oxygen or nitrogen that is sp²-hybridized, an etheroxygen, or the oxygen of a sulfoxide or N-oxide.

The term “hydrogen bond donor” refers to an oxygen, nitrogen, orheteroaromatic carbon that bears a hydrogen group containing a ringnitrogen or a heteroaryl group containing a ring nitrogen.

The compounds disclosed herein can be used in different enrichedisotopic forms, e.g., enriched in the content of ²H, ³H, ¹¹C, ¹³C and/or¹⁴C. In one particular embodiment, the compound is deuterated at leastone position. Such deuterated forms can be made by the proceduredescribed in U.S. Pat. Nos. 5,846,514 and 6,334,997. As described inU.S. Pat. Nos. 5,846,514 and 6,334,997, deuteration can improve theefficacy and increase the duration of action of drugs.

Deuterium substituted compounds can be synthesized using various methodssuch as described in: Dean, Dennis C.; Editor. Recent Advances in theSynthesis and Applications of Radiolabeled Compounds for Drug Discoveryand Development. [In: Curr., Pharm. Des., 2000; 6(10)] 2000, 110 pp;George W.; Varma, Rajender S. The Synthesis of Radiolabeled Compoundsvia Organometallic Intermediates, Tetrahedron, 1989, 45(21), 6601-21;and Evans, E. Anthony. Synthesis of radiolabeled compounds, J.Radioanal. Chem., 1981, 64(1-2), 9-32.

“Pharmaceutically acceptable salts” include, but are not limited tosalts with inorganic acids, such as hydrochlorate, carbonate, phosphate,hydrogenphosphate, diphosphate, hydrobromate, sulfate, sulfinate,nitrate, and like salts; as well as salts with an organic acid, such asmalate, malonate, maleate, fumarate, tartrate, succinate, citrate,acetate, lactate, gluconate, methanesulfonate, Tris(hydroxymethyl-aminomethane), p-toluenesulfonate, priopionate,2-hydroxyethylsulfonate, benzoate, salicylate, stearate, oxalate,pamoate, and alkanoate such as acetate, HOOC—(CH₂)_(n)—COOH where n is0-4, and like salts. Other salts include sulfate, methasulfonate,bromide, trifluoracetate, picrate, sorbate, benzilate, salicilate,nitrate, phthalate or morpholine. Pharmaceutically acceptable cationsinclude, but are not limited to sodium, potassium, calcium, aluminum,lithium, and ammonium.

In addition, if the compounds described herein are obtained as an acidaddition salt, the free base can be obtained by basifying a solution ofthe acid salt. Conversely, if the product is a free base, an additionsalt, particularly a pharmaceutically acceptable addition salt, may beproduced by dissolving the free base in a suitable organic solvent andtreating the solution with an acid, in accordance with conventionalprocedures for preparing acid addition salts from base compounds. Thoseskilled in the art will recognize various synthetic methodologies thatmay be used to prepare non-toxic pharmaceutically acceptable additionsalts.

“Prodrugs” described herein include any compound that becomes a compoundof Formula I when administered to a subject, e.g., upon metabolicprocessing of the prodrug. Similarly, “pharmaceutically acceptablesalts” includes “prodrugs” of pharmaceutically acceptable salts.Examples of prodrugs include derivatives of functional groups, such as acarboxylic acid group, in the compounds of Formula I. Exemplary prodrugsof a carboxylic acid group include, but are not limited to, carboxylicacid esters such as alkyl esters, hydroxyalkyl esters, arylalkyl esters,and aryloxyalkyl esters. Other exemplary prodrugs include lower alkylesters such as ethyl ester, acyloxyalkyl esters such aspivaloyloxymethyl (POM), glycosides, and ascorbic acid derivatives.

Other exemplary prodrugs include amides of carboxylic acids. Exemplaryamide prodrugs include metabolically labile amides that are formed, forexample, with an amine and a carboxylic acid. Exemplary amines includeNH₂, primary, and secondary amines such as NHR^(x), and NR^(x)R^(y),wherein R^(x) is hydrogen, (C₁-C₁₈)-alkyl, (C₃-C₇)-cycloalkyl,(C₃-C₇)-cycloalkyl-(C₁-C₄)-alkyl-, (C₆-C₁₄)-aryl which is unsubstitutedor substituted by a residue (C₁-C₂)-alkyl, (C₁-C₂)-alkoxy, fluoro, orchloro; heteroaryl-, (C₆-C₁₄)-aryl-(C₁-C₄)-alkyl- where aryl isunsubstituted or substituted by a residue (C₁-C₂)-alkyl, (C₁-C₂)-alkoxy,fluoro, or chloro; or heteroaryl-(C₁-C₄)-alkyl- and in which R^(y) hasthe meanings indicated for R with the exception of hydrogen or whereinR^(x) and R^(y), together with the nitrogen to which they are bound,form an optionally substituted 4- to 7-membered heterocycloalkyl ringwhich optionally includes one or two additional heteroatoms chosen fromnitrogen, oxygen, and sulfur. A discussion of prodrugs is provided in T.Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 ofthe A.C.S. Symposium Series, in Edward B. Roche, ed., BioreversibleCarriers in Drug Design, American Pharmaceutical Association andPergamon Press, 1987, and in Design of Prodrugs, ed. H. Bundgaard,Elsevier, 1985.

As used herein, the terms “group”, “radical” or “fragment” aresynonymous and are intended to indicate functional groups or fragmentsof molecules attachable to a bond or other fragments of molecules.

As used herein, the term “leaving group” refers to the meaningconventionally associated with it in synthetic organic chemistry, i.e.,an atom or group displaceable under nucleophilic displacementconditions. Examples of leaving groups include, but are not limited to,dimethylhydroxylamino (e.g. Weinreb amide), halogen, alkane- orarylsulfonyloxy, such as methanesulfonyloxy, ethanesulfonyloxy,thiomethyl, benzenesulfonyloxy, tosyloxy, and thienyloxy,dihalophosphinoyloxy, optionally substituted benzyloxy, isopropyloxy,acyloxy, and the like.

As used herein, the term “protective group” or “protecting group” refersto a group which selectively blocks one reactive site in amultifunctional compound such that a chemical reaction can be carriedout selectively at another unprotected reactive site in the meaningconventionally associated with it in synthetic chemistry. Certainprocesses of this invention rely upon the protective groups to blockcertain reactive sites present in the reactants. Examples of protectinggroups can be found in Wuts et al., Green's Protective Groups in OrganicSynthesis, (J. Wiley, 4th ed. 2006).

As used herein, the term “deprotection” or “deprotecting” refers to aprocess by which a protective group is removed after a selectivereaction is completed. Certain protective groups may be preferred overothers due to their convenience or relative ease of removal. Withoutbeing limiting, deprotecting reagents for protected amino or anilinogroup include strong acid such as trifluoroacetic acid (TFA),concentrated HCl, H₂SO₄, or HBr, and the like.

As used herein, “modulation” refers to a change in activity as a director indirect response to the presence of a chemical entity as describedherein, relative to the activity of in the absence of the chemicalentity. The change may be an increase in activity or a decrease inactivity, and may be due to the direct interaction of the compound withthe a target or due to the interaction of the compound with one or moreother factors that in turn affect the target's activity. For example,the presence of the chemical entity may, for example, increase ordecrease the target activity by directly binding to the target, bycausing (directly or indirectly) another factor to increase or decreasethe target activity, or by (directly or indirectly) increasing ordecreasing the amount of target present in the cell or organism.

As used herein, “active agent” is used to indicate a chemical entitywhich has biological activity. In certain embodiments, an “active agent”is a compound having pharmaceutical utility. For example an active agentmay be an anti-cancer therapeutic.

As used herein, “significant” refers to any detectable change that isstatistically significant in a standard parametric test of statisticalsignificance such as Student's T-test, where p<0.05.

As used herein, a “pharmaceutically acceptable” component is one that issuitable for use with humans and/or animals without undue adverse sideeffects (such as toxicity, irritation, and allergic response)commensurate with a reasonable benefit/risk ratio.

As used herein, “therapeutically effective amount” of a chemical entitydescribed herein refers to an amount effective, when administered to ahuman or non-human subject, to provide a therapeutic benefit such asamelioration of symptoms, slowing of disease progression, or preventionof disease.

“Treating” or “treatment” encompasses administration of at least onecompound of Formula I, or a pharmaceutically acceptable salt thereof, toa mammalian subject, particularly a human subject, in need of such anadministration and includes (i) arresting the development of clinicalsymptoms of the disease, such as cancer, (ii) bringing about aregression in the clinical symptoms of the disease, such as cancer,and/or (iii) prophylactic treatment for preventing the onset of thedisease, such as cancer.

As used herein, “cancer” refers to all types of cancer or neoplasm ormalignant tumors found in mammals, including carcinomas and sarcomas.Examples of cancer are cancer of the brain, breast, cervix, colon, head& neck, kidney, lung, non-small cell lung, melanoma, mesothelioma,ovary, sarcoma, stomach, uterus and Medulloblastoma.

As used herein, “subject” refers to a mammal that has been or will bethe object of treatment, observation or experiment. The methodsdescribed herein can be useful in both human therapy and veterinaryapplications. In some embodiments, the subject is a human.

The term “mammal” is intended to have its standard meaning, andencompasses humans, dogs, cats, sheep, and cows, for example.

As used herein, the term EGFR is used to refer the epidermal growthfactor receptor (EGFR), a receptor tyrosine kinase of the ErbB family.The terms “EGFR”, “Her1”, “ErbB1” and the like are used interchangeablyto refer to the gene or protein product of the gene.

A. Compounds

In one aspect, provided is a compound of Formula I

or a pharmaceutically acceptable salt thereof, wherein

is aryl or heteroaryl;

is selected from a group consisting of:

wherein

a is point of attachment for L and

b is point of attachment for G;

X₃ is C—R₃, or N; X₄ is C—R₄, or N; X₅ is C—R₅, or N; X₆ is C—R₁₉, or N;X₇ is C—R₂₀, or N; X₈ is C—R₂₁, or N; Y is O, S, or N—R₂₂;

L is —[(CR₃₀R₃₁)_(x)—O—(CR₃₂R₃₃)_(y)]_(z)—, —[(CR₃₀R₃₁)_(x)]_(z)—,—[(CR₃₀R₃₁)_(x)—S—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—NR₂₉—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CO—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—SO₂—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CO₂—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CONR₂₉—(CR₃₀R₃₁)_(y)]_(z)—, or—[(CR₃₀R₃₁)_(x)—SO₂NR₂₉—(CR₃₀R₃₁)_(y)]_(z)—;

each of R₃, R₄, R₅, R₆, R₁₅, R₁₆, R₁₉, R₂₀, R₂₁, R₃₀, R₃₁, R₃₂, R₃₃, andG is independently hydrogen, cyano, halo, hydroxy, azido, nitro,carboxy, oxo, sulfinyl, sulfanyl, sulfonyl, optionally substitutedalkoxy, optionally substituted cycloalkyloxy, optionally substitutedaryloxy, optionally substituted heteroaryloxy, optionally substitutedheterocycloalkyloxy, optionally substituted alkyl, optionallysubstituted cycloalkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted aryl, optionally substitutedheteroaryl, optionally substituted heterocycloalkyl, optionallysubstituted amino, optionally substituted acyl, optionally substitutedalkoxycarbonyl, optionally substituted aminocarbonyl, optionallysubstituted aminosulfonyl, or optionally substituted carbamimidoyl;

R₁₇, R₁₈, R₂₂, and R₂₉ are independently is independently hydrogen,sulfonyl, optionally substituted alkyl, optionally substitutedcycloalkyl, optionally substituted alkenyl, optionally substitutedalkynyl, optionally substituted aryl, optionally substituted heteroaryl,optionally substituted heterocycloalkyl, optionally substituted acyl,optionally substituted alkoxycarbonyl, optionally substitutedaminocarbonyl, optionally substituted aminosulfonyl, or optionallysubstituted carbamimidoyl;

or R₃ and R₄, R₄ and R₅, R₁₅ and R₁₆, R₁₅ and R₁₇, R₂₀ and R₂₁, R₂₀ andR₂₂, or R₂₁ and R₂₂ may optionally be joined together with anyintervening atoms to form an optionally substituted aryl, heteroaryl,cycloalkyl, or heterocycloalkyl ring;

each Z is independently hydrogen, cyano, halo, hydroxy, azido, nitro,carboxy, oxo, sulfinyl, sulfanyl, sulfonyl, optionally substitutedalkoxy, optionally substituted cycloalkyloxy, optionally substitutedaryloxy, optionally substituted heteroaryloxy, optionally substitutedheterocycloalkyloxy, optionally substituted alkyl, optionallysubstituted cycloalkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted aryl, optionally substitutedheteroaryl, optionally substituted heterocycloalkyl, optionallysubstituted amino, optionally substituted acyl, optionally substitutedalkoxycarbonyl, optionally substituted aminocarbonyl, optionallysubstituted aminosulfonyl, optionally substituted carbamimidoyl, or E;wherein E is an electrophilic group capable of forming a covalent bondwith a nucleophile;

n is 0, 1, 2, 3, 4 or 5; and x, y, or z is independently 0, 1, 2, 3, or4;

provided that when

G is

wherein

is aryl, heteroaryl, or heterocycloalkyl; m is 0, 1, 2, 3, 4, or 5 andeach Q is independently hydrogen, cyano, halo, hydroxy, azido, nitro,carboxy, oxo, sulfinyl, sulfanyl, sulfonyl, optionally substitutedalkoxy, optionally substituted cycloalkyloxy, optionally substitutedaryloxy, optionally substituted heteroaryloxy, optionally substitutedheterocycloalkyloxy, optionally substituted alkyl, optionallysubstituted cycloalkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted aryl, optionally substitutedheteroaryl, optionally substituted heterocycloalkyl, optionallysubstituted amino, optionally substituted acyl, optionally substitutedalkoxycarbonyl, optionally substituted aminocarbonyl, optionallysubstituted aminosulfonyl, optionally substituted carbamimidoyl, or E;and L is —NH—; then n is 1 2, 3, 4, or 5, and at least one Z is E.

In some embodiments, G is cyano, halo, optionally substituted alkoxy,optionally substituted cycloalkyloxy, optionally substituted aryloxy,optionally substituted heteroaryloxy, optionally substitutedheterocycloalkyloxy, optionally substituted alkyl, optionallysubstituted cycloalkyl, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted heterocycloalkyl,optionally substituted amino, optionally substituted acyl, optionallysubstituted alkoxycarbonyl, optionally substituted aminocarbonyl,optionally substituted aminosulfonyl. In some embodiments, G is halo oroptionally substituted alkoxy. In some embodiments, G is optionallysubstituted aryl, optionally substituted heteroaryl, or optionallysubstituted heterocycloalkyl.

In some embodiments,

is selected from the group consisting of: pyrrolyl, furanyl, thienyl,imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,1,2,3-triazolyl, 1,2,4-triazolyl, furazanyl, 1,2,3-oxadiazolyl,1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, thiadiazolyl,dithiazolyl, tetrazolyl, pyridinyl, pyranyl, thiopyranyl, diazinyl,pyrazinyl, pyrimidinyl, pyridazinyl, oxazinyl, thiazinyl, dioxinyl,dithiinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl,tetrazinyl, and phenyl; For example

is selected from the group consisting of: phenyl, pyridinyl,pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl, pyrazolyl,isoxazolyl, and thienyl. In some embodiments,

is phenyl or pyridinyl.

In some embodiments,

is selected from the group consisting of:

In some embodiments,

is selected from the group consisting of:

In some embodiments,

is selected from the group consisting of:

In some embodiments,

is selected from the group consisting of:

In some embodiments,

is selected from the group consisting of:

In some embodiments,

is selected from the group consisting of:

In some embodiments,

is selected from the group consisting of:

In some embodiments, L is —[(CR₃₀R₃₁)_(x)—O—(CR₃₂R₃₃)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)]_(z)—, —[(CR₃₀R₃₁)_(x)—S—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—NR₂₉—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CO—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—SO₂—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CO₂—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CONR₂₉—(CR₃₀R₃₁)_(y)]_(z)—, or—[(CR₃₀R₃₁)_(x)—SO₂NR₂₉—(CR₃₀R₃₁)_(y)]_(z)—; In some embodiments, L is—O—, —CH₂—, —NH—, —S—, —CO—, —CO₂—, —CONH—, SO₂—, —SO₂NH—; In someembodiments, L is —NH—.

In some embodiments each, Z is independently hydrogen, cyano, halo,optionally substituted amino, optionally substituted alkoxy, optionallysubstituted cycloalkyloxy, optionally substituted aryloxy, optionallysubstituted heteroaryloxy, optionally substituted heterocycloalkyloxy,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted aryloxy, optionally substituted heterocycloalkyl,optionally substituted aminocarbonyl, or E.

In some embodiments each, Z is independently hydrogen, cyano, halo,optionally substituted alkoxy, optionally substitutedheterocycloalkyloxy, optionally substituted heterocycloalkyl, oroptionally substituted amino, optionally substituted aminocarbonyl, orE.

In some embodiments, n is 1, 2, 3, 4, or 5; and at least one Z is cyano,fluoro, chloro, methoxy, —CONH₂, 2-methoxyethoxy,2-(dimethylamino)ethoxy, (1-methylpyrrolidin-3-yl)oxy,(1-methylpiperidin-4-yl)oxy, (1-methylpiperidin-3-yl)oxy,(1-methylazetidin-3-yl)oxy (2-(dimethylamino)ethyl)(methyl)amino,dimethylamino, methyl(1-methylazetidin-3-yl)amino,methyl(1-methylpyrrolidin-3-yl)amino,methyl(1-methylpiperidin-4-yl)amino, optionally substituted morpholinyl,optionally substituted piperazinyl, optionally substituted pyrrolidinyl,optionally substituted piperidinyl, optionally substituted azetidinyl.

In some embodiments, n is 1, 2, 3, 4, or 5; and at least one Z is E.

In some embodiments, each E is independently an electrophilic groupcapable of forming a covalent bond with a cysteine residue of a protein.

In some embodiments, each E is independently selected from a groupconsisting of

In some embodiments, at least one E is

In some embodiments, E at least one is

In some embodiments, at least one E is

In another aspect, the present disclosure provides the compound orpharmaceutically acceptable salt of Formula I wherein

X₁₀ is C—R₃₅, or N; and R₃₄, R₃₅, R₃₆, R₃₇, and R₃₈ are independentlyhydrogen, cyano, halo, hydroxy, azido, nitro, carboxy, sulfinyl,sulfanyl, sulfonyl, optionally substituted alkoxy, optionallysubstituted cycloalkyloxy, optionally substituted aryloxy, optionallysubstituted heteroaryloxy, optionally substituted heterocycloalkyloxy,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted aryl, optionally substituted heteroaryl,optionally substituted heterocycloalkyl, optionally substituted amino,optionally substituted acyl, optionally substituted alkoxycarbonyl,optionally substituted aminocarbonyl, optionally substitutedaminosulfonyl, optionally substituted carbamimidoyl, or E.

In some embodiments, R₃₄, R₃₅, R₃₆, R₃₇, and R₃₈ are independentlyhydrogen, cyano, halo, optionally substituted alkoxy, optionallysubstituted heterocycloalkyloxy, optionally substitutedheterocycloalkyl, optionally substituted amino, optionally substitutedaminocarbonyl, or E. In some embodiments, wherein R₃₅ or R₃₇ is E. Insome embodiments, R₃₅ or R₃₇ is

In some embodiments, R₃₅ or R₃₇ is

In some embodiments, R₃₄, R₃₅, R₃₇, and R₃₈ are independently hydrogen,cyano, fluoro, chloro, methoxy, or —CONH₂, and R₃₆ is optionallysubstituted morpholinyl, optionally substituted piperazinyl, optionallysubstituted pyrrolidinyl, optionally substituted piperidinyl, optionallysubstituted azetidinyl, or substituted amino.

In some embodiments, R₃₆ is

wherein R₂₈ is hydrogen, sulfonyl, optionally substituted alkyl,optionally substituted cycloalkyl, optionally substituted alkenyl,optionally substituted alkynyl, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted heterocycloalkyl,optionally substituted amino, optionally substituted acyl, optionallysubstituted alkoxycarbonyl, optionally substituted aminocarbonyl,optionally substituted aminosulfonyl, or optionally substitutedcarbamimidoyl. In some embodiments, R₂₈ is —C(O)C₁-C₄ alkyl or C₁-C₆alkyl optionally substituted with —OH, halo, C₁-C₄ alkyl, or —OC₁-C₄alkyl. In some embodiments, R₂₈ is —CH₃, —COCH₃, —CH₂CH₂OH, —CH₂CH₂F,—CH₂CH₂OMe, —CH₂C(CH₃)₂OH, or —CH₂CH(CH₃)OH.

In some embodiments, the compound or pharmaceutically acceptable salthas the Formula Ia:

wherein

Z, L, and n are as defined for Formula I;

is optionally substituted aryl, optionally substituted heteroaryl, oroptionally substituted heterocycloalkyl;

each Q is independently hydrogen, cyano, halo, hydroxy, azido, nitro,carboxy, oxo, sulfinyl, sulfanyl, sulfonyl, optionally substitutedalkoxy, optionally substituted cycloalkyloxy, optionally substitutedaryloxy, optionally substituted heteroaryloxy, optionally substitutedheterocycloalkyloxy, optionally substituted alkyl, optionallysubstituted cycloalkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted aryl, optionally substitutedheteroaryl, optionally substituted heterocycloalkyl, optionallysubstituted amino, optionally substituted acyl, optionally substitutedalkoxycarbonyl, optionally substituted aminocarbonyl, optionallysubstituted aminosulfonyl, optionally substituted carbamimidoyl, or E;wherein E each is independently an electrophilic group capable offorming a covalent bond with a nucleophile; and m is 0, 1, 2, 3, 4, or5.

In some embodiments,

is selected from the group consisting of: piperazinyl, morpholinyl,piperidinyl, thiomorpholinyl, pyrrolidinyl, tetrahydrofuranyl,diazepanyl, azetidinyl, oxetanyl, oxiranyl, aziridinyl, pyrrolyl,furanyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl,thiazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, furazanyl,1,2,3-oxadiazolyl, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole,thiadiazolyl, dithiazolyl, tetrazolyl, pyridinyl, pyranyl, thiopyranyl,diazinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazinyl, thiazinyl,dioxinyl, dithiinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl,tetrazinyl, and phenyl. In some embodiments,

is selected from the group consisting of: phenyl, pyridinyl,pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl, pyrazolyl,isoxazolyl, and thienyl. In other embodiments,

is phenyl or pyridinyl. In some embodiments,

is selected from the group consisting of: piperazinyl, morpholinyl,piperidinyl, thiomorpholinyl, pyrrolidinyl, tetrahydrofuranyl,diazepanyl, azetidinyl, oxetanyl, oxiranyl, aziridinyl. In someembodiments,

is selected from the group consisting of: piperazinyl, morpholinyl,piperidinyl, pyrrolidinyl, and tetrahydrofuranyl, and diazepanyl. Insome embodiments

is selected from the group consisting of: piperazinyl, morpholinyl,piperidinyl, and pyrrolidinyl. In some embodiments,

is attached to the core via a carbon-carbon bond. In some embodiments,

is attached to the core via a carbon-nitrogen bond. In some embodiments,

is selected from the group consisting of:

wherein each W is independently selected from the group consisting ofhydrogen, cyano, halo, hydroxy, azido, nitro, carboxy, oxo, sulfinyl,sulfanyl, sulfonyl, optionally substituted alkoxy, optionallysubstituted cycloalkyloxy, optionally substituted aryloxy, optionallysubstituted heteroaryloxy, optionally substituted heterocycloalkyloxy,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted aryloxy, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted heterocycloalkyl,optionally substituted amino, optionally substituted acyl, optionallysubstituted alkoxycarbonyl, optionally substituted aminocarbonyl,optionally substituted aminosulfonyl, optionally substitutedcarbamimidoyl, or E; wherein each E is independently an electrophilicgroup capable of forming a covalent bond with a nucleophile. In someembodiments, W is E; wherein E is an electrophilic group capable offorming a covalent bond with a nucleophile. In some embodiments, atleast one W is E. In some embodiments, W is selected from the groupconsisting of H, optionally substituted alkyl, and

In some embodiments, each W is selected from the group consisting of H,C₁-C₄ alkyl, and

In some embodiments, at least one Q is E; wherein E is an electrophilicgroup capable of forming a covalent bond with a cysteine residue of aprotein. In some embodiments, each E is independently selected from

For example, in some embodiments, at least one E is

In some embodiments, at least one E is

In some embodiments, at least one E is

In some embodiments,

X₁₁ is C—R₂₇, or N; and

R₂₃, R₂₄, R₂₅, R₂₆, and R₂₇ are independently, hydrogen, cyano, halo,hydroxy, azido, nitro, carboxy, oxo, sulfinyl, sulfanyl, sulfonyl,optionally substituted alkoxy, optionally substituted cycloalkyloxy,optionally substituted aryloxy, optionally substituted heteroaryloxy,optionally substituted heterocycloalkyloxy, optionally substitutedalkyl, optionally substituted cycloalkyl, optionally substitutedalkenyl, optionally substituted alkynyl, optionally substituted aryl,optionally substituted heteroaryl, optionally substitutedheterocycloalkyl, optionally substituted amino, optionally substitutedacyl, optionally substituted alkoxycarbonyl, optionally substitutedaminocarbonyl, optionally substituted aminosulfonyl, or optionallysubstituted carbamimidoyl, or E;

In some embodiments, R₂₃, R₂₄, R₂₅, R₂₆, and R₂₇ are independentlyhydrogen, cyano, halo, optionally substituted alkoxy, optionallysubstituted amino, optionally substituted aminocarbonyl, or E. In someembodiments, R₂₄, R₂₅, or R₂₆ is E. In some embodiments, R₂₄, R₂₅, orR₂₆ is

In some embodiments, R₂₄, R₂₅, or R₂₆ is

In some embodiments, R₂₃, R₂₅, R₂₆, and R₂₇ are independently hydrogen,cyano, halo, optionally substituted alkoxy, optionally substitutedamino, optionally substituted aminocarbonyl, and R₂₄ is E. In someembodiments, R₂₃, R₂₅, R₂₆, and R₂₇ are independently hydrogen, cyano,halo, methoxy, or —CONH₂, and R₂₄ is E.

In some embodiments, R₂₃, R₂₄, R₂₆, and R₂₇ are independently hydrogen,cyano, halo, optionally substituted alkoxy, optionally substitutedamino, optionally substituted aminocarbonyl, and R₂₅ is E. In someembodiments, R₂₃, R₂₄, R₂₆, and R₂₇ are independently hydrogen, cyano,halo, methoxy, or —CONH₂, and R₂₅ is E.

In some embodiments, the compound or pharmaceutically acceptable salthas the Formula Ib:

wherein

Z, L, R₆, X₆, X₅, X₄, X₃, G and n are as defined for Formula I.

In some embodiments, X₃, X₄ and X₅ are respectively C—R₃, C—R₄, andC—R₅. In some embodiments, X₅, X₄ and X₃ are respectively N, C—R₄, andC—R₃. In some embodiments, X₅, X₄ and X₃ are respectively C—R₅, N, andC—R₃. In some embodiments, X₅, X₄ and X₃ are respectively C—R₅, C—R₄,and N. In some embodiments, X₅, X₄ and X₃ are respectively N, C—R4, andN.

In some embodiments, n is 1, 2, 3, 4, or 5; and at least one Z is E.

In some embodiments, the compound or pharmaceutically acceptable salthas the Formula Ic:

wherein E, R₃₄, R₃₆, R₃₇, R₃₈, R₃, R₄, R₅, R₆ and G are as describedabove for Formula I.

In some embodiments, R₆, R₃, R₄, and R₅ are independently hydrogen,cyano, halo, optionally substituted alkoxy, optionally substitutedheterocycloalkyloxy, optionally substituted heterocycloalkyl, optionallysubstituted amino, or optionally substituted aminocarbonyl. In someembodiments, R₃, R₄, and R₅ are independently hydrogen, cyano, fluoro,chloro, methyl, hydroxymethyl, —CH₂F, —CONH₂, or methoxy.

In some embodiments, G is halo or optionally substituted alkoxy,optionally substituted aryl, optionally substituted heteroaryl, oroptionally substituted heterocycloalkyl. In some embodiments, G isoptionally substituted aryl. In some embodiments, G is optionallysubstituted phenyl or pyridinyl.

In some embodiments, R₃₄, R₃₇, and R₃₈ are independently hydrogen,cyano, halo, optionally substituted alkoxy, optionally substitutedheterocycloalkyloxy, optionally substituted heterocycloalkyl, optionallysubstituted amino, or optionally substituted aminocarbonyl. In someembodiments, R₃₄, R₃₇, and R₃₈ are independently hydrogen, cyano,fluoro, chloro, methoxy, or —CONH₂.

In some embodiments, R₃₆ is optionally substituted alkoxy, optionallysubstituted heterocycloalkyloxy, optionally substitutedheterocycloalkyl, or optionally substituted amino.

In some embodiments, R₃₆ is methoxy, 2-methoxyethoxy,2-(dimethylamino)ethoxy, (1-methylpyrrolidin-3-yl)oxy,(1-methylpiperidin-4-yl)oxy, (1-methylpiperidin-3-yl)oxy,(1-methylazetidin-3-yl)oxy (2-(dimethylamino)ethyl)(methyl)amino,dimethylamino, methyl(1-methylazetidin-3-yl)amino,methyl(1-methylpyrrolidin-3-yl)amino,methyl(1-methylpiperidin-4-yl)amino, optionally substituted morpholinyl,optionally substituted piperazinyl, optionally substituted pyrrolidinyl,optionally substituted piperidinyl, or optionally substitutedazetidinyl.

In some embodiments, E is selected from a group consisting of

In some embodiments, E is

In some embodiments, E is

In some embodiments, at least one E is

In some embodiments, the compound or pharmaceutically acceptable salthas the Formula Id:

wherein

X₁₀, X₁₁, R₂₃, R₂₅, R₂₆, R₃₄, R₃₆, R₃₇, R₃₈ and E are as defined forFormula I.

In some embodiments, X₁₀ is C—R₂₅, or N. In some embodiments, X₁₁ isC—R₂₇, or N.

In some embodiments, R₃₄, R₃₇, and R₃₈ are independently hydrogen,cyano, fluoro, chloro, methoxy, or —CONH₂, and R₃₆ is optionallysubstituted morpholinyl, optionally substituted piperazinyl, optionallysubstituted pyrrolidinyl, optionally substituted piperidinyl, optionallysubstituted azetidinyl, or substituted amino.

In some embodiments, R₃₆ is

wherein R₂₈ is hydrogen, sulfonyl, optionally substituted alkyl,optionally substituted cycloalkyl, optionally substituted alkenyl,optionally substituted alkynyl, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted heterocycloalkyl,optionally substituted amino, optionally substituted acyl, optionallysubstituted alkoxycarbonyl, optionally substituted aminocarbonyl,optionally substituted aminosulfonyl, or optionally substitutedcarbamimidoyl. In some embodiments, R₂sis —C(O)C₁-C₄ alkyl or C₁-C₆alkyl optionally substituted with —OH, halo, C₁-C₄ alkyl, or —OC₁-C₄alkyl. In some embodiments, R₂₈ is —CH₃, —COCH₃, —CH₂CH₂OH, —CH₂CH₂F,—CH₂CH₂OMe, —CH₂C(CH₃)₂OH, or —CH₂CH(CH₃)OH.

In some embodiments, E is selected from a group consisting of

In some embodiments, E is

In some embodiments, E is

In some embodiments, at least one E is

In one aspect, provided is a compound of Formula Ie:

wherein:

is aryl or heteroaryl;

is selected from a group consisting of:

wherein

a is point of attachment for L and

b is point of attachment for

X₆ is C—R₁₉, or N;

X₇ is C—R₂₀, or N;

X₈ is C—R₂₁, or N;

Y is O, S, or N—R₂₂;

L is —[(CR₃₀R₃₁)_(x)—O—(CR₃₂R₃₃)_(y)]_(z)—, —[(CR₃₀R₃₁)_(x)]_(z)—,—[(CR₃₀R₃₁)_(x)—S—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—NR₂₉—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CO—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—SO₂—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CO₂—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CONR₂₉—(CR₃₀R₃₁)_(y)]_(z)—, or—[(CR₃₀R₃₁)_(x)—SO₂NR₂₉—(CR₃₀R₃₁)_(y)]_(z)—;

each of R₆, R₁₉, R₂₀, R₂₁, R₃₀, R₃₁, R₃₂, R₃₃ is independently hydrogen,cyano, halo, hydroxy, azido, nitro, carboxy, oxo, sulfinyl, sulfanyl,sulfonyl, optionally substituted alkoxy, optionally substitutedcycloalkyloxy, optionally substituted aryloxy, optionally substitutedheteroaryloxy, optionally substituted heterocycloalkyloxy, optionallysubstituted alkyl, optionally substituted cycloalkyl, optionallysubstituted alkenyl, optionally substituted alkynyl, optionallysubstituted aryl, optionally substituted heteroaryl, optionallysubstituted heterocycloalkyl, optionally substituted amino, optionallysubstituted acyl, optionally substituted alkoxycarbonyl, optionallysubstituted aminocarbonyl, optionally substituted aminosulfonyl, oroptionally substituted carbamimidoyl;

R₂₂, and R₂₉ are independently is independently hydrogen, sulfonyl,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted aryl, optionally substituted heteroaryl,optionally substituted heterocycloalkyl, optionally substituted acyl,optionally substituted alkoxycarbonyl, optionally substitutedaminocarbonyl, optionally substituted aminosulfonyl, or optionallysubstituted carbamimidoyl;

or R₂₀ and R₂₁, R₂₀ and R₂₂, or R₂₁ and R₂₂ may optionally be joinedtogether with any intervening atoms to form an optionally substitutedaryl, heteroaryl, cycloalkyl, or heterocycloalkyl ring;

each Z is independently hydrogen, cyano, halo, hydroxy, azido, nitro,carboxy, oxo, sulfinyl, sulfanyl, sulfonyl, optionally substitutedalkoxy, optionally substituted cycloalkyloxy, optionally substitutedaryloxy, optionally substituted heteroaryloxy, optionally substitutedheterocycloalkyloxy, optionally substituted alkyl, optionallysubstituted cycloalkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted aryl, optionally substitutedheteroaryl, optionally substituted heterocycloalkyl, optionallysubstituted amino, optionally substituted acyl, optionally substitutedalkoxycarbonyl, optionally substituted aminocarbonyl, optionallysubstituted aminosulfonyl, optionally substituted carbamimidoyl, or E;wherein E is an electrophilic group capable of forming a covalent bondwith a nucleophile;

is optionally substituted aryl, optionally substituted heteroaryl, oroptionally substituted heterocycloalkyl;

each Q is independently hydrogen, cyano, halo, hydroxy, azido, nitro,carboxy, oxo, sulfinyl, sulfanyl, sulfonyl, optionally substitutedalkoxy, optionally substituted cycloalkyloxy, optionally substitutedaryloxy, optionally substituted heteroaryloxy, optionally substitutedheterocycloalkyloxy, optionally substituted alkyl, optionallysubstituted cycloalkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted aryl, optionally substitutedheteroaryl, optionally substituted heterocycloalkyl, optionallysubstituted amino, optionally substituted acyl, optionally substitutedalkoxycarbonyl, optionally substituted aminocarbonyl, optionallysubstituted aminosulfonyl, optionally substituted carbamimidoyl, or E;wherein E each is independently an electrophilic group capable offorming a covalent bond with a nucleophile;

m is 0, 1, 2, 3, 4, or 5;

n is 0, 1, 2, 3, 4 or 5; and

each of x, y, or z is independently 0, 1, 2, 3, or 4.

In some embodiments,

is selected from the group consisting of piperazinyl, morpholinyl,piperidinyl, thiomorpholinyl, pyrrolidinyl, tetrahydrofuranyl,diazepanyl, azetidinyl, oxetanyl, oxiranyl, aziridinyl, pyrrolyl,furanyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl,thiazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, furazanyl,1,2,3-oxadiazolyl, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole,thiadiazolyl, dithiazolyl, tetrazolyl, pyridinyl, pyranyl, thiopyranyl,diazinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazinyl, thiazinyl,dioxinyl, dithiinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl,tetrazinyl, and phenyl. In some embodiments,

is selected from the group consisting of phenyl, pyridinyl, pyrimidinyl,pyrazinyl, thiazolyl, oxazolyl, imidazolyl, pyrazolyl, isoxazolyl, andthienyl. In other embodiments,

is phenyl or pyridinyl. In some embodiments,

is selected from the group consisting of piperazinyl, morpholinyl,piperidinyl, thiomorpholinyl, pyrrolidinyl, tetrahydrofuranyl,diazepanyl, azetidinyl, oxetanyl, oxiranyl, aziridinyl. In someembodiments,

is selected from the group consisting of piperazinyl, morpholinyl,piperidinyl, pyrrolidinyl, and tetrahydrofuranyl, and diazepanyl. Insome embodiments,

is selected from the group consisting of piperazinyl, morpholinyl,piperidinyl, and pyrrolidinyl. In some embodiments,

is attached to the core via a carbon-carbon bond. In some embodiments,

is attached to the core via a carbon-nitrogen bond. In some embodiments,

is selected from the group consisting of:

wherein each W is independently selected from the group consisting ofhydrogen, cyano, halo, hydroxy, azido, nitro, carboxy, oxo, sulfinyl,sulfanyl, sulfonyl, optionally substituted alkoxy, optionallysubstituted cycloalkyloxy, optionally substituted aryloxy, optionallysubstituted heteroaryloxy, optionally substituted heterocycloalkyloxy,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted aryloxy, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted heterocycloalkyl,optionally substituted amino, optionally substituted acyl, optionallysubstituted alkoxycarbonyl, optionally substituted aminocarbonyl,optionally substituted aminosulfonyl, optionally substitutedcarbamimidoyl, or E; wherein each E is independently an electrophilicgroup capable of forming a covalent bond with a nucleophile. In someembodiments, W is E; wherein E is an electrophilic group capable offorming a covalent bond with a nucleophile. In some embodiments, atleast one W is E. In some embodiments, W is selected from the groupconsisting of H, optionally substituted alkyl, and

In some embodiments, W is selected from the group consisting of H, C₁-C₄alkyl, and

In some embodiments, at least one Q is E; wherein E is an electrophilicgroup capable of forming a covalent bond with a cysteine residue of aprotein. In some embodiments, each E is independently selected from

For example, in some embodiments, at least one E is

In some embodiments, at least one E is

In some embodiments, at least one E is

In some embodiments,

X₁₁ is C—R₂₇, or N; and

R₂₃, R₂₄, R₂₅, R₂₆, and R₂₇ are independently, hydrogen, cyano, halo,hydroxy, azido, nitro, carboxy, oxo, sulfinyl, sulfanyl, sulfonyl,optionally substituted alkoxy, optionally substituted cycloalkyloxy,optionally substituted aryloxy, optionally substituted heteroaryloxy,optionally substituted heterocycloalkyloxy, optionally substitutedalkyl, optionally substituted cycloalkyl, optionally substitutedalkenyl, optionally substituted alkynyl, optionally substituted aryl,optionally substituted heteroaryl, optionally substitutedheterocycloalkyl, optionally substituted amino, optionally substitutedacyl, optionally substituted alkoxycarbonyl, optionally substitutedaminocarbonyl, optionally substituted aminosulfonyl, or optionallysubstituted carbamimidoyl, or E.

In some embodiments, R₂₃, R₂₄, R₂₅, R₂₆, and R₂₇ are independentlyhydrogen, cyano, halo, optionally substituted alkoxy, optionallysubstituted amino, optionally substituted aminocarbonyl, or E. In someembodiments, R₂₄, R₂₅, or R₂₆ is E. In some embodiments, R₂₄, R₂₅, orR₂₆ is

In some embodiments, R₂₄, R₂₅, or R₂₆ is

In some embodiments, R₂₄, R₂₅, or R₂₆ is

In some embodiments, R₂₃, R₂₅, R₂₆, and R₂₇ are independently hydrogen,cyano, halo, optionally substituted alkoxy, optionally substitutedamino, optionally substituted aminocarbonyl, and R₂₄ is E. In someembodiments, R₂₃, R₂₅, R₂₆, and R₂₇ are independently hydrogen, cyano,halo, methoxy, or —CONH₂, and R₂₄ is E.

In some embodiments, R₂₃, R₂₄, R₂₆, and R₂₇ are independently hydrogen,cyano, halo, optionally substituted alkoxy, optionally substitutedamino, optionally substituted aminocarbonyl, and R₂₅ is E. In someembodiments, R₂₃, R₂₄, R₂₆, and R₂₇ are independently hydrogen, cyano,halo, methoxy, or —CONH₂, and R₂₅ is E.

In some embodiment,

X₁₀ is C—R₃₅, or N; and R₃₄, R₃₅, R₃₆, R₃₇, and R₃₈ are independentlyhydrogen, cyano, halo, hydroxy, azido, nitro, carboxy, sulfinyl,sulfanyl, sulfonyl, optionally substituted alkoxy, optionallysubstituted cycloalkyloxy, optionally substituted aryloxy, optionallysubstituted heteroaryloxy, optionally substituted heterocycloalkyloxy,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted aryl, optionally substituted heteroaryl,optionally substituted heterocycloalkyl, optionally substituted amino,optionally substituted acyl, optionally substituted alkoxycarbonyl,optionally substituted aminocarbonyl, optionally substitutedaminosulfonyl, optionally substituted carbamimidoyl, or E.

In some embodiments, R₃₄, R₃₅, R₃₆, R₃₇, and R₃₈ are independentlyhydrogen, cyano, halo, optionally substituted alkoxy, optionallysubstituted heterocycloalkyloxy, optionally substitutedheterocycloalkyl, optionally substituted amino, optionally substitutedaminocarbonyl, or E. In some embodiments, wherein R₃₅ or R₃₇ is E. Insome embodiments, R₃₈ or R₃₇ is

In some embodiments, R₃₅ or R₃₇ is

In some embodiments, R₃₅ or R₃₇ is

In some embodiments, R₃₄, R₃₅, R₃₇, and R₃₈ are independently hydrogen,cyano, fluoro, chloro, methoxy, or —CONH₂, and R₃₆ is optionallysubstituted morpholinyl, optionally substituted piperazinyl, optionallysubstituted pyrrolidinyl, optionally substituted piperidinyl, optionallysubstituted azetidinyl, or substituted amino.

In some embodiments, R₃₆ is

wherein R₂₈ is hydrogen, sulfonyl, optionally substituted alkyl,optionally substituted cycloalkyl, optionally substituted alkenyl,optionally substituted alkynyl, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted heterocycloalkyl,optionally substituted amino, optionally substituted acyl, optionallysubstituted alkoxycarbonyl, optionally substituted aminocarbonyl,optionally substituted aminosulfonyl, or optionally substitutedcarbamimidoyl. In some embodiments, R₂₈ is —C(O)C₁-C₄ alkyl or C₁-C₆alkyl optionally substituted with —OH, halo, C₁-C₄ alkyl, or —OC₁-C₄alkyl. In some embodiments, R₂₈ is —CH₃, —COCH₃, —CH₂CH₂OH, —CH₂CH₂F,—CH₂CH₂OMe, —CH₂C(CH₃)₂OH, or —CH₂CH(CH₃)OH.

In some embodiments,

is selected from the group consisting of pyrrolyl, furanyl, thienyl,imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,1,2,3-triazolyl, 1,2,4-triazolyl, furazanyl, 1,2,3-oxadiazolyl,1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, thiadiazolyl,dithiazolyl, tetrazolyl, pyridinyl, pyranyl, thiopyranyl, diazinyl,pyrazinyl, pyrimidinyl, pyridazinyl, oxazinyl, thiazinyl, dioxinyl,dithiinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl,tetrazinyl, and phenyl; For example

is selected from the group consisting of phenyl, pyridinyl, pyrimidinyl,pyrazinyl, thiazolyl, oxazolyl, imidazolyl, pyrazolyl, isoxazolyl, andthienyl. In some embodiments,

is phenyl or pyridinyl.

In some embodiments

is selected from the group consisting of:

In some embodiments,

is selected from the group consisting of:

In some embodiments,

is selected from the group consisting of:

In some embodiments,

is selected from the group consisting of:

In some embodiments, L is —[(CR₃₀R₃₁)_(x)—O—(CR₃₂R₃₃)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)]_(z)—, —[(CR₃₀R₃₁)_(x)—S—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—NR₂₉—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CO—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—SO₂—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CO₂—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CONR₂₉—(CR₃₀R₃₁)_(y)]_(z)—, or—[(CR₃₀R₃₁)_(x)—SO₂NR₂₉—(CR₃₀R₃₁)_(y)]_(z)—; In some embodiments, L is—O—, —CH₂—, —NH—, —S—, —CO—, —CO₂—, —CONH—, SO₂—, —SO₂NH—. In someembodiments, L is —NH—.

In some embodiments each, Z is independently hydrogen, cyano, halo,optionally substituted amino, optionally substituted alkoxy, optionallysubstituted cycloalkyloxy, optionally substituted aryloxy, optionallysubstituted heteroaryloxy, optionally substituted heterocycloalkyloxy,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted aryloxy, optionally substituted heterocycloalkyl,optionally substituted aminocarbonyl, or E.

In some embodiments each, Z is independently hydrogen, cyano, halo,optionally substituted alkoxy, optionally substitutedheterocycloalkyloxy, optionally substituted heterocycloalkyl, oroptionally substituted amino, optionally substituted aminocarbonyl, orE.

In some embodiments, n is 1, 2, 3, 4, or 5; and at least one Z is cyano,fluoro, chloro, methoxy, —CONH₂, 2-methoxyethoxy,2-(dimethylamino)ethoxy, (1-methylpyrrolidin-3-yl)oxy,(1-methylpiperidin-4-yl)oxy, (1-methylpiperidin-3-yl)oxy,(1-methylazetidin-3-yl)oxy (2-(dimethylamino)ethyl)(methyl)amino,dimethylamino, methyl(1-methylazetidin-3-yl)amino,methyl(1-methylpyrrolidin-3-yl)amino,methyl(1-methylpiperidin-4-yl)amino, optionally substituted morpholinyl,optionally substituted piperazinyl, optionally substituted pyrrolidinyl,optionally substituted piperidinyl, optionally substituted azetidinyl.

In some embodiments, n is 1, 2, 3, 4, or 5; and at least one Z is E.

In some embodiments, each E is independently an electrophilic groupcapable of forming a covalent bond with a cysteine residue of a protein.

In some embodiments, each E is independently selected from a groupconsisting of

In some embodiments, at least one E is

In some embodiments, E at least one is

In some embodiments, at least one E is

In one aspect, provided is a compound of Formula If:

or a pharmaceutically acceptable salt thereof, wherein:

is aryl or heteroaryl;

L is —[(CR₃₀R₃₁)_(x)—O—(CR₃₂R₃₃)_(y)]_(z)—, —[(CR₃₀R₃₁)_(x)]_(z)—,—[(CR₃₀R₃₁)_(x)—S—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—NR₂₉—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CO—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—SO₂—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CO₂—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CONR₂₉—(CR₃₀R₃₁)_(y)]_(z)—, or—[(CR₃₀R₃₁)_(x)—SO₂NR₂₉—(CR₃₀R₃₁)_(y)]_(z)—;

each of R₃₀, R₃₁, R₃₂, R₃₃ is independently hydrogen, cyano, halo,hydroxy, azido, nitro, carboxy, oxo, sulfinyl, sulfanyl, sulfonyl,optionally substituted alkoxy, optionally substituted cycloalkyloxy,optionally substituted aryloxy, optionally substituted heteroaryloxy,optionally substituted heterocycloalkyloxy, optionally substitutedalkyl, optionally substituted cycloalkyl, optionally substitutedalkenyl, optionally substituted alkynyl, optionally substituted aryl,optionally substituted heteroaryl, optionally substitutedheterocycloalkyl, optionally substituted amino, optionally substitutedacyl, optionally substituted alkoxycarbonyl, optionally substitutedaminocarbonyl, optionally substituted aminosulfonyl, or optionallysubstituted carbamimidoyl;

R₂₉ are independently is hydrogen, sulfonyl, optionally substitutedalkyl, optionally substituted cycloalkyl, optionally substitutedalkenyl, optionally substituted alkynyl, optionally substituted aryl,optionally substituted heteroaryl, optionally substitutedheterocycloalkyl, optionally substituted acyl, optionally substitutedalkoxycarbonyl, optionally substituted aminocarbonyl, optionallysubstituted aminosulfonyl, or optionally substituted carbamimidoyl;

each Z is independently hydrogen, cyano, halo, hydroxy, azido, nitro,carboxy, oxo, sulfinyl, sulfanyl, sulfonyl, optionally substitutedalkoxy, optionally substituted cycloalkyloxy, optionally substitutedaryloxy, optionally substituted heteroaryloxy, optionally substitutedheterocycloalkyloxy, optionally substituted alkyl, optionallysubstituted cycloalkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted aryl, optionally substitutedheteroaryl, optionally substituted heterocycloalkyl, optionallysubstituted amino, optionally substituted acyl, optionally substitutedalkoxycarbonyl, optionally substituted aminocarbonyl, optionallysubstituted aminosulfonyl, optionally substituted carbamimidoyl, or E;wherein E is an electrophilic group capable of forming a covalent bondwith a nucleophile;

is optionally substituted aryl, optionally substituted heteroaryl, oroptionally substituted heterocycloalkyl;

each Q is independently hydrogen, cyano, halo, hydroxy, azido, nitro,carboxy, oxo, sulfinyl, sulfanyl, sulfonyl, optionally substitutedalkoxy, optionally substituted cycloalkyloxy, optionally substitutedaryloxy, optionally substituted heteroaryloxy, optionally substitutedheterocycloalkyloxy, optionally substituted alkyl, optionallysubstituted cycloalkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted aryl, optionally substitutedheteroaryl, optionally substituted heterocycloalkyl, optionallysubstituted amino, optionally substituted acyl, optionally substitutedalkoxycarbonyl, optionally substituted aminocarbonyl, optionallysubstituted aminosulfonyl, optionally substituted carbamimidoyl, or E;wherein E each is independently an electrophilic group capable offorming a covalent bond with a nucleophile;

m is 0, 1, 2, 3, 4, or 5;

n is 0, 1, 2, 3, 4 or 5; and

each of x, y, or z is independently 0, 1, 2, 3, or 4.

In some embodiments,

is selected from the group consisting of: piperazinyl, morpholinyl,piperidinyl, thiomorpholinyl, pyrrolidinyl, tetrahydrofuranyl,diazepanyl, azetidinyl, oxetanyl, oxiranyl, aziridinyl, pyrrolyl,furanyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl,thiazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, furazanyl,1,2,3-oxadiazolyl, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole,thiadiazolyl, dithiazolyl, tetrazolyl, pyridinyl, pyranyl, thiopyranyl,diazinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazinyl, thiazinyl,dioxinyl, dithiinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl,tetrazinyl, and phenyl. In some embodiments

is selected from the group consisting of: phenyl, pyridinyl,pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl, pyrazolyl,isoxazolyl, and thienyl. In other embodiments,

is phenyl or pyridinyl. In some embodiments,

is selected from the group consisting of: piperazinyl, morpholinyl,piperidinyl, thiomorpholinyl, pyrrolidinyl, tetrahydrofuranyl,diazepanyl, azetidinyl, oxetanyl, oxiranyl, aziridinyl. In someembodiments,

is selected from the group consisting of: piperazinyl, morpholinyl,piperidinyl, pyrrolidinyl, and tetrahydrofuranyl, and diazepanyl. Insome embodiments,

is selected from the group consisting of: piperazinyl, morpholinyl,piperidinyl, and pyrrolidinyl. In some embodiments,

is attached to the core via a carbon-carbon bond. In some embodiments,

is attached to the core via a carbon-nitrogen bond. In some embodiments,

is selected from the group consisting of:

wherein each W is independently selected from the group consisting ofhydrogen, cyano, halo, hydroxy, azido, nitro, carboxy, oxo, sulfinyl,sulfanyl, sulfonyl, optionally substituted alkoxy, optionallysubstituted cycloalkyloxy, optionally substituted aryloxy, optionallysubstituted heteroaryloxy, optionally substituted heterocycloalkyloxy,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted aryloxy, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted heterocycloalkyl,optionally substituted amino, optionally substituted acyl, optionallysubstituted alkoxycarbonyl, optionally substituted aminocarbonyl,optionally substituted aminosulfonyl, optionally substitutedcarbamimidoyl, or E; wherein each E is independently an electrophilicgroup capable of forming a covalent bond with a nucleophile. In someembodiments, W is E; wherein E is an electrophilic group capable offorming a covalent bond with a nucleophile. In some embodiments, atleast one W is E. In some embodiments, W is selected from the groupconsisting of H, optionally substituted alkyl, and

In some embodiments, each W is selected from the group consisting of H,C₁-C₄ alkyl, and

In some embodiments, at least one Q is E; wherein E is an electrophilicgroup capable of forming a covalent bond with a cysteine residue of aprotein. In some embodiments, each E is independently selected from

For example, in some embodiments, at least one E is

In some embodiments, at least one E is

In some embodiments, at least one E is

In some embodiments,

wherein

X₁₁ is C—R₂₇, or N; and

R₂₃, R₂₄, R₂₅, R₂₆, and R₂₇ are independently, hydrogen, cyano, halo,hydroxy, azido, nitro, carboxy, oxo, sulfinyl, sulfanyl, sulfonyl,optionally substituted alkoxy, optionally substituted cycloalkyloxy,optionally substituted aryloxy, optionally substituted heteroaryloxy,optionally substituted heterocycloalkyloxy, optionally substitutedalkyl, optionally substituted cycloalkyl, optionally substitutedalkenyl, optionally substituted alkynyl, optionally substituted aryl,optionally substituted heteroaryl, optionally substitutedheterocycloalkyl, optionally substituted amino, optionally substitutedacyl, optionally substituted alkoxycarbonyl, optionally substitutedaminocarbonyl, optionally substituted aminosulfonyl, or optionallysubstituted carbamimidoyl, or E;

In some embodiments, R₂₃, R₂₄, R₂₅, R₂₆, and R₂₇ are independentlyhydrogen, cyano, halo, optionally substituted alkoxy, optionallysubstituted amino, optionally substituted aminocarbonyl, or E. In someembodiments, R₂₄, R₂₅, or R₂₆ is E. In some embodiments, R₂₄, R₂₅, orR₂₆ is

In some embodiments, R₂₄, R₂₅, or R₂₆ is

In some embodiments, R₂₄, R₂₅, or R₂₆ is

In some embodiments, R₂₃, R₂₅, R₂₆, and R₂₇ are independently hydrogen,cyano, halo, optionally substituted alkoxy, optionally substitutedamino, optionally substituted aminocarbonyl, and R₂₄ is E. In someembodiments, R₂₃, R₂₅, R₂₆, and R₂₇ are independently hydrogen, cyano,halo, methoxy, or —CONH₂, and R₂₄ is E.

In some embodiments, R₂₃, R₂₄, R₂₆, and R₂₇ are independently hydrogen,cyano, halo, optionally substituted alkoxy, optionally substitutedamino, optionally substituted aminocarbonyl, and R₂₅ is E. In someembodiments, R₂₃, R₂₄, R₂₆, and R₂₇ are independently hydrogen, cyano,halo, methoxy, or —CONH₂, and R₂₅ is E.

In some embodiment,

wherein

X₁₀ is C—R₃₅, or N; and

R₃₄, R₃₅, R₃₆, R₃₇, and R₃₈ are independently hydrogen, cyano, halo,hydroxy, azido, nitro, carboxy, sulfinyl, sulfanyl, sulfonyl, optionallysubstituted alkoxy, optionally substituted cycloalkyloxy, optionallysubstituted aryloxy, optionally substituted heteroaryloxy, optionallysubstituted heterocycloalkyloxy, optionally substituted alkyl,optionally substituted cycloalkyl, optionally substituted alkenyl,optionally substituted alkynyl, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted heterocycloalkyl,optionally substituted amino, optionally substituted acyl, optionallysubstituted alkoxycarbonyl, optionally substituted aminocarbonyl,optionally substituted aminosulfonyl, optionally substitutedcarbamimidoyl, or E.

In some embodiments, R₃₄, R₃₅, R₃₆, R₃₇, and R₃₈ are independentlyhydrogen, cyano, halo, optionally substituted alkoxy, optionallysubstituted heterocycloalkyloxy, optionally substitutedheterocycloalkyl, optionally substituted amino, optionally substitutedaminocarbonyl, or E. In some embodiments, wherein R₃₅ or R₃₇ is E. Insome embodiments, R₃₅ or R₃₇ is

In some embodiments, R₃₅ or R₃₇ is

In some embodiments, R₃₅ or R₃₇ is

In some embodiments, R₃₄, R₃₅, R₃₇, and R₃₈ are independently hydrogen,cyano, fluoro, chloro, methoxy, or —CONH₂, and R₃₆ is optionallysubstituted morpholinyl, optionally substituted piperazinyl, optionallysubstituted pyrrolidinyl, optionally substituted piperidinyl, optionallysubstituted azetidinyl, or substituted amino.

In some embodiments, R₃₆ is

wherein R₂₈ is hydrogen, sulfonyl, optionally substituted alkyl,optionally substituted cycloalkyl, optionally substituted alkenyl,optionally substituted alkynyl, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted heterocycloalkyl,optionally substituted amino, optionally substituted acyl, optionallysubstituted alkoxycarbonyl, optionally substituted aminocarbonyl,optionally substituted aminosulfonyl, or optionally substitutedcarbamimidoyl. In some embodiments, R₂₈ is —C(O)C₁-C₄ alkyl or C₁-C₆alkyl optionally substituted with —OH, halo, C₁-C₄ alkyl, or —OC₁-C₄alkyl. In some embodiments, R₂₈ is —CH₃, —COCH₃, —CH₂CH₂OH, —CH₂CH₂F,—CH₂CH₂OMe, —CH₂C(CH₃)₂OH, or —CH₂CH(CH₃)OH.

In some embodiments,

is selected from the group consisting of: pyrrolyl, furanyl, thienyl,imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,1,2,3-triazolyl, 1,2,4-triazolyl, furazanyl, 1,2,3-oxadiazolyl,1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, thiadiazolyl,dithiazolyl, tetrazolyl, pyridinyl, pyranyl, thiopyranyl, diazinyl,pyrazinyl, pyrimidinyl, pyridazinyl, oxazinyl, thiazinyl, dioxinyl,dithiinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl,tetrazinyl, and phenyl; For example

is selected from the group consisting of: phenyl, pyridinyl,pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl, pyrazolyl,isoxazolyl, and thienyl. In some embodiments,

is phenyl or pyridinyl.

In some embodiments, L is —[(CR₃₀R₃₁)_(x)—O—(CR₃₂R₃₃)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)]_(z)—, —[(CR₃₀R₃₁)_(x)—S—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—NR₂₉—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CO—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—SO₂—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CO₂—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CONR₂₉—(CR₃₀R₃₁)_(y)]_(z)—, or—[(CR₃₀R₃₁)_(x)—SO₂NR₂₉—(CR₃₀R₃₁)_(y)]_(z)—; In some embodiments, L is—O—, —CH₂—, —NH—, —S—, —CO—, —CO₂—, —CONH—, SO₂—, —SO₂NH—. In someembodiments, L is —NH—.

In some embodiments each, Z is independently hydrogen, cyano, halo,optionally substituted amino, optionally substituted alkoxy, optionallysubstituted cycloalkyloxy, optionally substituted aryloxy, optionallysubstituted heteroaryloxy, optionally substituted heterocycloalkyloxy,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted aryloxy, optionally substituted heterocycloalkyl,optionally substituted aminocarbonyl, or E.

In some embodiments each, Z is independently hydrogen, cyano, halo,optionally substituted alkoxy, optionally substitutedheterocycloalkyloxy, optionally substituted heterocycloalkyl, oroptionally substituted amino, optionally substituted aminocarbonyl, orE.

In some embodiments, n is 1, 2, 3, 4, or 5; and at least one Z is cyano,fluoro, chloro, methoxy, —CONH₂, 2-methoxyethoxy,2-(dimethylamino)ethoxy, (1-methylpyrrolidin-3-yl)oxy,(1-methylpiperidin-4-yl)oxy, (1-methylpiperidin-3-yl)oxy,(1-methylazetidin-3-yl)oxy (2-(dimethylamino)ethyl)(methyl)amino,dimethylamino, methyl(1-methylazetidin-3-yl)amino,methyl(1-methylpyrrolidin-3-yl)amino,methyl(1-methylpiperidin-4-yl)amino, optionally substituted morpholinyl,optionally substituted piperazinyl, optionally substituted pyrrolidinyl,optionally substituted piperidinyl, optionally substituted azetidinyl.

In some embodiments, n is 1, 2, 3, 4, or 5; and at least one Z is E.

In some embodiments, each E is independently an electrophilic groupcapable of forming a covalent bond with a cysteine residue of a protein.

In some embodiments, each E is independently selected from a groupconsisting of

In some embodiments, at least one E is

In some embodiments, E at least one is

In some embodiments, at least one E is

In some embodiments, the compound or pharmaceutically acceptable salthas the Formula Ig:

wherein:

X₁₀ is C—R₃₅, or N;

R₃₄, R₃₅, R₃₆, R₃₇, and R₃₈ are independently hydrogen, cyano, halo,hydroxy, azido, nitro, carboxy, sulfinyl, sulfanyl, sulfonyl, optionallysubstituted alkoxy, optionally substituted cycloalkyloxy, optionallysubstituted aryloxy, optionally substituted heteroaryloxy, optionallysubstituted heterocycloalkyloxy, optionally substituted alkyl,optionally substituted cycloalkyl, optionally substituted alkenyl,optionally substituted alkynyl, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted heterocycloalkyl,optionally substituted amino, optionally substituted acyl, optionallysubstituted alkoxycarbonyl, optionally substituted aminocarbonyl,optionally substituted aminosulfonyl, optionally substitutedcarbamimidoyl, or E;

is optionally substituted aryl, optionally substituted heteroaryl, oroptionally substituted heterocycloalkyl;

each Q is independently hydrogen, cyano, halo, hydroxy, azido, nitro,carboxy, oxo, sulfinyl, sulfanyl, sulfonyl, optionally substitutedalkoxy, optionally substituted cycloalkyloxy, optionally substitutedaryloxy, optionally substituted heteroaryloxy, optionally substitutedheterocycloalkyloxy, optionally substituted alkyl, optionallysubstituted cycloalkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted aryl, optionally substitutedheteroaryl, optionally substituted heterocycloalkyl, optionallysubstituted amino, optionally substituted acyl, optionally substitutedalkoxycarbonyl, optionally substituted aminocarbonyl, optionallysubstituted aminosulfonyl, optionally substituted carbamimidoyl, or E;wherein E each is independently an electrophilic group capable offorming a covalent bond with a nucleophile; and

m is 0, 1, 2, 3, 4, or 5.

In some embodiments, R₃₄, R₃₅, R₃₇, and R₃₈ are independently hydrogen,cyano, fluoro, chloro, methoxy, or —CONH₂, and R₃₆ is optionallysubstituted morpholinyl, optionally substituted piperazinyl, optionallysubstituted pyrrolidinyl, optionally substituted piperidinyl, optionallysubstituted azetidinyl, or substituted amino. In some embodiments, R₃₆is

wherein R₂₈ is hydrogen, sulfonyl, optionally substituted alkyl,optionally substituted cycloalkyl, optionally substituted alkenyl,optionally substituted alkynyl, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted heterocycloalkyl,optionally substituted amino, optionally substituted acyl, optionallysubstituted alkoxycarbonyl, optionally substituted aminocarbonyl,optionally substituted aminosulfonyl, or optionally substitutedcarbamimidoyl. In some embodiments, R₂₈ is —C(O)C₁-C₄ alkyl or C₁-C₆alkyl optionally substituted with —OH, halo, C₁-C₄ alkyl, or —OC₁-C₄alkyl. In some embodiments, R₂₈ is —CH₃, —COCH₃, —CH₂CH₂OH, —CH₂CH₂F,—CH₂CH₂OMe, —CH₂C(CH₃)₂OH, or —CH₂CH(CH₃)OH.

In some embodiments,

is selected from the group consisting of piperazinyl, morpholinyl,piperidinyl, thiomorpholinyl, pyrrolidinyl, tetrahydrofuranyl,diazepanyl, azetidinyl, oxetanyl, oxiranyl, aziridinyl, pyrrolyl,furanyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl,thiazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, furazanyl,1,2,3-oxadiazolyl, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole,thiadiazolyl, dithiazolyl, tetrazolyl, pyridinyl, pyranyl, thiopyranyl,diazinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazinyl, thiazinyl,dioxinyl, dithiinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl,tetrazinyl, and phenyl. In some embodiments,

is selected from the group consisting of: phenyl, pyridinyl,pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl, pyrazolyl,isoxazolyl, and thienyl. In other embodiments,

is phenyl or pyridinyl. In some embodiments,

is selected from the group consisting of: piperazinyl, morpholinyl,piperidinyl, thiomorpholinyl, pyrrolidinyl, tetrahydrofuranyl,diazepanyl, azetidinyl, oxetanyl, oxiranyl, aziridinyl. In someembodiments,

is selected from the group consisting of: piperazinyl, morpholinyl,piperidinyl, pyrrolidinyl, and tetrahydrofuranyl, and diazepanyl. Insome embodiments,

is selected from the group consisting of: piperazinyl, morpholinyl,piperidinyl, and pyrrolidinyl. In some embodiments,

is attached to the core via a carbon-carbon bond. In some embodiments,

is attached to the core via a carbon-nitrogen bond. In some embodiments,

is selected from the group consisting of:

wherein each W is independently selected from the group consisting ofhydrogen, cyano, halo, hydroxy, azido, nitro, carboxy, oxo, sulfinyl,sulfanyl, sulfonyl, optionally substituted alkoxy, optionallysubstituted cycloalkyloxy, optionally substituted aryloxy, optionallysubstituted heteroaryloxy, optionally substituted heterocycloalkyloxy,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted aryloxy, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted heterocycloalkyl,optionally substituted amino, optionally substituted acyl, optionallysubstituted alkoxycarbonyl, optionally substituted aminocarbonyl,optionally substituted aminosulfonyl, optionally substitutedcarbamimidoyl, or E; wherein each E is independently an electrophilicgroup capable of forming a covalent bond with a nucleophile. In someembodiments, W is E; wherein E is an electrophilic group capable offorming a covalent bond with a nucleophile. In some embodiments, atleast one W is E. In some embodiments, W is selected from the groupconsisting of H, optionally substituted alkyl, and

In some embodiments, each W is selected from the group consisting of H,C₁-C₄ alkyl, and

In some embodiments, at least one Q is E; wherein E is an electrophilicgroup capable of forming a covalent bond with a cysteine residue of aprotein. In some embodiments, each E is independently selected from

For example, in some embodiments, at least one E is

In some embodiments, at least one E is

In some embodiments, at least one E is

In some embodiments,

X₁₁ is C—R₂₇, or N; and

R₂₃, R₂₄, R₂₅, R₂₆, and R₂₇ are independently, hydrogen, cyano, halo,hydroxy, azido, nitro, carboxy, oxo, sulfinyl, sulfanyl, sulfonyl,optionally substituted alkoxy, optionally substituted cycloalkyloxy,optionally substituted aryloxy, optionally substituted heteroaryloxy,optionally substituted heterocycloalkyloxy, optionally substitutedalkyl, optionally substituted cycloalkyl, optionally substitutedalkenyl, optionally substituted alkynyl, optionally substituted aryl,optionally substituted heteroaryl, optionally substitutedheterocycloalkyl, optionally substituted amino, optionally substitutedacyl, optionally substituted alkoxycarbonyl, optionally substitutedaminocarbonyl, optionally substituted aminosulfonyl, or optionallysubstituted carbamimidoyl, or E;

In some embodiments, R₂₃, R₂₄, R₂₅, R₂₆, and R₂₇ are independentlyhydrogen, cyano, halo, optionally substituted alkoxy, optionallysubstituted amino, optionally substituted aminocarbonyl, or E. In someembodiments, R₂₄, R₂₅, or R₂₆ is E. In some embodiments, R₂₄, R₂₅, orR₂₆ is

In some embodiments, R₂₄, R₂₅, or R₂₆ is

In some embodiments, R₂₄, R₂₅, or R₂₆ is

In some embodiments, R₂₃, R₂₅, R₂₆, and R₂₇ are independently hydrogen,cyano, halo, optionally substituted alkoxy, optionally substitutedamino, optionally substituted aminocarbonyl, and R₂₄ is E. In someembodiments, R₂₃, R₂₅, R₂₆, and R₂₇ are independently hydrogen, cyano,halo, methoxy, or —CONH₂, and R₂₄ is E.

In some embodiments, R₂₃, R₂₄, R₂₆, and R₂₇ are independently hydrogen,cyano, halo, optionally substituted alkoxy, optionally substitutedamino, optionally substituted aminocarbonyl, and R₂₅ is E. In someembodiments, R₂₃, R₂₄, R₂₆, and R₂₇ are independently hydrogen, cyano,halo, methoxy, or —CONH₂, and R₂₅ is E.

In some embodiments, E is selected from a group consisting of:

In some embodiments, E is

In some embodiments, E is

In some embodiments, at least one E is

In another aspect, the present disclosure provides a compound orpharmaceutically acceptable salt thereof, wherein the compound is chosenfrom the group consisting of:

-   N-(3-(7-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2,3-difluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   (R)—N-(3-(7-((2,3-difluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   (S)—N-(3-(7-((2,3-difluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2,3-difluoro-4-(4-(2-fluoroethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-ethylpiperazin-1-yl)-2,3-difluorophenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-acetylpiperazin-1-yl)-2,3-difluorophenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2,3-difluoro-4-(piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2,3-difluoro-4-morpholinophenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((3,5-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2,5-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2,6-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((3,5-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2,5-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2,6-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((3,5-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2,5-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2,6-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((3,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2-fluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   (R)—N-(3-(7-((2-fluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   (S)—N-(3-(7-((2-fluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2-fluoro-4-(4-(2-fluoroethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-ethylpiperazin-1-yl)-2-fluorophenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-acetylpiperazin-1-yl)-2-fluorophenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2-fluoro-4-(piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2-fluoro-4-morpholinophenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((3-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((3-fluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   (R)—N-(3-(7-((3-fluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   (S)—N-(3-(7-((3-fluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((3-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((3-fluoro-4-(4-(2-fluoroethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-ethylpiperazin-1-yl)-3-fluorophenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-acetylpiperazin-1-yl)-3-fluorophenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((3-fluoro-4-(piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((3-fluoro-4-morpholinophenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2,3-difluoro-4-((1-methylpiperidin-4-yl)amino)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2-fluoro-4-((1-methylpiperidin-4-yl)amino)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((3-fluoro-4-((1-methylpiperidin-4-yl)amino)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((4-((1-methylpiperidin-4-yl)amino)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   (R)—N-(3-(7-((4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   (S)—N-(3-(7-((4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-(2-fluoroethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-ethylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-acetylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(4-oxo-7-((4-(piperazin-1-yl)phenyl)amino)pyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((4-morpholinophenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2-chloro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2-cyano-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methoxyphenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)-2-(hydroxymethyl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   2-((8-(3-acrylamidophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-5-(4-(2-hydroxyethyl)piperazin-1-yl)benzamide-   N-(3-(7-((3-chloro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)-3-methoxyphenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)-3-(hydroxymethyl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   5-((8-(3-acrylamidophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-2-(4-(2-hydroxyethyl)piperazin-1-yl)benzamide-   N-(3-(7-((2-chloro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2-cyano-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2-(hydroxymethyl)-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   2-((8-(3-acrylamidophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-5-(4-methylpiperazin-1-yl)benzamide-   N-(3-(7-((3-chloro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((3-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((3-(hydroxymethyl)-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   5-((8-(3-acrylamidophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-2-(4-methylpiperazin-1-yl)benzamide-   N-(3-(7-((6-(4-(2-hydroxyethyl)piperazin-1-yl)pyridin-3-yl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((5-(4-(2-hydroxyethyl)piperazin-1-yl)pyridin-2-yl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((6-(4-methylpiperazin-1-yl)pyridin-3-yl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(6-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamide-   N-(4-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamide-   N-(5-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-3-yl)acrylamide-   N-(2-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-4-yl)acrylamide-   N-(3-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)-4-fluorophenyl)acrylamide-   N-(3-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)-2-fluorophenyl)acrylamide-   N-(5-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)-2-fluorophenyl)acrylamide-   N-(3-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)-5-fluorophenyl)acrylamide-   N-(6-(7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamide-   N-(4-(7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamide-   N-(5-(7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-3-yl)acrylamide-   N-(2-(7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-4-yl)acrylamide-   N-(4-fluoro-3-(7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(2-fluoro-3-(7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(2-fluoro-5-(7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-fluoro-5-(7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(6-(7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamide-   N-(4-(7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamide-   N-(5-(7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-3-yl)acrylamide-   N-(2-(7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-4-yl)acrylamide-   N-(4-fluoro-3-(7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(2-fluoro-3-(7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(2-fluoro-5-(7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-fluoro-5-(7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(6-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamide-   N-(4-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamide-   N-(5-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-3-yl)acrylamide-   N-(2-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-4-yl)acrylamide-   N-(4-fluoro-3-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(2-fluoro-3-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(2-fluoro-5-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-fluoro-5-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(6-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamide-   N-(4-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamide-   N-(5-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-3-yl)acrylamide-   N-(2-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-4-yl)acrylamide-   N-(3-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)-4-fluorophenyl)acrylamide-   N-(3-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)-2-fluorophenyl)acrylamide-   N-(5-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)-2-fluorophenyl)acrylamide-   N-(3-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)-5-fluorophenyl)acrylamide-   N-(6-(7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamide-   N-(4-(7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamide-   N-(5-(7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-3-yl)acrylamide-   N-(2-(7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-4-yl)acrylamide-   N-(4-fluoro-3-(7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(2-fluoro-3-(7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(2-fluoro-5-(7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-fluoro-5-(7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(6-(7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamide-   N-(4-(7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamide-   N-(5-(7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-3-yl)acrylamide-   N-(2-(7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-4-yl)acrylamide-   N-(4-fluoro-3-(7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(2-fluoro-3-(7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(2-fluoro-5-(7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-fluoro-5-(7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(6-(7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamide-   N-(4-(7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamide-   N-(5-(7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-3-yl)acrylamide-   N-(2-(7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-4-yl)acrylamide-   N-(4-fluoro-3-(7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(2-fluoro-3-(7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(2-fluoro-5-(7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-fluoro-5-(7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-2-methyl-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-2-(hydroxymethyl)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   1-(3-acrylamidophenyl)-7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxo-1,4-dihydropyrimido[4,5-d]pyrimidine-2-carboxamide-   N-(3-(2-cyano-7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-2-methyl-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-2-(hydroxymethyl)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   1-(3-acrylamidophenyl)-7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxo-1,4-dihydropyrimido[4,5-d]pyrimidine-2-carboxamide-   N-(3-(2-cyano-7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-2-methyl-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-2-(hydroxymethyl)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   1-(3-acrylamidophenyl)-7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxo-1,4-dihydropyrimido[4,5-d]pyrimidine-2-carboxamide-   N-(3-(2-cyano-7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-2-methyl-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-2-(hydroxymethyl)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   1-(3-acrylamidophenyl)-7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxo-1,4-dihydropyrimido[4,5-d]pyrimidine-2-carboxamide-   N-(3-(2-cyano-7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-2-methyl-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-2-(hydroxymethyl)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   1-(3-acrylamidophenyl)-7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxo-1,4-dihydropyrimido[4,5-d]pyrimidine-2-carboxamide-   N-(3-(2-cyano-7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-2-methyl-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-2-(hydroxymethyl)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   1-(3-acrylamidophenyl)-7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxo-1,4-dihydropyrimido[4,5-d]pyrimidine-2-carboxamide-   N-(3-(2-cyano-7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-2-methyl-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-2-(hydroxymethyl)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   1-(3-acrylamidophenyl)-7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxo-1,4-dihydropyrimido[4,5-d]pyrimidine-2-carboxamide-   N-(3-(2-cyano-7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(2-methyl-7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(2-(hydroxymethyl)-7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   1-(3-acrylamidophenyl)-7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxo-1,4-dihydropyrimido[4,5-d]pyrimidine-2-carboxamide-   N-(3-(2-cyano-7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-fluoroethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-ethylpiperazin-1-yl)-2,3-difluorophenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-acetylpiperazin-1-yl)-2,3-difluorophenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-fluoroethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-ethylpiperazin-1-yl)-2-fluorophenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-acetylpiperazin-1-yl)-2-fluorophenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-morpholinophenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-fluoroethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-ethylpiperazin-1-yl)-3-fluorophenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-acetylpiperazin-1-yl)-3-fluorophenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-morpholinophenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-((1-methylpiperidin-4-yl)amino)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-((1-methylpiperidin-4-yl)amino)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-((1-methylpiperidin-4-yl)amino)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((4-((1-methylpiperidin-4-yl)amino)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   (R)—N-(3-(2-((4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   (S)—N-(3-(2-((4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-fluoroethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-ethylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-acetylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(5-oxo-2-((4-(piperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((4-morpholinophenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2-chloro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2-cyano-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methoxyphenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((3-chloro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)-3-methoxyphenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2-chloro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2-cyano-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((3-chloro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((3-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)pyridin-3-yl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((5-(4-(2-hydroxyethyl)piperazin-1-yl)pyridin-2-yl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((6-(4-methylpiperazin-1-yl)pyridin-3-yl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(6-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamide-   N-(4-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamide-   N-(5-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-3-yl)acrylamide-   N-(2-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-4-yl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)-4-fluorophenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)-2-fluorophenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)-5-fluorophenyl)acrylamide-   N-(6-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamide-   N-(4-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamide-   N-(5-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-3-yl)acrylamide-   N-(2-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-4-yl)acrylamide-   N-(4-fluoro-3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(2-fluoro-3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-fluoro-5-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(6-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamide-   N-(4-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamide-   N-(5-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-3-yl)acrylamide-   N-(2-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-4-yl)acrylamide-   N-(4-fluoro-3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(2-fluoro-3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-fluoro-5-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(6-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamide-   N-(4-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamide-   N-(5-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-3-yl)acrylamide-   N-(2-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-4-yl)acrylamide-   N-(4-fluoro-3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(2-fluoro-3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-fluoro-5-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(6-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamide-   N-(4-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamide-   N-(5-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-3-yl)acrylamide-   N-(2-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-4-yl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)-4-fluorophenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)-2-fluorophenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)-5-fluorophenyl)acrylamide-   N-(6-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamide-   N-(4-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamide-   N-(5-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-3-yl)acrylamide-   N-(2-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-4-yl)acrylamide-   N-(4-fluoro-3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(2-fluoro-3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-fluoro-5-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(6-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamide-   N-(4-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamide-   N-(5-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-3-yl)acrylamide-   N-(2-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-4-yl)acrylamide-   N-(4-fluoro-3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(2-fluoro-3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-fluoro-5-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(6-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamide-   N-(4-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamide-   N-(5-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-3-yl)acrylamide-   N-(2-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-4-yl)acrylamide-   N-(4-fluoro-3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(2-fluoro-3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-fluoro-5-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-(hydroxymethyl)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   8-(3-acrylamidophenyl)-2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-7-carboxamide-   N-(3-(7-cyano-2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-(hydroxymethyl)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   8-(3-acrylamidophenyl)-2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-7-carboxamide-   N-(3-(7-cyano-2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-(hydroxymethyl)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   8-(3-acrylamidophenyl)-2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-7-carboxamide-   N-(3-(7-cyano-2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-(hydroxymethyl)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   8-(3-acrylamidophenyl)-2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-7-carboxamide-   N-(3-(7-cyano-2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-(hydroxymethyl)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   8-(3-acrylamidophenyl)-2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-7-carboxamide-   N-(3-(7-cyano-2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-(hydroxymethyl)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   8-(3-acrylamidophenyl)-2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-7-carboxamide-   N-(3-(7-cyano-2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-(hydroxymethyl)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   8-(3-acrylamidophenyl)-2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-7-carboxamide-   N-(3-(7-cyano-2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(7-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(7-(hydroxymethyl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   8-(3-acrylamidophenyl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-7-carboxamide-   N-(3-(7-cyano-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-6-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-6-(hydroxymethyl)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-6,7-dimethyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   8-(3-acrylamidophenyl)-2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamide-   N-(3-(6-cyano-2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(6-cyano-2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(7-cyano-2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-6-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-6-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-6-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-6-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-6-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-6-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-6-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(6-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-acetylpiperazin-1-yl)-2,3-difluorophenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-acetylpiperazin-1-yl)-2-fluorophenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-morpholinophenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-acetylpiperazin-1-yl)-3-fluorophenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-morpholinophenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-morpholinophenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-morpholinophenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(7-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((4-morpholinophenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-morpholinophenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-morpholinophenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)-9H-purin-9-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-morpholinophenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(5-((2-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2-fluoro-4-morpholinophenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2-fluoro-4-morpholinophenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-morpholinophenyl)amino)-9H-purin-9-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((2-fluoro-4-morpholinophenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-morpholinophenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(5-((3-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((3-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((3-fluoro-4-morpholinophenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((3-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((3-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((3-fluoro-4-morpholinophenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-morpholinophenyl)amino)-9H-purin-9-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((3-fluoro-4-morpholinophenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((4-morpholinophenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(5-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((4-morpholinophenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((4-(4-methylpiperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((4-morpholinophenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide-   N-(3-(2-((4-morpholinophenyl)amino)-9H-purin-9-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(2-((4-morpholinophenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-morpholinophenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-morpholinophenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)acrylamide-   N-(3-(6-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(6-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(6-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(6-((4-morpholinophenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(6-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)acrylamide-   N-(3-(6-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)acrylamide-   N-(3-(6-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)acrylamide-   N-(3-(6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)acrylamide-   N-(3-(6-((4-morpholinophenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)acrylamide-   N-(3-(6-((3-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(6-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(6-((3-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(6-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(6-((3-fluoro-4-morpholinophenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(6-((2-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(6-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(6-((2-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(6-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(6-((2-fluoro-4-morpholinophenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-morpholinophenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2-fluoro-4-morpholinophenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((3-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((3-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((3-fluoro-4-morpholinophenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((4-(4-methylpiperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((4-morpholinophenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(3-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)phenyl)acrylamide-   N-(3-(3-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)phenyl)acrylamide-   N-(3-(3-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)phenyl)acrylamide-   N-(3-(3-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)phenyl)acrylamide-   N-(3-(3-((2,3-difluoro-4-morpholinophenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[1,2-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,2-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,2-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,2-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-morpholinophenyl)amino)imidazo[1,2-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,5-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-morpholinophenyl)amino)imidazo[1,5-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((2,3-difluoro-4-morpholinophenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(3-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)phenyl)acrylamide-   N-(3-(3-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)phenyl)acrylamide-   N-(3-(3-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)phenyl)acrylamide-   N-(3-(3-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)phenyl)acrylamide-   N-(3-(3-((2,3-difluoro-4-morpholinophenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)phenyl)acrylamide-   N-(3-(7-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(7-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(7-((2,3-difluoro-4-morpholinophenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-morpholinophenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((2,3-difluoro-4-morpholinophenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((4-morpholinophenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((4-morpholinophenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(2-((4-morpholinophenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)phenyl)acrylamide-   N-(3-(3-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)phenyl)acrylamide-   N-(3-(3-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)phenyl)acrylamide-   N-(3-(3-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)phenyl)acrylamide-   N-(3-(3-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)phenyl)acrylamide-   N-(3-(3-((4-morpholinophenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)phenyl)acrylamide-   N-(3-(6-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[1,2-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,2-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,2-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,2-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((4-morpholinophenyl)amino)imidazo[1,2-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,5-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((4-morpholinophenyl)amino)imidazo[1,5-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(6-((4-morpholinophenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((4-morpholinophenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((4-morpholinophenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(2-((4-morpholinophenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamide-   N-(3-(3-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)phenyl)acrylamide-   N-(3-(3-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)phenyl)acrylamide-   N-(3-(3-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)phenyl)acrylamide-   N-(3-(3-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)phenyl)acrylamide-   N-(3-(3-((4-morpholinophenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(7-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(7-((4-morpholinophenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)phenyl)acrylamide-   N-(3-(5-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((4-morpholinophenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((4-(4-methylpiperazin-1-yl)phenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamide-   N-(3-(5-((4-morpholinophenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpiperidin-4-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpiperidin-4-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpiperidin-4-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpiperidin-4-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamide-   N-(2-(3-(dimethylamino)pyrrolidin-1-yl)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(3-(dimethylamino)azetidin-1-yl)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(3-(dimethylamino)pyrrolidin-1-yl)-4-methoxyphenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(3-(dimethylamino)azetidin-1-yl)-4-methoxyphenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-(3-(dimethylamino)pyrrolidin-1-yl)-4-methoxyphenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-(3-(dimethylamino)azetidin-1-yl)-4-methoxyphenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamide-   N-(2-(3-(dimethylamino)pyrrolidin-1-yl)-5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(3-(dimethylamino)azetidin-1-yl)-5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)-4-methoxyphenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylpiperidin-4-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylpiperidin-4-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylpiperidin-4-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylpiperidin-4-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)-4-methoxyphenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)-4-methoxyphenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)-4-methoxyphenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-2-(methyl(1-methylpiperidin-4-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(methyl(1-methylpiperidin-4-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-(methyl(1-methylpiperidin-4-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-2-(methyl(1-methylpiperidin-4-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-2-(4-methylpiperazin-1-yl)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-2-morpholinophenyl)acrylamide-   N-(2-(3-(dimethylamino)pyrrolidin-1-yl)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)phenyl)acrylamide-   N-(2-(3-(dimethylamino)azetidin-1-yl)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(4-methylpiperazin-1-yl)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-morpholinophenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(3-(dimethylamino)pyrrolidin-1-yl)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(3-(dimethylamino)azetidin-1-yl)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-(4-methylpiperazin-1-yl)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-morpholinophenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-(3-(dimethylamino)pyrrolidin-1-yl)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-(3-(dimethylamino)azetidin-1-yl)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-2-(4-methylpiperazin-1-yl)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-2-morpholinophenyl)acrylamide-   N-(2-(3-(dimethylamino)pyrrolidin-1-yl)-5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)phenyl)acrylamide-   N-(2-(3-(dimethylamino)azetidin-1-yl)-5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-2-((1-methylpiperidin-4-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-((1-methylpiperidin-4-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-((1-methylpiperidin-4-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-2-((1-methylpiperidin-4-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((7-(3-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)isoxazolo[4,5-d]pyrimidin-5-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((9-(3-fluorophenyl)-9H-purin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((7-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((1-(3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)isoxazolo[4,3-d]pyrimidin-5-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrrolo[1,2-a][1,3,5]triazin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)imidazo[1,5-a][1,3,5]triazin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)-[1,2,3]triazolo[1,5-c]pyrimidin-5-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((7-(3-fluorophenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((7-(3-fluorophenyl)imidazo[2,1-f][1,2,4]triazin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((7-(3-fluorophenyl)imidazo[5,1-f][1,2,4]triazin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)-[1,2,4]triazolo[4,3-a]pyrazin-6-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-5-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)isoxazolo[5,4-c]pyridin-5-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((1-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((1-(3-fluorophenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((1-(3-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)isoxazolo[3,4-c]pyridin-5-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((5-(3-fluorophenyl)pyrrolo[1,2-c]pyrimidin-3-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((1-(3-fluorophenyl)imidazo[1,5-c]pyrimidin-7-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)pyrazolo[1,5-c]pyrimidin-5-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((6-(3-fluorophenyl)pyrrolo[1,2-a]pyrazin-3-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)imidazo[1,2-a]pyrazin-6-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)imidazo[1,5-a]pyrazin-6-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((7-(3-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)isoxazolo[4,5-d]pyrimidin-5-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((9-(3-fluorophenyl)-9H-purin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((7-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((1-(3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)isoxazolo[4,3-d]pyrimidin-5-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)pyrrolo[1,2-a][1,3,5]triazin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)imidazo[1,5-a][1,3,5]triazin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)-[1,2,3]triazolo[1,5-c]pyrimidin-5-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((7-(3-fluorophenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((7-(3-fluorophenyl)imidazo[2,1-f][1,2,4]triazin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((7-(3-fluorophenyl)imidazo[5,1-f][1,2,4]triazin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)-[1,2,4]triazolo[4,3-a]pyrazin-6-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-5-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)isoxazolo[5,4-c]pyridin-5-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((1-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((1-(3-fluorophenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((1-(3-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)isoxazolo[3,4-c]pyridin-5-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((5-(3-fluorophenyl)pyrrolo[1,2-c]pyrimidin-3-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((1-(3-fluorophenyl)imidazo[1,5-c]pyrimidin-7-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)pyrazolo[1,5-c]pyrimidin-5-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((6-(3-fluorophenyl)pyrrolo[1,2-a]pyrazin-3-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)imidazo[1,2-a]pyrazin-6-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)imidazo[1,5-a]pyrazin-6-yl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((7-(3-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)isoxazolo[4,5-d]pyrimidin-5-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((9-(3-fluorophenyl)-9H-purin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((7-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((1-(3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)isoxazolo[4,3-d]pyrimidin-5-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrrolo[1,2-a][1,3,5]triazin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)imidazo[1,5-a][1,3,5]triazin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)-[1,2,3]triazolo[1,5-c]pyrimidin-5-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((7-(3-fluorophenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((7-(3-fluorophenyl)imidazo[2,1-f][1,2,4]triazin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((7-(3-fluorophenyl)imidazo[5,1-f][1,2,4]triazin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)-[1,2,4]triazolo[4,3-a]pyrazin-6-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-5-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)isoxazolo[5,4-c]pyridin-5-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((1-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((1-(3-fluorophenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((1-(3-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)isoxazolo[3,4-c]pyridin-5-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((5-(3-fluorophenyl)pyrrolo[1,2-c]pyrimidin-3-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((1-(3-fluorophenyl)imidazo[1,5-c]pyrimidin-7-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)pyrazolo[1,5-c]pyrimidin-5-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((6-(3-fluorophenyl)pyrrolo[1,2-a]pyrazin-3-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)imidazo[1,2-a]pyrazin-6-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)imidazo[1,5-a]pyrazin-6-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((7-(3-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)isoxazolo[4,5-d]pyrimidin-5-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((9-(3-fluorophenyl)-9H-purin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((7-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((1-(3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)isoxazolo[4,3-d]pyrimidin-5-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)pyrrolo[1,2-a][1,3,5]triazin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)imidazo[1,5-a][1,3,5]triazin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)-[1,2,3]triazolo[1,5-c]pyrimidin-5-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((7-(3-fluorophenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((7-(3-fluorophenyl)imidazo[2,1-f][1,2,4]triazin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((7-(3-fluorophenyl)imidazo[5,1-f][1,2,4]triazin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)-[1,2,4]triazolo[4,3-a]pyrazin-6-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-5-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)isoxazolo[5,4-c]pyridin-5-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((1-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((1-(3-fluorophenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((1-(3-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)isoxazolo[3,4-c]pyridin-5-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((5-(3-fluorophenyl)pyrrolo[1,2-c]pyrimidin-3-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((1-(3-fluorophenyl)imidazo[1,5-c]pyrimidin-7-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)pyrazolo[1,5-c]pyrimidin-5-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((6-(3-fluorophenyl)pyrrolo[1,2-a]pyrazin-3-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)imidazo[1,2-a]pyrazin-6-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)imidazo[1,5-a]pyrazin-6-yl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((7-(3-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)isoxazolo[4,5-d]pyrimidin-5-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((9-(3-fluorophenyl)-9H-purin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((7-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((1-(3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)isoxazolo[4,3-d]pyrimidin-5-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrrolo[1,2-a][1,3,5]triazin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)imidazo[1,5-a][1,3,5]triazin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)-[1,2,3]triazolo[1,5-c]pyrimidin-5-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((7-(3-fluorophenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((7-(3-fluorophenyl)imidazo[2,1-f][1,2,4]triazin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((7-(3-fluorophenyl)imidazo[5,1-f][1,2,4]triazin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)-[1,2,4]triazolo[4,3-a]pyrazin-6-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-5-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)isoxazolo[5,4-c]pyridin-5-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((1-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((1-(3-fluorophenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((1-(3-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)isoxazolo[3,4-c]pyridin-5-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((5-(3-fluorophenyl)pyrrolo[1,2-c]pyrimidin-3-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((1-(3-fluorophenyl)imidazo[1,5-c]pyrimidin-7-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)pyrazolo[1,5-c]pyrimidin-5-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((6-(3-fluorophenyl)pyrrolo[1,2-a]pyrazin-3-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)imidazo[1,2-a]pyrazin-6-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)imidazo[1,5-a]pyrazin-6-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((7-(3-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)isoxazolo[4,5-d]pyrimidin-5-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((9-(3-fluorophenyl)-9H-purin-2-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((7-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((1-(3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)isoxazolo[4,3-d]pyrimidin-5-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)pyrrolo[1,2-a][1,3,5]triazin-2-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)imidazo[1,5-a][1,3,5]triazin-2-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)-[1,2,3]triazolo[1,5-c]pyrimidin-5-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((7-(3-fluorophenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((7-(3-fluorophenyl)imidazo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((7-(3-fluorophenyl)imidazo[5,1-f][1,2,4]triazin-2-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)-[1,2,4]triazolo[4,3-a]pyrazin-6-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-5-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)isoxazolo[5,4-c]pyridin-5-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((1-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((1-(3-fluorophenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((1-(3-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)isoxazolo[3,4-c]pyridin-5-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((5-(3-fluorophenyl)pyrrolo[1,2-c]pyrimidin-3-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((1-(3-fluorophenyl)imidazo[1,5-c]pyrimidin-7-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)pyrazolo[1,5-c]pyrimidin-5-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((6-(3-fluorophenyl)pyrrolo[1,2-a]pyrazin-3-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)imidazo[1,2-a]pyrazin-6-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)imidazo[1,5-a]pyrazin-6-yl)amino)phenyl)acrylamide-   N-(5-((7-(3-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)isoxazolo[4,5-d]pyrimidin-5-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((9-(3-fluorophenyl)-9H-purin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((7-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((1-(3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)isoxazolo[4,3-d]pyrimidin-5-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrrolo[1,2-a][1,3,5]triazin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)imidazo[1,5-a][1,3,5]triazin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)-[1,2,3]triazolo[1,5-c]pyrimidin-5-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((7-(3-fluorophenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((7-(3-fluorophenyl)imidazo[2,1-f][1,2,4]triazin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((7-(3-fluorophenyl)imidazo[5,1-f][1,2,4]triazin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)-[1,2,4]triazolo[4,3-a]pyrazin-6-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-5-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)isoxazolo[5,4-c]pyridin-5-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((1-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((1-(3-fluorophenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((1-(3-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)isoxazolo[3,4-c]pyridin-5-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((5-(3-fluorophenyl)pyrrolo[1,2-c]pyrimidin-3-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((1-(3-fluorophenyl)imidazo[1,5-c]pyrimidin-7-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)pyrazolo[1,5-c]pyrimidin-5-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((6-(3-fluorophenyl)pyrrolo[1,2-a]pyrazin-3-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)imidazo[1,2-a]pyrazin-6-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((3-(3-fluorophenyl)imidazo[1,5-a]pyrazin-6-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((7-(3-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)isoxazolo[4,5-d]pyrimidin-5-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((9-(3-fluorophenyl)-9H-purin-2-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((7-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((1-(3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)isoxazolo[4,3-d]pyrimidin-5-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)pyrrolo[1,2-a][1,3,5]triazin-2-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)imidazo[1,5-a][1,3,5]triazin-2-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)-[1,2,3]triazolo[1,5-c]pyrimidin-5-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((7-(3-fluorophenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((7-(3-fluorophenyl)imidazo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((7-(3-fluorophenyl)imidazo[5,1-f][1,2,4]triazin-2-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)-[1,2,4]triazolo[4,3-a]pyrazin-6-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-5-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)isoxazolo[5,4-c]pyridin-5-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((1-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((1-(3-fluorophenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((1-(3-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)isoxazolo[3,4-c]pyridin-5-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((5-(3-fluorophenyl)pyrrolo[1,2-c]pyrimidin-3-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((1-(3-fluorophenyl)imidazo[1,5-c]pyrimidin-7-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)pyrazolo[1,5-c]pyrimidin-5-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((6-(3-fluorophenyl)pyrrolo[1,2-a]pyrazin-3-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)imidazo[1,2-a]pyrazin-6-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)imidazo[1,5-a]pyrazin-6-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-6-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-6-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-6-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-6-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-6-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-6-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-6-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(5-((8-(3-fluorophenyl)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-6-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)phenyl)acrylamide-   N-(5-((8-bromoquinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide-   N-(5-((8-chloroquinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-methoxyquinazolin-2-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-phenylquinazolin-2-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(pyridin-4-yl)quinazolin-2-yl)amino)phenyl)acrylamide-   N-(5-((8-(2-chlorophenyl)quinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(2-fluorophenyl)quinazolin-2-yl)amino)phenyl)acrylamide-   N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(pyridin-3-yl)quinazolin-2-yl)amino)phenyl)acrylamide-   N-(5-((8-(2-chlorophenyl)quinazolin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamide-   N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(2-methoxyethoxy)phenyl)acrylamide-   N-(5-((3-(3-chlorophenyl)imidazo[1,5-a]pyrazin-6-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamide-   1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(6-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(5-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(5-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(5-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(6-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(6-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a]pyrazin-3-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(6-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,2-a]pyrazin-3-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(3-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(5-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(3-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(5-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)piperidin-1-yl)prop-2-en-1-one-   1-(1-acryloylpiperidin-3-yl)-7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrimido[4,5-d]pyrimidin-4(1H)-one-   8-(1-acryloylpiperidin-3-yl)-2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-5(8H)-one-   8-(1-acryloylpiperidin-3-yl)-2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrido[3,2-d]pyrimidin-6(5H)-one-   8-(1-acryloylpiperidin-3-yl)-2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-methylpyrido[3,2-d]pyrimidin-6(5H)-one-   1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(5-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(5-((4-(4-methylpiperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(5-((4-(4-methylpiperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(6-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,5-a]pyrazin-3-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(6-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,2-a]pyrazin-3-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(3-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(5-((4-(4-methylpiperazin-1-yl)phenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(7-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(3-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(5-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)piperidin-1-yl)prop-2-en-1-one-   1-(1-acryloylpiperidin-3-yl)-7-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimido[4,5-d]pyrimidin-4(1H)-one-   8-(1-acryloylpiperidin-3-yl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-5(8H)-one-   8-(1-acryloylpiperidin-3-yl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[3,2-d]pyrimidin-6(5H)-one-   8-(1-acryloylpiperidin-3-yl)-5-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[3,2-d]pyrimidin-6(5H)-one-   1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one-   1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one-   1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one-   1-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one-   1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one-   1-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one-   1-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one-   1-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one-   1-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one-   1-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one    and-   1-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one.

In yet another aspect, the present disclosure provides a compound chosenfrom the compounds set forth in Table 1 below and pharmaceuticallyacceptable salts thereof.

TABLE 1 Illustrative Compounds of the Present Invention Compound No.Chemical Structure Chemical Name C001

N-(5-((8-bromoquinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acryl- amide C002

N-(5-((8-chloroquinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acryl- amide C003

N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5- ((8-methoxyquinazolin-2-yl)amino)phenyl)acrylamide C004

N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5- ((8-phenylquinazolin-2-yl)amino)phenyl)acrylamide C005

N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)- 2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acryl- amide C006

N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)quinazolin-2- yl)amino)phenyl)acrylamide C007

N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(pyridin-4-yl)quinazolin-2- yl)amino)phenyl)acrylamide C008

N-(5-((8-(2-chlorophenyl)quinazolin-2-yl)amino)- 2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acryl- amide C009

N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(2-fluorophenyl)quinazolin-2- yl)amino)phenyl)acrylamide C010

N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(pyridin-3-yl)quinazolin-2- yl)amino)phenyl)acrylamide C011

N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(4-methylpiperazin-1-yl)phenyl)acrylamide C012

N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamide C013

N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-((1-methylpiperidin-4-yl)oxy)phenyl)acrylamide C014

N-(5-((8-(2-chlorophenyl)quinazolin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamide C015

N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(2-methoxyethoxy)phenyl)acrylamide C016

N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-morpholinophenyl)acrylamide C017

N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4- methoxyphenyl)acrylamideC018

N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4- methoxyphenyl)acrylamideC019

N-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3- yl)oxy)phenyl)acrylamide C020

N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3- yl)oxy)phenyl)acrylamide C021

N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2- yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acryl- amide C022

N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(5-fluoropyridin-3-yl)quinazolin-2- yl)amino)phenyl)acrylamide C023

N-(2-(3-(dimethylamino)pyrrolidin-1-yl)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4- methoxyphenyl)acrylamide C024

N-(2-(3-(dimethylamino)pyrrolidin-1-yl)-5-((8-(3-fluorophenyl)quinazolin-2- yl)amino)phenyl)acrylamide C025

N-(2-(3-(dimethylamino)azetidin-1-yl)-5-((8-(3-fluorophenyl)quinazolin-2- yl)amino)phenyl)acrylamide A001

1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1- yl)prop-2-en-1-one A002

N-(3-(2-((4-(4-methylpiperazin-1- yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide A003

N-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9- yl)phenyl)acrylamide A004

1-(3-(2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1- yl)prop-2-en-1-one A005

1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1- yl)prop-2-en-1-one A006

1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1- yl)prop-2-en-1-one A007

1-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1- yl)prop-2-en-1-one A008

1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1- yl)prop-2-en-1-one A009

1-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1- yl)prop-2-en-1-one A010

N-(3-(2-((3-fluoro-4-(4-methylpiperazin-1- yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide A011

1-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1- yl)prop-2-en-1-one A012

1-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1- yl)prop-2-en-1-one A013

1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1- yl)prop-2-en-1-one A014

N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide A015

N-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1- yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide A016

1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1- yl)prop-2-en-1-one A017

1-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1- yl)prop-2-en-1-one A018

1-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1- yl)prop-2-en-1-one A019

N-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9- yl)phenyl)acrylamide A020

N-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9- yl)phenyl)acrylamide A021

N-(3-(2-((2-fluoro-4-(4-methylpiperazin-1- yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide A022

1-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one A023

1-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1- yl)prop-2-en-1-one A024

1-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one

In some embodiments, a compound of Formula I binds to a kinaseincluding, but not limited to, Abl, Akt1, Akt2, Akt3, ALK, Alk5, A-Raf,B-Raf, Brk, BTK, Cdk2, CDK4, CDK5, CDK6, CHK1, c-Raf-1, Csk, EGFR,EphA1, EphA2, EphB2, EphB4, Erk2, Fak, FGFR1, FGFR2, FGFR3, FGFR4, Flt1,Flt3, Flt4, Fins, Frk, Fyn, Gsk3alpha, Gsk3beta, HCK, Her2/Erbb2,Her4/Erbb4, IGF1R, IKK beta, Irak4, Itk, Jak1, Jak2, Jak3, Jnk1, Jnk2,Jnk3, KDR, Kit, Lck, Lyn, MAP2K1, MAP2K2, MAP4K4, MAPKAPK2, Met, Mnk1,MLK1, p38, PDGFRA, PDGFRB, PDPK1, Pim1, Pim2, Pim3, PKC alpha, PKC beta,PKC theta, Plk1, Pyk2, ROCK1, ROCK2, Ron, Src, Stk6, Syk, TEC, Tie2,TrkA, TrkB, Yes, and Zap70, including any mutated versions thereof. Forexample, the compound of Formula I binds to a kinase selected from thegroup consisting of EGFR, HER2, HER4, KDR, ALK, ARK5, BLK, BTK, FMS,ITK, JAK1, JAK2, JAK3, PLK1, PLK2, PLK3, PLK4, FAK, and SNARK In someembodiments, the compound of Formula I binds to a kinase selected fromthe group consisting of EGFR mutants such as EGFR del E746-A750, EGFRdel E747-E749/A750P, EGFR del E747-S752/P753S, EGFR delE747-T751/Sins/A750P, EGFR del S752-I759, EGFR G719S, EGFR G719C, EGFRL861Q, EGFR L858R, EGFR T790M, EGFR L858R/T790M. For example, thecompound of Formula I binds to a kinase which is EGFR L858R, EGFR T790Mor EGFR L858R/T790M mutant. In some embodiments, a compound of Formula Ibinds to a kinase including, but not limited to, Abl, Akt1, Akt2, Akt3,ALK, Alk5, A-Raf, B-Raf, Brk, BTK, Cdk2, CDK4, CDK5, CDK6, CHK1,c-Raf-1, Csk, EGFR, EphA1, EphA2, EphB2, EphB4, Erk2, Fak, FGFR1, FGFR2,FGFR3, FGFR4, Flt1, Flt3, Flt4, Fins, Frk, Fyn, Gsk3alpha, Gsk3beta,HCK, Her2/Erbb2, Her4/Erbb4, IGF1R, IKK beta, Irak4, Itk, Jak1, Jak2,Jak3, Jnk1, Jnk2, Jnk3, KDR, Kit, Lck, Lyn, MAP2K1, MAP2K2, MAP4K4,MAPKAPK2, Met, Mnk1, MLK1, p38, PDGFRA, PDGFRB, PDPK1, Pim1, Pim2, Pim3,PKC alpha, PKC beta, PKC theta, Plk1, Pyk2, ROCK1, ROCK2, Ron, Src,Stk6, Syk, TEC, Tie2, TrkA, TrkB, Yes, and Zap70, including any mutatedversions thereof, with a Kd which is lower than 50 μM, 25 μM, 10 μM, 5μM, or 1 μM as measured in an in vitro assay. For example, the compoundof Formula I binds to a kinase selected from the group consisting ofEGFR, EGFR L858R, EGFR T790M, EGFR del E746-A750, or EGFR L858R/T790Mmutant, Her2, Her4, Fak, FGFR1, FGFR2, FGFR3, FGFR4, BTK, Met, Pim1,Pim2, Pim3, Pyk2, KDR, Src and Ret, and any mutated versions thereofwith a Kd which is lower than 50 μM, 25 μM, 10 μM, 5 μM, or 1 μM asmeasured in an in vitro assay. In some embodiments, the compound ofFormula I binds to a kinase selected from the group consisting of BTK,KDR, EGFR, EGFR L858R, EGFR T790M or EGFR L858R/T790M mutant with a Kdwhich is lower than 50 μM, 25 μM, 10 μM, 5 μM, or 1 μM as measured in anin vitro assay. For example, the compound of Formula I binds to a kinasewhich is EGFR, EGFR L858R, EGFR T790M, EGFR del E746-A750, EGFRL858R/T790M mutant with a Kd which is lower than 50 μM, 25 μM, 10 μM, 5μM, or 1 μM as measured in an in vitro assay.

In some embodiments, a compound of Formula I inhibits a kinaseincluding, but not limited to, Abl, Akt1, Akt2, Akt3, ALK, Alk5, A-Raf,B-Raf, Brk, BTK, Cdk2, CDK4, CDK5, CDK6, CHK1, c-Raf-1, Csk, EGFR,EphA1, EphA2, EphB2, EphB4, Erk2, Fak, FGFR1, FGFR2, FGFR3, FGFR4, Flt1,Flt3, Flt4, Fins, Frk, Fyn, Gsk3alpha, Gsk3beta, HCK, Her2/Erbb2,Her4/Erbb4, IGF1R, IKK beta, Irak4, Itk, Jak1, Jak2, Jak3, Jnk1, Jnk2,Jnk3, KDR, Kit, Lck, Lyn, MAP2K1, MAP2K2, MAP4K4, MAPKAPK2, Met, Mnk1,MLK1, p38, PDGFRA, PDGFRB, PDPK1, Pim1, Pim2, Pim3, PKC alpha, PKC beta,PKC theta, Plk1, Pyk2, ROCK1, ROCK2, Ron, Src, Stk6, Syk, TEC, Tie2,TrkA, TrkB, Yes, and Zap70, including any mutated versions thereof. Forexample, the compound of Formula I inhibits a kinase selected from thegroup consisting of EGFR, BTK, Fak, FGFR1, FGFR2, FGFR3, FGFR4, Jnk1,Jnk2, Jnk3, Lck, Lyn, Met, Pim1, Pim2, Pim3, Pyk2, KDR, Src and Ret, andany mutated versions thereof. In some embodiments, the compound ofFormula I inhibits a kinase selected from the group consisting of BTK,EGFR, EGFR L858R, EGFR del E746-A750, EGFR T790M or EGFR L858R/T790Mmutant. For example, the compound of Formula I inhibits a kinase whichis EGFR or EGFR L858R/T790M mutant. In some embodiments, a compound ofFormula I inhibits a kinase including, but not limited to, Abl, Akt1,Akt2, Akt3, ALK, Alk5, A-Raf, B-Raf, Brk, BTK, Cdk2, CDK4, CDK5, CDK6,CHK1, c-Raf-1, Csk, EGFR, EphA1, EphA2, EphB2, EphB4, Erk2, Fak, FGFR1,FGFR2, FGFR3, FGFR4, Flt1, Flt3, Flt4, Fins, Frk, Fyn, Gsk3alpha,Gsk3beta, HCK, Her2/Erbb2, Her4/Erbb4, IGF1R, IKK beta, Irak4, Itk,Jak1, Jak2, Jak3, Jnk1, Jnk2, Jnk3, KDR, Kit, Lck, Lyn, MAP2K1, MAP2K2,MAP4K4, MAPKAPK2, Met, Mnk1, MLK1, p38, PDGFRA, PDGFRB, PDPK1, Pim1,Pim2, Pim3, PKC alpha, PKC beta, PKC theta, Plk1, Pyk2, ROCK1, ROCK2,Ron, Src, Stk6, Syk, TEC, Tie2, TrkA, TrkB, Yes, and Zap70, includingany mutated versions thereof with an IC₅₀ in an in vitro assay of 10 μM,5 μM, 2 μM, 1 μM, 500 nM, 200 nM, 100 nM or less as ascertained in an invitro kinase assay. For example, the compound of Formula I inhibits akinase selected from the group consisting of EGFR., HER2, HER3, HER4,KDR, ALK, ARK5, BLK, BTK, FGFR1, FGFR2, FGFR3, FMS, ITK, JAK1, JAK2,JAK3, PLK1, PLK2, PLK3, PLK4, FAK, and SNARK, Src and Ret, and anymutated versions thereof with an IC₅₀ in an in vitro assay of 10 μM, 5μM, 2 μM, 1 μM, 500 nM, 200 nM, 100 nM or less as ascertained in an invitro kinase assay. In some embodiments, the compound of Formula Iinhibits a kinase selected from the group consisting of EGFR, EGFRL858R, EGFR del E746-A750, EGFR T790M or EGFR L858R/T790M mutant with anIC₅₀ in an in vitro assay of 10 μM, 5 μM, 2 μM, 1 μM, 500 nM, 200 nM,100 nM or less as ascertained in an in vitro kinase assay. For example,the compound of Formula I inhibits a kinase which is EGFR or EGFRL858R/T790M mutant with an IC₅₀ in an in vitro assay of 10 μM, 5 μM, 2μM, 1 μM, 500 nM, 200 nM, 100 nM or less as ascertained in an in vitrokinase assay.

In some embodiments, the compound of Formula I inhibits the activity ofone or more kinases selected from the group consisting of BTK, EGFR,EGFR L858R, EGFR T790M or EGFR L858R/T790M with an IC₅₀ in an in vitroassay of 1 μM, 500 nM, 200 nM, 100 nM, 50 nM, 25 nM or less asascertained in an in vitro kinase assay.

In some embodiments, the compound of Formula I selectively inhibits theactivity of one or more kinases selected from the group consisting ofAbl, Akt1, Akt2, Akt3, ALK, Alk5, A-Raf, B-Raf, Brk, BTK, Cdk2, CDK4,CDK5, CDK6, CHK1, c-Raf-1, Csk, EGFR, EphA1, EphA2, EphB2, EphB4, Erk2,Fak, FGFR1, FGFR2, FGFR3, FGFR4, Flt1, Flt3, Flt4, Fins, Frk, Fyn,Gsk3alpha, Gsk3beta, HCK, Her2/Erbb2, Her4/Erbb4, IGF1R, IKK beta,Irak4, Itk, Jak1, Jak2, Jak3, Jnk1, Jnk2, Jnk3, KDR, Kit, Lck, Lyn,MAP2K1, MAP2K2, MAP4K4, MAPKAPK2, Met, Mnk1, MLK1, p38, PDGFRA, PDGFRB,PDPK1, Pim1, Pim2, Pim3, PKC alpha, PKC beta, PKC theta, Plk1, Pyk2,ROCK1, ROCK2, Ron, Src, Stk6, Syk, TEC, Tie2, TrkA, TrkB, Yes, andZap70, including any mutated versions thereof. For example, the compoundof Formula I selectively inhibits the activity of one or more kinasesselected from the group consisting of EGFR, EGFR L858R, EGFR T790M, EGFRdel E746-A750 or EGFR L858R/T790M, HER2, HER3, HER4, KDR, ALK, ARK5,BLK, BTK, FGFR1, FGFR2, FGFR3, FMS, ITK, JAK1, JAK2, JAK3, PLK1, PLK2,PLK3, PLK4, FAK, and SNARK, Src and Ret, In some embodiments, thecompound of Formula I selectively inhibits the activity of one or morekinases selected from the group consisting of EGFR, EGFR L858R, EGFRT790M, EGFR del E746-A750 or EGFR L858R/T790M mutant.

In some embodiments, the compound of Formula I selectively inhibits theactivity of, EGFR L858R, EGFR T790M, EGFR del E746-A750, or EGFRL858R/T790M mutant relative to one or more kinases selected from thegroup consisting of ABL1, AKT1 (PKB alpha), AURKB (Aurora B), BLK, BTK,CDK1/cyclin B, CHEK1 (CHK1), CSF1R (FMS), CSNK1G2 (CK1 gamma 2), EGFR(ErbB1), FGFR1, FGFR2, FGFR3, FGR, FLT3, FRAP1 (mTOR), FYN, IGF1R, IKBKB(IKK beta), INSR, JAK1, JAK2, JAK3, KDR, KIT, LCK, LYN A, MAP2K1 (MEK1),MAP4K5 (KHS1), MAPK1 (ERK2), MAPK14 (p38 alpha), MAPKAPK2, MET (cMet),PDGFRB (PDGFRbeta), PIK3CA/PIK3R1 (p110 alpha/p85 alpha)PRKCB2 (PKC betaII), PTK2B (FAK2), PTK6 (Brk), RAF1 (cRAF) Y340D Y341D, RET, RPS6KB1(p70S6K), SRC, SRMS (Srm), and YES1. In some embodiments, the compoundof Formula I selectively inhibits the activity of one or more kinasesselected from the group consisting of BTK, EGFR L858R, EGFR T790M EGFRdel E746-A750, or EGFR L858R/T790M with an IC₅₀ which is ½, ⅓^(rd),¼^(th), ⅕^(th), 1/7^(th), 1/10^(th), 1/15^(th), 1/20^(th), 1/25^(th),1/30^(th), 1/40^(th), 1/50^(th), 1/100^(th), 1/150^(th), 1/200^(th)1/300^(th), 1/400^(th), 1/500^(th), 1/1000^(th), 1/2000^(th) or lessthan the IC₅₀ for a kinase selected from the group consisting of ABL1,AKT1 (PKB alpha), AURKB (Aurora B), BLK, BTK, CDK1/cyclin B, CHEK1(CHK1), CSNK1G2 (CK1 gamma 2), EGFR (ErbB1), FGFR1, FGFR2, FGFR3, FGR,FLT3, FRAP1 (mTOR), FYN, IGF1R, IKBKB (IKK beta), INSR, JAK1, JAK2,JAK3, KDR, KIT, LCK, LYN A, MAP2K1 (MEK1), MAP4K5 (KHS1), MAPK1 (ERK2),MAPK14 (p38 alpha), MAPKAPK2, MET (cMet), PDGFRB (PDGFR beta),PIK3CA/PIK3R1 (p110 alpha/p85 alpha)PRKCB2 (PKC beta II), PTK2B (FAK2),PTK6 (Brk), RAF1 (cRAF) Y340D Y341D, RET, RPS6KB1 (p70S6K), SRC, SRMS(Srm), and YES1.

In some embodiments, one or more compounds of Formula I are capable ofinhibiting cellular proliferation. For example, In some embodiments, oneor more compounds of Formula I inhibit proliferation of tumor cells ortumor cell lines. For example, such cell lines express a kinase which isEGFR L858R, EGFR T790M, EGFR del E746-A750, or EGFR L858R/T790M mutant.In some embodiments, the compounds of Formula I inhibit A549, A431,HCC827 or H1975 cell proliferation in vitro or in an in vivo model suchas a xenograft mouse model. In some embodiments, in vitro culturedHCC827 or H1975 cell proliferation may be inhibited with an IC₅₀ of lessthan 100 μM, 75 μM, 50 μM, 25 μM, 15 μM, 10 μM, 5 μM, 3 μM, 2 μM, 1 μMor less by one or more compounds of Formula I.

B. Methods of Making

Compounds disclosed herein may be prepared by the routes describedbelow. Materials used herein are either commercially available orprepared by synthetic methods generally known in the art. These schemesare not limited to the compounds listed or by any particularsubstituents, which are employed for illustrative purposes. Althoughvarious steps of are described and depicted in Scheme A, the steps insome cases may be performed in a different order than the order shown inScheme A. Various modifications to these synthetic reaction schemes maybe made and will be suggested to one skilled in the art having referredto the disclosure contained in this Application. Numbering does notnecessarily correspond to that of claims or other tables.

In Scheme A, A-1 is reacted with A-2 in the presence of a base or acidgives compounds of Formula I. Suitable bases include, but are notlimited to, Cs₂CO₃, NaH, KH, t-BuOK, LiH, and CaH₂. Suitable acidsinclude, but are not limited to, HCl, TFA, acetic acid, MeSO₃H, andp-toluenesulfonic acid. Suitable solvents include, but are not limitedto, DMF, DMSO, DMA, and N-methyl piperidone. The reaction are generallycarried out at a temperature ranging from 25 to 240° C.

In Scheme B, A-3 is reacted with A-4 in the presence of a base or acidgives compounds of Formula I. Suitable bases include, but are notlimited to, Cs₂CO₃, NaH, KH, t-BuOK, LiH, and CaH₂. Suitable acidsinclude, but are not limited to, HCl, TFA, acetic acid, MeSO₃H, andp-toluenesulfonic acid. Suitable solvents include, but are not limitedto, DMF, DMSO, DMA, and N-methyl piperidone. The reaction are generallycarried out at a temperature ranging from 25 to 240° C. Suzukicross-coupling reaction of A-5 with boronic acid or ester A-6 in thepresence of a base, such as Na₂CO₃, K₂CO₃, Cs₂CO₃, and a Pd catalyst,gives compounds of Formula I. The reaction is generally carried out at atemperature ranging from 25 to 180° C. in a suitable solvent such as1,4-dioxane, water, tetrahydrofuran, or a mixture thereof.

C. Pharmaceutical Compositions and Formulations

In some embodiments, the compounds described herein are formulated intopharmaceutical compositions. In specific embodiments, pharmaceuticalcompositions are formulated in a conventional manner using one or morephysiologically acceptable carriers comprising excipients andauxiliaries which facilitate processing of the active compounds intopreparations which can be used pharmaceutically. Proper formulation isdependent upon the route of administration chosen. Any pharmaceuticallyacceptable techniques, carriers, and excipients are used as suitable toformulate the pharmaceutical compositions described herein: Remington:The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: MackPublishing Company, 1995); Hoover, John E., Remington's PharmaceuticalSciences, Mack Publishing Co., Easton, Pa. 1975; Liberman, H. A. andLachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York,N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems,Seventh Ed. (Lippincott Williams & Wilkins 1999).

Provided herein are pharmaceutical compositions comprising a compound ofFormula I, and a pharmaceutically acceptable diluent(s), excipient(s),or carrier(s). In certain embodiments, the compounds described areadministered as pharmaceutical compositions in which compounds ofFormula I, are mixed with other active ingredients, as in combinationtherapy. Encompassed herein are all combinations of actives set forth inthe combination therapies section below and throughout this disclosure.In specific embodiments, the pharmaceutical compositions include one ormore compounds of Formula I.

A pharmaceutical composition, as used herein, refers to a mixture of acompound of Formula I, with other chemical components, such as carriers,stabilizers, diluents, dispersing agents, suspending agents, thickeningagents, and/or excipients. In certain embodiments, the pharmaceuticalcomposition facilitates administration of the compound to an organism.In some embodiments, practicing the methods of treatment or use providedherein, therapeutically effective amounts of compounds of Formula I,provided herein are administered in a pharmaceutical composition to amammal having a disease or condition to be treated. In specificembodiments, the mammal is a human. In certain embodiments,therapeutically effective amounts vary depending on the severity of thedisease, the age and relative health of the subject, the potency of thecompound used and other factors. The compounds described herein are usedsingly or in combination with one or more therapeutic agents ascomponents of mixtures.

In one embodiment, one or more compounds of Formula I, is formulated inan aqueous solution. In specific embodiments, the aqueous solution isselected from, by way of example only, a physiologically compatiblebuffer, such as Hank's solution, Ringer's solution, or physiologicalsaline buffer. In other embodiments, one or more compound of Formula I,is formulated for transmucosal administration. In specific embodiments,transmucosal formulations include penetrants that are appropriate to thebarrier to be permeated. In still other embodiments wherein thecompounds described herein are formulated for other parenteralinjections, appropriate formulations include aqueous or nonaqueoussolutions. In specific embodiments, such solutions includephysiologically compatible buffers and/or excipients.

In another embodiment, compounds described herein are formulated fororal administration. Compounds described herein, including compounds ofFormula I, are formulated by combining the active compounds with, e.g.,pharmaceutically acceptable carriers or excipients. In variousembodiments, the compounds described herein are formulated in oraldosage forms that include, by way of example only, tablets, powders,pills, dragees, capsules, liquids, gels, syrups, elixirs, slurries,suspensions and the like.

In certain embodiments, pharmaceutical preparations for oral use areobtained by mixing one or more solid excipient with one or more of thecompounds described herein, optionally grinding the resulting mixture,and processing the mixture of granules, after adding suitableauxiliaries, if desired, to obtain tablets or dragee cores. Suitableexcipients are, in particular, fillers such as sugars, includinglactose, sucrose, mannitol, or sorbitol; cellulose preparations such as:for example, maize starch, wheat starch, rice starch, potato starch,gelatin, gum tragacanth, methylcellulose, microcrystalline cellulose,hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or otherssuch as: polyvinylpyrrolidone (PVP or povidone) or calcium phosphate. Inspecific embodiments, disintegrating agents are optionally added.Disintegrating agents include, by way of example only, cross-linkedcroscarmellose sodium, polyvinylpyrrolidone, agar, or alginic acid or asalt thereof such as sodium alginate.

In one embodiment, dosage forms, such as dragee cores and tablets, areprovided with one or more suitable coating. In specific embodiments,concentrated sugar solutions are used for coating the dosage form. Thesugar solutions, optionally contain additional components, such as byway of example only, gum arabic, talc, polyvinylpyrrolidone, carbopolgel, polyethylene glycol, and/or titanium dioxide, lacquer solutions,and suitable organic solvents or solvent mixtures. Dyestuffs and/orpigments are also optionally added to the coatings for identificationpurposes. Additionally, the dyestuffs and/or pigments are optionallyutilized to characterize different combinations of active compounddoses.

In certain embodiments, therapeutically effective amounts of at leastone of the compounds described herein are formulated into other oraldosage forms. Oral dosage forms include push-fit capsules made ofgelatin, as well as soft, sealed capsules made of gelatin and aplasticizer, such as glycerol or sorbitol. In specific embodiments,push-fit capsules contain the active ingredients in admixture with oneor more filler. Fillers include, by way of example only, lactose,binders such as starches, and/or lubricants such as talc or magnesiumstearate and, optionally, stabilizers. In other embodiments, softcapsules, contain one or more active compound that is dissolved orsuspended in a suitable liquid. Suitable liquids include, by way ofexample only, one or more fatty oil, liquid paraffin, or liquidpolyethylene glycol. In addition, stabilizers are optionally added.

In other embodiments, therapeutically effective amounts of at least oneof the compounds described herein are formulated for buccal orsublingual administration. Formulations suitable for buccal orsublingual administration include, by way of example only, tablets,lozenges, or gels. In still other embodiments, the compounds describedherein are formulated for parental injection, including formulationssuitable for bolus injection or continuous infusion. In specificembodiments, formulations for injection are presented in unit dosageform (e.g., in ampoules) or in multi-dose containers. Preservatives are,optionally, added to the injection formulations. In still otherembodiments, the pharmaceutical composition of a compound of Formula Iis formulated in a form suitable for parenteral injection as sterilesuspension, solution or emulsion in oily or aqueous vehicles. Parenteralinjection formulations optionally contain formulatory agents such assuspending, stabilizing and/or dispersing agents. In specificembodiments, pharmaceutical formulations for parenteral administrationinclude aqueous solutions of the active compounds in water-soluble form.In additional embodiments, suspensions of the active compounds areprepared as appropriate oily injection suspensions. Suitable lipophilicsolvents or vehicles for use in the pharmaceutical compositionsdescribed herein include, by way of example only, fatty oils such assesame oil, or synthetic fatty acid esters, such as ethyl oleate ortriglycerides, or liposomes. In certain specific embodiments, aqueousinjection suspensions contain substances which increase the viscosity ofthe suspension, such as sodium carboxymethyl cellulose, sorbitol, ordextran. Optionally, the suspension contains suitable stabilizers oragents which increase the solubility of the compounds to allow for thepreparation of highly concentrated solutions. Alternatively, in otherembodiments, the active ingredient is in powder form for constitutionwith a suitable vehicle, e.g., sterile pyrogen-free water, before use.

In still other embodiments, the compounds of Formula I are administeredtopically. The compounds described herein are formulated into a varietyof topically administrable compositions, such as solutions, suspensions,lotions, gels, pastes, medicated sticks, balms, creams or ointments.Such pharmaceutical compositions optionally contain solubilizers,stabilizers, tonicity enhancing agents, buffers and preservatives.

In yet other embodiments, the compounds of Formula I are formulated fortransdermal administration. In specific embodiments, transdermalformulations employ transdermal delivery devices and transdermaldelivery patches and can be lipophilic emulsions or buffered, aqueoussolutions, dissolved and/or dispersed in a polymer or an adhesive. Invarious embodiments, such patches are constructed for continuous,pulsatile, or on demand delivery of pharmaceutical agents. In additionalembodiments, the transdermal delivery of the compounds of Formula I, isaccomplished by means of iontophoretic patches and the like. In certainembodiments, transdermal patches provide controlled delivery of thecompounds of Formula I. In specific embodiments, the rate of absorptionis slowed by using rate-controlling membranes or by trapping thecompound within a polymer matrix or gel. In alternative embodiments,absorption enhancers are used to increase absorption. Absorptionenhancers or carriers include absorbable pharmaceutically acceptablesolvents that assist passage through the skin. For example, in oneembodiment, transdermal devices are in the form of a bandage comprisinga backing member, a reservoir containing the compound optionally withcarriers, optionally a rate controlling barrier to deliver the compoundto the skin of the host at a controlled and predetermined rate over aprolonged period of time, and means to secure the device to the skin.

In other embodiments, the compounds of Formula I, are formulated foradministration by inhalation. Various forms suitable for administrationby inhalation include, but are not limited to, aerosols, mists orpowders. Pharmaceutical compositions of Formula I, are convenientlydelivered in the form of an aerosol spray presentation from pressurizedpacks or a nebuliser, with the use of a suitable propellant (e.g.,dichlorodifluoromethane, trichlorofluoromethane,dichlorotetrafluoroethane, carbon dioxide or other suitable gas). Inspecific embodiments, the dosage unit of a pressurized aerosol isdetermined by providing a valve to deliver a metered amount. In certainembodiments, capsules and cartridges of, such as, by way of exampleonly, gelatin for use in an inhaler or insufflator are formulatedcontaining a powder mix of the compound and a suitable powder base suchas lactose or starch.

In still other embodiments, the compounds of Formula I, are formulatedin rectal compositions such as enemas, rectal gels, rectal foams, rectalaerosols, suppositories, jelly suppositories, or retention enemas,containing conventional suppository bases such as cocoa butter or otherglycerides, as well as synthetic polymers such as polyvinylpyrrolidone,PEG, and the like. In suppository forms of the compositions, alow-melting wax such as, but not limited to, a mixture of fatty acidglycerides, optionally in combination with cocoa butter is first melted.

In certain embodiments, pharmaceutical compositions are formulated inany conventional manner using one or more physiologically acceptablecarriers comprising excipients and auxiliaries which facilitateprocessing of the active compounds into preparations which can be usedpharmaceutically. Proper formulation is dependent upon the route ofadministration chosen. Any pharmaceutically acceptable techniques,carriers, and excipients are optionally used as suitable. Pharmaceuticalcompositions comprising a compound of Formula I, are manufactured in aconventional manner, such as, by way of example only, by means ofconventional mixing, dissolving, granulating, dragee-making, levigating,emulsifying, encapsulating, entrapping or compression processes.

Pharmaceutical compositions include at least one pharmaceuticallyacceptable carrier, diluent or excipient and at least one compound ofFormula I, described herein as an active ingredient. The activeingredient is in free-acid or free-base form, or in a pharmaceuticallyacceptable salt form. In addition, the methods and pharmaceuticalcompositions described herein include the use of N-oxides, crystallineforms (also known as polymorphs), as well as active metabolites of thesecompounds having the same type of activity. All tautomers of thecompounds described herein are included within the scope of thecompounds presented herein. Additionally, the compounds described hereinencompass unsolvated as well as solvated forms with pharmaceuticallyacceptable solvents such as water, ethanol, and the like. The solvatedforms of the compounds presented herein are also considered to bedisclosed herein. In addition, the pharmaceutical compositionsoptionally include other medicinal or pharmaceutical agents, carriers,adjuvants, such as preserving, stabilizing, wetting or emulsifyingagents, solution promoters, salts for regulating the osmotic pressure,buffers, and/or other therapeutically valuable substances.

Methods for the preparation of compositions comprising the compoundsdescribed herein include formulating the compounds with one or moreinert, pharmaceutically acceptable excipients or carriers to form asolid, semi-solid or liquid. Solid compositions include, but are notlimited to, powders, tablets, dispersible granules, capsules, cachets,and suppositories. Liquid compositions include solutions in which acompound is dissolved, emulsions comprising a compound, or a solutioncontaining liposomes, micelles, or nanoparticles comprising a compoundas disclosed herein. Semi-solid compositions include, but are notlimited to, gels, suspensions and creams. The form of the pharmaceuticalcompositions described herein include liquid solutions or suspensions,solid forms suitable for solution or suspension in a liquid prior touse, or as emulsions. These compositions also optionally contain minoramounts of nontoxic, auxiliary substances, such as wetting oremulsifying agents, pH buffering agents, and so forth.

In some embodiments, a pharmaceutical composition comprising at leastone compound of Formula I, illustratively takes the form of a liquidwhere the agents are present in solution, in suspension or both.Typically when the composition is administered as a solution orsuspension a first portion of the agent is present in solution and asecond portion of the agent is present in particulate form, insuspension in a liquid matrix. In some embodiments, a liquid compositionincludes a gel formulation. In other embodiments, the liquid compositionis aqueous.

In certain embodiments, useful aqueous suspension contain one or morepolymers as suspending agents. Useful polymers include water-solublepolymers such as cellulosic polymers, e.g., hydroxypropylmethylcellulose, and water-insoluble polymers such as cross-linkedcarboxyl-containing polymers. Certain pharmaceutical compositionsdescribed herein comprise a mucoadhesive polymer, selected for examplefrom carboxymethylcellulose, carbomer (acrylic acid polymer),poly(methylmethacrylate), polyacrylamide, polycarbophil, acrylicacid/butyl acrylate copolymer, sodium alginate and dextran.

Useful pharmaceutical compositions also, optionally, includesolubilizing agents to aid in the solubility of a compound of Formula I.The term “solubilizing agent” generally includes agents that result information of a micellar solution or a true solution of the agent.Certain acceptable nonionic surfactants, for example polysorbate 80, areuseful as solubilizing agents, as can ophthalmically acceptable glycols,polyglycols, e.g., polyethylene glycol 400, and glycol ethers.

Furthermore, useful pharmaceutical compositions optionally include oneor more pH adjusting agents or buffering agents, including acids such asacetic, boric, citric, lactic, phosphoric and hydrochloric acids; basessuch as sodium hydroxide, sodium phosphate, sodium borate, sodiumcitrate, sodium acetate, sodium lactate andtris-hydroxymethylaminomethane; and buffers such as citrate/dextrose,sodium bicarbonate and ammonium chloride. Such acids, bases and buffersare included in an amount required to maintain pH of the composition inan acceptable range.

Additionally, useful compositions also, optionally, include one or moresalts in an amount required to bring osmolality of the composition intoan acceptable range. Such salts include those having sodium, potassiumor ammonium cations and chloride, citrate, ascorbate, borate, phosphate,bicarbonate, sulfate, thiosulfate or bisulfite anions; suitable saltsinclude sodium chloride, potassium chloride, sodium thiosulfate, sodiumbisulfite and ammonium sulfate.

Other useful pharmaceutical compositions optionally include one or morepreservatives to inhibit microbial activity. Suitable preservativesinclude mercury-containing substances such as merfen and thiomersal;stabilized chlorine dioxide; and quaternary ammonium compounds such asbenzalkonium chloride, cetyltrimethylammonium bromide andcetylpyridinium chloride.

Still other useful compositions include one or more surfactants toenhance physical stability or for other purposes. Suitable nonionicsurfactants include polyoxyethylene fatty acid glycerides and vegetableoils, e.g., polyoxyethylene (60) hydrogenated castor oil; andpolyoxyethylene alkylethers and alkylphenyl ethers, e.g., octoxynol 10,octoxynol 40.

Still other useful compositions include one or more antioxidants toenhance chemical stability where required. Suitable antioxidantsinclude, by way of example only, ascorbic acid and sodium metabisulfite.

In certain embodiments, aqueous suspension compositions are packaged insingle-dose non-reclosable containers. Alternatively, multiple-dosereclosable containers are used, in which case it is typical to include apreservative in the composition.

In alternative embodiments, other delivery systems for hydrophobicpharmaceutical compounds are employed. Liposomes and emulsions areexamples of delivery vehicles or carriers useful herein. In certainembodiments, organic solvents such as N-methylpyrrolidone are alsoemployed. In additional embodiments, the compounds described herein aredelivered using a sustained-release system, such as semipermeablematrices of solid hydrophobic polymers containing the therapeutic agent.Various sustained-release materials are useful herein. In someembodiments, sustained-release capsules release the compounds for a fewweeks up to over 100 days. Depending on the chemical nature and thebiological stability of the therapeutic reagent, additional strategiesfor protein stabilization are employed.

In certain embodiments, the formulations described herein comprise oneor more antioxidants, metal chelating agents, thiol containing compoundsand/or other general stabilizing agents. Examples of such stabilizingagents, include, but are not limited to: (a) about 0.5% to about 2% w/vglycerol, (b) about 0.1% to about 1% w/v methionine, (c) about 0.1% toabout 2% w/v monothioglycerol, (d) about 1 mM to about 10 mM EDTA, (e)about 0.01% to about 2% w/v ascorbic acid, (f) 0.003% to about 0.02% w/vpolysorbate 80, (g) 0.001% to about 0.05% w/v. polysorbate 20, (h)arginine, (i) heparin, (j) dextran sulfate, (k) cyclodextrins, (1)pentosan polysulfate and other heparinoids, (m) divalent cations such asmagnesium and zinc; or (n) combinations thereof.

D. Routes of Administration

Suitable routes of administration include, but are not limited to, oral,intravenous, rectal, aerosol, parenteral, ophthalmic, pulmonary,transmucosal, transdermal, vaginal, otic, nasal, and topicaladministration. In addition, by way of example only, parenteral deliveryincludes intramuscular, subcutaneous, intravenous, intramedullaryinjections, as well as intrathecal, direct intraventricular,intraperitoneal, intralymphatic, and intranasal injections.

In certain embodiments, a compound as described herein is administeredin a local rather than systemic manner, for example, via injection ofthe compound directly into an organ, often in a depot preparation orsustained release formulation. In specific embodiments, long actingformulations are administered by implantation (for examplesubcutaneously or intramuscularly) or by intramuscular injection.Furthermore, in other embodiments, the drug is delivered in a targeteddrug delivery system, for example, in a liposome coated withorgan-specific antibody. In such embodiments, the liposomes are targetedto and taken up selectively by the organ. In yet other embodiments, thecompound as described herein is provided in the form of a rapid releaseformulation, in the form of an extended release formulation, or in theform of an intermediate release formulation. In yet other embodiments,the compound described herein is administered topically.

E. Kits/Articles of Manufacture

For use in the therapeutic applications described herein, kits andarticles of manufacture are also provided. In some embodiments, suchkits comprise a carrier, package, or container that is compartmentalizedto receive one or more containers such as vials, tubes, and the like,each of the container(s) comprising one of the separate elements to beused in a method described herein. Suitable containers include, forexample, bottles, vials, syringes, and test tubes. The containers areformed from a variety of materials such as glass or plastic.

The articles of manufacture provided herein contain packaging materials.Packaging materials for use in packaging pharmaceutical products Includethose found in, e.g., U.S. Pat. Nos. 5,323,907, 5,052,558 and 5,033,252.Examples of pharmaceutical packaging materials include, but are notlimited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials,containers, syringes, bottles, and any packaging material suitable for aselected formulation and intended mode of administration and treatment.For example, the container(s) includes one or more compounds describedherein, optionally in a composition or in combination with another agentas disclosed herein. The container(s) optionally have a sterile accessport (for example the container is an intravenous solution bag or a vialhaving a stopper pierceable by a hypodermic injection needle). Such kitsoptionally comprising a compound with an identifying description orlabel or instructions relating to its use in the methods describedherein.

For example, a kit typically includes one or more additional containers,each with one or more of various materials (such as reagents, optionallyin concentrated form, and/or devices) desirable from a commercial anduser standpoint for use of a compound described herein. Non-limitingexamples of such materials include, but not limited to, buffers,diluents, filters, needles, syringes; carrier, package, container, vialand/or tube labels listing contents and/or instructions for use, andpackage inserts with instructions for use. A set of instructions willalso typically be included. A label is optionally on or associated withthe container. For example, a label is on a container when letters,numbers or other characters forming the label are attached, molded oretched into the container itself, a label is associated with a containerwhen it is present within a receptacle or carrier that also holds thecontainer, e.g., as a package insert. In addition, a label is used toindicate that the contents are to be used for a specific therapeuticapplication. In addition, the label indicates directions for use of thecontents, such as in the methods described herein. In certainembodiments, the pharmaceutical compositions is presented in a pack ordispenser device which contains one or more unit dosage forms containinga compound provided herein. The pack for example contains metal orplastic foil, such as a blister pack. Or, the pack or dispenser deviceis accompanied by instructions for administration. Or, the pack ordispenser is accompanied with a notice associated with the container inform prescribed by a governmental agency regulating the manufacture,use, or sale of pharmaceuticals, which notice is reflective of approvalby the agency of the form of the drug for human or veterinaryadministration. Such notice, for example, is the labeling approved bythe U.S. Food and Drug Administration for prescription drugs, or theapproved product insert. In some embodiments, compositions containing acompound provided herein formulated in a compatible pharmaceuticalcarrier are prepared, placed in an appropriate container, and labeledfor treatment of an indicated condition.

F. Methods of Use

The chemical entities described herein are useful in the treatment, orin the preparation of a medicament for the treatment of variousdisorders. For example, compounds of Formula I are useful as inhibitorsof protein kinases. In some embodiments, the chemical entities describedherein are inhibitors of one or more kinases. For example, compounds ofFormula I are inhibitors of BTK or EGFR or mutants of such kinases,including the EGFR del E746-A750, EGFR del E747-E749/A750P, EGFR delE747-S752/P753S, EGFR del E747-T751/Sins/A750P, EGFR del S752-I759, EGFRG719S, EGFR G719C, EGFR L861Q, EGFR L858R, EGFR T790M or EGFRL858R/T790M mutant. Thus, without wishing to be bound by any particulartheory, the compounds of Formula I are particularly useful for treatingor lessening the severity of a disease, condition, or disorder whereactivation of one or more kinases, such as EGFR, which is implicated inthe disease, condition, or disorder. When activation of EGFR kinase isimplicated in a particular disease, condition, or disorder, the disease,condition, or disorder may also be referred to as “EGFR-mediateddisease” or disease symptom. Accordingly, in another aspect, the presentinvention provides a method for treating or lessening the severity of adisease, condition, or disorder where activation of EGFR and/or otherkinases is implicated in the disease state.

The inhibition of kinases may be assayed in vitro, in vivo or in a cellline. In vitro assays include assays that determine inhibition of eitherthe phosphorylation activity or ATPase activity of activated kinase.Alternate in vitro assays quantitate the ability of the inhibitor tobind to kinase. Inhibitor binding may be measured by radiolabelling theinhibitor prior to binding, isolating the inhibitor, complex anddetermining the amount of radiolabel bound. Alternatively, inhibitorbinding may be determined by running a competition experiment where newinhibitors are incubated with kinase bound to known radioligands. At 1micro-molar concentration, one or more compounds of the presentinvention exhibits at least about 50%, 60%, 70, 80%, 90% or even higherinhibition of kinases including BTK, EGFR, EGFR L858R, EGFR delE746-A750, EGFR T790M or EGFR L858R/T790M.

The chemical entities described herein may be prepared in substantiallypure form, typically by standard chromatographic methods, prior toformulation in a pharmaceutically acceptable form.

The chemical entities described herein may be used in treating a varietyof cancers. Cancers that can be prevented and/or treated by the chemicalentities, compositions, and methods described herein include, but arenot limited to, human sarcomas and carcinomas, e.g. carcinomas, e.g.,colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer,prostate cancer, thyroid cancer, fibrosarcoma, myxosarcoma, liposarcoma,chondrosarcoma, osteogenic sarcoma, chondroma, angiosarcoma,endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma,synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma,rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma,adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma,papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma,medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma,hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonalcarcinoma, Wilms' tumor, cervical cancer, testicular tumor, lungcarcinoma, small cell lung carcinoma, bladder carcinoma, epithelialcarcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma,ependymoma, pinealoma, hemangioblastoma, acoustic neuroma,oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma,leukemias, e.g., acute lymphocytic leukemia and acute myelocyticleukemia (myeloblastic, promyelocytic, myelomonocytic, monocytic anderythroleukemia); chronic leukemia (chronic myelocytic (granulocytic)leukemia and chronic lymphocytic leukemia); and polycythemia vera,lymphoma (Hodgkin's disease and non-Hodgkin's disease), multiplemyeloma, Waldenstrom's macroglobulinemia, and heavy chain disease.

In some embodiments, the chemical entities described herein are used forthe treatment of cancers of the

-   -   i. digestive system including, without limitation, the        esophagus, stomach, small intestine, colon (including        colorectal), liver & intrahepatic bile duct, gallbladder & other        biliary, pancreas, and other digestive organs;    -   ii. respiratory system, including without limitation, larynx,        lung & bronchus, and other respiratory organs;    -   iii. skin;    -   iv. thyroid;    -   v. breast;    -   vi. genital system, including without limitation, uterine        cervix, ovary, and prostate;    -   vii. urinary system, including without limitation, urinary        bladder and kidney and renal pelvis; and    -   viii. oral cavity & pharynx, including without limitation,        tongue, mouth, pharynx, and other oral cavity.

In some embodiments, the chemical entities described herein are used forthe treatment of colon cancer, liver cancer, lung cancer, melanoma,thyroid cancer, breast cancer, ovarian cancer, and oral cancer.

The chemical entities described herein may also be used in conjunctionwith other well known therapeutic agents that are selected for theirparticular usefulness against the condition that is being treated. Forexample, the chemical entities described herein may be useful incombination with at least one additional anti-cancer and/or cytotoxicagents. Further, the chemical entities described herein may also beuseful in combination with other inhibitors of parts of the signalingpathway that links cell surface growth factor receptors to nuclearsignals initiating cellular proliferation.

Such known anti-cancer and/or cytotoxic agents that may be used incombination with the chemical entities described herein include:

(i) other antiproliferative/antineoplastic drugs and combinationsthereof, as used in medical oncology, such as alkylating agents (forexample cis-platin, oxaliplatin, carboplatin, cyclophosphamide, nitrogenmustard, melphalan, chlorambucil, busulphan, temozolamide andnitrosoureas); antimetabolites (for example gemcitabine and antifolatessuch as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed,methotrexate, cytosine arabinoside, and hydroxyurea); antitumorantibiotics (for example anthracyclines like adriamycin, bleomycin,doxorubicin, daunomycin, epirubicin, idarubicin, mitomycinC,dactinomycin and mithramycin); antimitotic agents (for example vincaalkaloids like vincristine, vinblastine, vindesine and vinorelbine andtaxoids like taxol and taxotere and polokinase inhibitors); andtopoisomerase inhibitors (for example epipodophyllotoxins like etoposideand teniposide, amsacrine, topotecan and camptothecin);

(ii) cytostatic agents such as antioestrogens (for example tamoxifen,fulvestrant, toremifene, raloxifene, droloxifene and iodoxyfene),antiandrogens (for example bicalutamide, flutamide, nilutamide andcyproterone acetate), LHRH antagonists or LHRH agonists (for examplegoserelin, leuprorelin and buserelin), progestogens (for examplemegestrol acetate), aromatase inhibitors (for example as anastrozole,letrozole, vorazole and exemestane) and inhibitors of 5a-reductase suchas finasteride;

(iii) anti-invasion agents[for example c-Src kinase family inhibitorslike4-(6-chloro-2,3methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4yloxyquinazoline(AZD0530; International Patent Application WO 01/94341),N-(2-chloro-6-methylphenyl)-2-{6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4ylamino}thiazole-5-carboxamide(dasatinib, BMS-354825; J. Med. Chem., 2004, 47, 66586661) and bosutinib(SK1-606), and metalloproteinase inhibitors like marimastat, inhibitorsof urokinase plasminogen activator receptor function or antibodies toHeparanase];

(iv) inhibitors of growth factor function: for example such inhibitorsinclude growth factor antibodies and growth factor receptor antibodies(for example the anti-erbB2 antibody trastuzumab [Herceptin™], theanti-EGFR antibody panitumumab, the anti-erbB 1 antibody cetuximab[Erbitux, C225] and any growth factor or growth factor receptorantibodies disclosed by Stem et al. Critical reviews inoncology/haematology, 2005, Vol. 54, pp 11-29); such inhibitors alsoinclude tyrosine kinase inhibitors, for example inhibitors of theepidermal growth factor family (for example EGFR family tyrosine kinaseinhibitors such asN-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine(gefitinib, ZD1839),N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine(erlotinib, OSI-774) and6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)-quinazolin-4-amine(CI 1033), erbB2 tyrosine kinase inhibitors such as lapatinib);inhibitors of the hepatocyte growth factor family; inhibitors of theinsulin growth factor family; inhibitors of the platelet-derived growthfactor family such as imatinib and/or nilotinib (AMN107); inhibitors ofserine/threonine kinases (for example Ras/Raf signalling inhibitors suchas farnesyl transferase inhibitors, for example sorafenib (BAY 43-9006),tipifarnib (RI15777) and lonafarnib (SCH66336)), inhibitors of cellsignalling through MEK and/or AKT kinases, c-kit inhibitors, abl kinaseinhibitors, P13 kinase inhibitors, Plt3 kinase inhibitors, CSF-IR kinaseinhibitors, IGF receptor (insulin like growth factor) kinase inhibitors;aurora kinase inhibitors (for example AZD1152, PH739358, VX-680,MLN8054, R763, MP235, MP529, VX-528 and AX39459) and cyclin dependentkinase inhibitors such as CDK2 and/or CDK4 inhibitors;

(v) antiangiogenic agents such as those which inhibit the effects ofvascular endothelial growth factor, [for example the anti-vascularendothelial cell growth factor antibody bevacizumab (Avastin™) and forexample, a VEGF receptor tyrosine kinase inhibitor such asvandetanib(ZD6474), vatalanib (PTK787), sunitinib (SU11248), axitinib(AG-013736), pazopanib (GW 786034) and4-{4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3pyrrolidin-1-ylpropoxy)quinazoline(AZD2171; Example 240 within WO 00/47212), compounds such as thosedisclosed in International Patent Applications WO 97/22596, WO 97/30035,WO 97/32856 and WO 98/13354 and compounds that work by other mechanisms(for example linomide, inhibitors of integrin av˜3 function andangiostatin)); (vi) vascular damaging agents such as Combretastatin A4and compounds disclosed in International Patent Applications WO99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO02/08213;

(vii) an endothelin receptor antagonist, for example zibotentan (ZD4054)or atrasentan;

(viii) antisense therapies, for example those which are directed to thetargets listed above, such as ISIS 2503, an anti-ras antisense;

(ix) gene therapy approaches, including for example approaches toreplace aberrant genes such as aberrant p53 or aberrant BRCA or BRCA2,GDEPT (gene-directed enzyme pro-drug therapy) approaches such as thoseusing cytosine deaminase, thymidine kinase or a bacterial nitroreductaseenzyme and approaches to increase subject tolerance to chemotherapy orradiotherapy such as multi-drug resistance gene therapy; and

(x) immunotherapy approaches, including for example ex-vivo and in-vivoapproaches to increase the immunogenicity of subject's tumor cells, suchas transfection with cytokines such as interleukin 2, interleukin 4 orgranulocyte-macrophage colony stimulating factor, approaches to decreaseT-cell energy, approaches using transfected immune cells such ascytokine-transfected dendritic cells, approaches usingcytokine-transfected tumor cell lines and approaches usinganti-idiotypic antibodies.

(xi) checkpoint inhibitors, including for example inhibitors ofcheckpoint proteins such as PD-1, PD-L1 or TCLA-4. Some examples ofcheckpoint inhibitors are pembrolizumab, nivoluma and Ipilimumab.

In certain embodiments, the at least one chemical entity is administeredin combination with one or more agents chosen from pacliataxel,bortezomib, dacarbazine, gemcitabine, trastuzumab, bevacizumab,capecitabine, docetaxel, erlotinib, aromatase inhibitors, such asAROMASIN™ (exemestane), and estrogen receptor inhibitors, such asFASLODEX™ (fulvestrant).

When a chemical entity described herein is administered into a humansubject, the daily dosage will normally be determined by the prescribingphysician with the dosage generally varying according to the age,weight, and response of the individual subject, as well as the severityof the subject's symptoms.

In one exemplary application, a suitable amount of at least one chemicalentity is administered to a mammal undergoing treatment for cancer, forexample, breast cancer. Administration typically occurs in an amount ofbetween about 0.01 mg/kg of body weight to about 100 mg/kg of bodyweight per day (administered in single or divided doses), such as atleast about 0.1 mg/kg of body weight per day. A particular therapeuticdosage can include, e.g., from about 0.01 mg to about 1000 mg of thechemical entity, such as including, e.g., from about 1 mg to about 1000mg. The quantity of the at least one chemical entity in a unit dose ofpreparation may be varied or adjusted from about 0.1 mg to 1000 mg, suchas from about 1 mg to 300 mg, for example 10 mg to 200 mg, according tothe particular application. The amount administered will vary dependingon the particular IC₅₀ value of the at least one chemical entity usedand the judgment of the attending clinician taking into considerationfactors such as health, weight, and age. In combinational applicationsin which the at least one chemical entity described herein is not thesole active ingredient, it may be possible to administer lesser amountsof the at least one chemical entity and still have therapeutic orprophylactic effect.

In some embodiments, the pharmaceutical preparation is in unit dosageform. In such form, the preparation is subdivided into unit dosescontaining appropriate quantities of the active component, e.g., aneffective amount to achieve the desired purpose.

The actual dosage employed may be varied depending upon the requirementsof the subject and the severity of the condition being treated.Determination of the proper dosage for a particular situation is withinthe skill of the art. Generally, treatment is initiated with smallerdosages which are less than the optimum dose of the at least onechemical entity. Thereafter, the dosage is increased by small amountsuntil the optimum effect under the circumstances is reached. Forconvenience, the total daily dosage may be divided and administered inportions during the day if desired.

The amount and frequency of administration of the at least one chemicalentities described herein, and if applicable other chemotherapeuticagents and/or radiation therapy, will be regulated according to thejudgment of the attending clinician (physician) considering such factorsas age, condition and size of the subject as well as severity of thedisease being treated.

The chemotherapeutic agent and/or radiation therapy can be administeredaccording to therapeutic protocols well known in the art. It will beapparent to those skilled in the art that the administration of thechemotherapeutic agent and/or radiation therapy can be varied dependingon the disease being treated and the known effects of thechemotherapeutic agent and/or radiation therapy on that disease. Also,in accordance with the knowledge of the skilled clinician, thetherapeutic protocols (e.g., dosage amounts and times of administration)can be varied in view of the observed effects of the administeredtherapeutic agents (i.e., antineoplastic agent or radiation) on thesubject, and in view of the observed responses of the disease to theadministered therapeutic agents.

Also, in general, the at least one chemical entities described hereinneed not be administered in the same pharmaceutical composition as achemotherapeutic agent, and may, because of different physical andchemical characteristics, be administered by a different route. Forexample, the chemical entities/compositions may be administered orallyto generate and maintain good blood levels thereof, while thechemotherapeutic agent may be administered intravenously. Thedetermination of the mode of administration and the advisability ofadministration, where possible, in the same pharmaceutical composition,is well within the knowledge of the skilled clinician. The initialadministration can be made according to established protocols known inthe art, and then, based upon the observed effects, the dosage, modes ofadministration and times of administration can be modified by theskilled clinician.

The particular choice of chemical entity (and where appropriate,chemotherapeutic agent and/or radiation) will depend upon the diagnosisof the attending physicians and their judgment of the condition of thesubject and the appropriate treatment protocol.

The chemical entities described herein (and where appropriatechemotherapeutic agent and/or radiation) may be administeredconcurrently (e.g., simultaneously, essentially simultaneously or withinthe same treatment protocol) or sequentially, depending upon the natureof the proliferative disease, the condition of the subject, and theactual choice of chemotherapeutic agent and/or radiation to beadministered in conjunction (i.e., within a single treatment protocol)with the chemical entity/composition.

In combinational applications and uses, the chemical entity/compositionand the chemotherapeutic agent and/or radiation need not be administeredsimultaneously or essentially simultaneously, and the initial order ofadministration of the chemical entity/composition, and thechemotherapeutic agent and/or radiation, may not be important. Thus, theat least one chemical entity described herein may be administered firstfollowed by the administration of the chemotherapeutic agent and/orradiation; or the chemotherapeutic agent and/or radiation may beadministered first followed by the administration of the at least onechemical entity described herein. This alternate administration may berepeated during a single treatment protocol. The determination of theorder of administration, and the number of repetitions of administrationof each therapeutic agent during a treatment protocol, is well withinthe knowledge of the skilled physician after evaluation of the diseasebeing treated and the condition of the subject. For example, thechemotherapeutic agent and/or radiation may be administered first, andthen the treatment continued with the administration of the at least onechemical entity described herein followed, where determinedadvantageous, by the administration of the chemotherapeutic agent and/orradiation, and so on until the treatment protocol is complete.

Thus, in accordance with experience and knowledge, the practicingphysician can modify each protocol for the administration of a chemicalentity/composition for treatment according to the individual subject'sneeds, as the treatment proceeds.

The attending clinician, in judging whether treatment is effective atthe dosage administered, will consider the general well-being of thesubject as well as more definite signs such as relief of disease-relatedsymptoms, inhibition of tumor growth, actual shrinkage of the tumor, orinhibition of metastasis. Size of the tumor can be measured by standardmethods such as radiological studies, e.g., CAT or MRI scan, andsuccessive measurements can be used to judge whether or not growth ofthe tumor has been retarded or even reversed. Relief of disease-relatedsymptoms such as pain, and improvement in overall condition can also beused to help judge effectiveness of treatment.

EXAMPLES

The following examples serve to more fully describe the manner of usingthe invention. These examples are presented for illustrative purposesand should not serve to limit the true scope of the invention.

In carrying out the procedures of the methods described herein, it is ofcourse to be understood that references to particular buffers, media,reagents, cells, culture conditions and the like are not intended to belimiting, but are to be read so as to include all related materials thatone of ordinary skill in the art would recognize as being of interest orvalue in the particular context in which that discussion is presented.For example, it is often possible to substitute one buffer system orculture medium for another and still achieve similar, if not identical,results. Those of skill in the art will have sufficient knowledge ofsuch systems and methodologies so as to be able, without undueexperimentation, to make such substitutions as will optimally servetheir purposes in using the methods and procedures disclosed herein.

Example 1: Preparation ofN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-phenylquinazolin-2-yl)amino)phenyl)acrylamide

A mixture of 2-amino-3-bromobenzoic acid (10.8 g, 50 mmol, 1 eq.) andurea (15 g, 250 mmol, 5 eq.) was stirred at 200° C. for 3 h, then cooledand poured into ice-water. The solid was collected by filtration, washedwith H₂O for three times and dried in vacuo to afford8-bromoquinazoline-2,4(1H,3H)-dione as a yellow solid (12.1 g, quant.yield).

To a mixture of 8-bromoquinazoline-2,4(1H,3H)-dione (12.1 g, 50 mmol, 1eq.) in POCl₃ (130 mL) was added DMF (0.5 mL). The mixture was stirredat 130° C. for 12 h, then cooled to r.t. and concentrated. The resultingresidue was dissolved in EA (100 mL) and poured into ice-water withvigorous stirring. The organic phase was separated and washed withbrine, dried over anhydrous Na₂SO₄ and concentrated. The resultingresidue was purified via column chromatography (PE/EA==10:1, v/v) toafford 8-bromo-2,4-dichloroquinazoline as a yellow solid (9.1 g, 60%yield).

To a solution of ammonia hydroxide (25 mL, 330 mmol, 10 eq.) in THF (50mL) cooled to 0° C. was added a solution of8-bromo-2,4-dichloroquinazoline (9.1 g, 32.7 mmol, 1 eq.) in THF (50mL). The mixture was stirred at 0° C. for 30 min, then diluted with EA(100 mL), washed with brine, dried over anhydrous Na₂SO₄ andconcentrated. The resulting residue was purified via columnchromatography (PE/EA=10:1, v/v) to afford8-bromo-2-chloroquinazolin-4-amine as a yellow solid (7.1 g, 83.5%yield).

To a solution of 8-bromo-2-chloroquinazoline (200 mg, 0.83 mmol, 1 eq.)and phenylboronic acid (122 mg, 0.99 mmol, 1.2 eq.) in dioxane/water (5mL/0.5 mL) was added Na₂CO₃ (352 mg, 3.32 mmol, 4 eq.), followed byPd(dppf)Cl₂ (33.9 mg, 0.04 mmol, 0.05 eq.) under N₂. The mixture wasstirred at 90° C. for 12 h, then cooled to r.t. and concentrated. Theresulting residue was purified via column chromatography (PE/EA=5/1,v/v) to afford 2-chloro-8-phenylquinazoline as a white solid (150 mg,75% yield).

A mixture of 2-fluoro-5-nitroaniline (4.7 g, 30 mmol, 1 eq.) andN¹,N¹,N²-trimethylethane-1,2-diamine (11.6 mL, 90 mmol, 3 eq.) in DMSO(10 mL) was heated at 120° C. for 12 h in a sealed autoclave, thencooled and poured into ice-water. The mixture was extracted with EA(3×150 mL), the combined organic phases were dried over anhydrous Na₂SO₄and concentrated. The resulting residue was purified via columnchromatography (DCM/MeOH=10:1, v/v) to affordN1-(2-(dimethylamino)ethyl)-N1-methyl-4-nitrobenzene-1,2-diamine as abrown solid (4.5 g, 63% yield).

To a solution ofN-(2-(dimethylamino)ethyl)-N1-methyl-4-nitrobenzene-1,2-diamine (476 mg,2 mmol, 1 eq.) in DCM (20 mL) was added TEA (810 mg, 8 mmol, 4 eq.),followed by acryloyl chloride (360 mg, 4 mmol, 2 eq.) at 0° C. Theresulting mixture was stirred at r.t. for 1 h, then diluted with DCM (50mL), washed with brine, dried over anhydrous Na₂SO₄ and concentrated.The resulting residue was purified via column chromatography(DCM/MeOH=10:1, v/v) to affordN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-nitrophenyl)acrylamide asa yellow solid (360 mg, 62% yield).

To a solution ofN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-nitrophenyl)acrylamide(360 mg, 1.2 mmol, 1 eq.) and Fe powder (360 mg, 6 mmol, 5 eq.) inEtOH/H₂O (10 mL/2 mL) was added conc.HCl (0.1 mL, 1.2 mmol, 1 eq.), andthe resulting mixture was stirred at 80° C. for 1 h. The mixture wasfiltered and the filtrate was concentrated. The resulting residue wasre-crystallized from EtOH (50 mL) to affordN-(5-amino-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide asa brown solid (260 mg, 83% yield).

To a solution ofN-(5-amino-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide(180 mg, 0.68 mmol, 1.1 eq.) and 2-chloro-8-phenylquinazoline (150 mg,0.62 mmol, 1 eq.) in n-BuOH (10 mL) was added TFA (356 mg, 3.12 mmol, 5eq.), and the resulting mixture was stirred at 90° C. for 24 h. Themixture was concentrated, and the residue was dissolved in DCM, washedwith Na₂CO₃ solution, dried over anhydrous Na₂SO₄, then purified viasilica column (DCM/MeOH=100/1-50/1, v/v) to affordN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-phenylquinazolin-2-yl)amino)phenyl)acrylamideas a brown solid (68.7 mg, 23.6% yield). LRMS (M+H⁺) m/z calculated467.2, found 467.2. ¹H NMR. (DMSO-d6, 400 MHz) δ 10.25 (s, 1H), 9.80 (s,1H), 9.33 (s, 1H), 8.40 (s, 1H), 7.92 (d, 1H), 7.71-7.83 (m, 4H),7.37-7.47 (m, 4H), 7.08 (d, 1H), 6.24-6.40 (m, 2H), 5.76-5.80 (m, 1H),2.79 (m, 2H), 2.65 (s, 3H), 2.21-2.29 (m, 8H).

Example 2: Preparation ofN-(5-((8-chloroquinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide

N-(5-((8-chloroquinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide(36.0 mg) was prepared as described forN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-phenylquinazolin-2-yl)amino)phenyl)acrylamide.LRMS (M+H⁺) m/z calculated 425.2, found 425.2. ¹H NMR (DMSO-d6, 300 MHz)δ 10.19 (s, 1H), 10.12 (s, 1H), 8.57 (d, 1H), 8.23-8.27 (m, 1H),7.89-7.99 (m, 2H), 7.29-7.37 (m, 2H), 6.24-6.46 (m, 2H), 5.76-5.80 (m,1H), 2.83 (t, 2H), 2.71 (s, 3H), 2.16-2.28 (m, 8H).

Example 3: Preparation ofN-(5-((8-bromoquinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)-(methyl)amino)phenyl)acrylamide

N-(5-((8-bromoquinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide(109 mg) was prepared as described forN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-phenylquinazolin-2-yl)amino)phenyl)acrylamide.LRMS (M+H⁺) m/z calculated 469.1, found 469.1. ¹H NMR (DMSO-d6, 400 MHz)δ 10.20 (s, 1H), 10.14 (s, 1H), 9.31 (s, 1H), 8.53 (d, 1H), 8.38-8.40(m, 1H), 8.14 (dd, 1H), 7.94 (dd, 1H), 7.28-7.32 (m, 2H), 6.38-6.44 (m,1H), 6.27 (dd, 1H), 5.78 (dd, 1H), 2.83 (t, 2H), 2.68 (s, 3H), 2.28 (t,2H), 2.19 (s, 6H).

Example 4: Preparation ofN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-((2-(dimethylamino)-ethyl)(methyl)amino)phenyl)acrylamide

N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide(34.7 mg) was prepared as described forN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-phenylquinazolin-2-yl)amino)phenyl)acrylamide.LRMS (M+H⁺) m/z calculated 501.2, found 501.2. ¹H NMR (DMSO-d6, 400 MHz)δ 10.19 (s, 1H), 9.87 (s, 1H), 9.34 (s, 1H), 8.34 (s, 1H), 7.82-7.96 (m,4H), 7.66-7.67 (m, 1H), 7.43-7.49 (m, 3H), 7.14 (d, 1H), 6.36-6.38 (m,1H), 6.24 (dd, 1H), 5.77 (d, 1H), 2.80 (t, 2H), 2.65 (s, 3H), 2.26 (s,2H), 2.20 (s, 6H).

Example 5: Preparation ofN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)phenyl)acrylamide

N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)phenyl)acrylamide(60.3 mg) was prepared as described forN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-phenylquinazolin-2-yl)amino)phenyl)acrylamide.LRMS (M+H⁺) m/z calculated 485.2, found 485.2. ¹H NMR (DMSO-d6, 400 MHz)δ 10.20 (s, 1H), 9.84 (s, 1H), 9.34 (s, 1H), 8.38 (s, 1H), 7.80-7.96 (m,3H), 7.43-7.62 (m, 4H), 7.08-7.23 (m, 2H), 6.21-6.39 (m, 2H), 6.24 (dd,1H), 5.77 (d, 1H), 2.80 (s, 2H), 2.65 (s, 3H), 2.18-2.28 (m, 8H).

Example 6: Preparation ofN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-methoxyquinazolin-2-yl)amino)phenyl)acrylamide

N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-methoxyquinazolin-2-yl)amino)phenyl)acrylamide(29.5 mg) was prepared as described forN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-phenylquinazolin-2-yl)amino)phenyl)acrylamide.LRMS (M+H⁺) m/z calculated 421.2, found 421.2. ¹H NMR (CD3OD, 400 MHz) δ9.13 (s, 1H), 8.37 (s, 1H), 7.91 (d, 1H), 7.39 (d, 1H), 7.26-7.28 (m,3H), 6.71-6.74 (m, 1H), 6.46 (d, 1H), 5.86 (d, 1H), 4.02 (s, 3H), 3.26(s, 2H), 2.96 (s, 2H), 2.64-2.68 (m, 9H).

Example 7: Preparation ofN-(5-((8-(2-chlorophenyl)quinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide

N-(5-((8-(2-chlorophenyl)quinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide(42.1 mg) was prepared as described forN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-phenylquinazolin-2-yl)amino)phenyl)acrylamide.LRMS (M+H⁺) m/z calculated 501.2, found 501.2. ¹H NMR (CDCl3, 300 MHz)δ10.19 (s, 1H), 9.20 (s, 1H), 8.31 (d, 1H), 7.74-7.90 (m, 3H), 7.39-7.61(m, 6H), 6.90 (d, 1H), 6.31-6.48 (m, 2H), 6.24 (dd, 1H), 5.70-5.74 (m,1H), 2.84 (s, 2H), 2.69 (s, 3H), 2.21-2.32 (m, 8H).

Example 8: Preparation ofN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(pyridin-3-yl)quinazolin-2-yl)amino)phenyl)acrylamide

N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(pyridin-3-yl)quinazolin-2-yl)amino)phenyl)acrylamide(58.6 mg) was prepared as described forN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-phenylquinazolin-2-yl)amino)phenyl)acrylamide.LRMS (M+H⁺) m/z calculated 468.2, found 468.2. ¹H NMR (DMSO-d6, 400 MHz)δ 10.22 (s, 1H), 9.84 (s, 1H), 9.36 (s, 1H), 8.83 (d, 1H), 8.56-8.57 (m,1H), 8.15-8.20 (m, 1H), 7.88-7.98 (dd, 2H), 7.65-7.67 (m, 1H), 7.42-7.49(m, 2H), 7.09 (d, 1H), 6.21-6.38 (m, 2H), 5.76-5.79 (m, 1H), 2.79 (t,2H), 2.65 (s, 3H), 2.20-2.27 (m, 8H).

Example 9: Preparation ofN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(pyridin-4-yl)quinazolin-2-yl)amino)phenyl)acrylamide

N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(pyridin-4-yl)quinazolin-2-yl)amino)phenyl)acrylamide(2 mg) was prepared as described forN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-phenylquinazolin-2-yl)amino)phenyl)acrylamide.LRMS (M+H⁺) m/z calculated 468.2, found 468.2. ¹H NMR (DMSO-d6, 300 MHz)δ 9.14 (s, 1H), 8.50 (d, 1H), 8.02 (s, 1H), 7.73-7.68 (m, 4H), 7.53 (dd,1H), 7.40 (t, 1H), 7.05 (d, 1H), 6.36-6.46 (m, 2H), 5.80 (d, 1H), 3.24(s, 3H), 2.85 (m, 2H), 2.56-2.59 (m, 8H).

Example 10: Preparation ofN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(2-fluorophenyl)quinazolin-2-yl)amino)phenyl)acrylamide

N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(2-fluorophenyl)quinazolin-2-yl)amino)phenyl)acrylamide(5.3 mg) was prepared as described forN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-phenylquinazolin-2-yl)amino)phenyl)acrylamide.LRMS (M+H⁺) m/z calculated 485.2, found 485.2. ¹H NMR (CDCl₃, 400 MHz)δ10.19 (s, 1H), 9.16 (s, 1H), 8.31 (s, 1H), 7.97 (d, 1H), 7.79 (d, 2H),7.39-7.60 (m, 4H), 7.27-7.29 (m, 1H), 7.20-7.23 (m, 1H), 6.93 (d, 1H),6.44-6.45 (m, 2H), 2.94 (m, 2H), 2.67 (s, 3H), 2.37-2.46 (m, 8H).

Example 11: Preparation ofN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(4-methylpiperazin-1-yl)phenyl)acrylamide

N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(4-methylpiperazin-1-yl)phenyl)acrylamide(33 mg) was prepared as described forN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-phenylquinazolin-2-yl)amino)phenyl)acrylamide.LRMS (M+H⁺) m/z calculated 499.2, found 499.2. ¹H NMR (DMSO-d6, 400 MHz)δ 9.86 (s, 1H), 9.34 (s, 1H), 9.02 (s, 1H), 7.82-8.08 (m, 5H), 7.42-7.67(m, 4H), 7.02 (d, 1H), 6.56-6.60 (m, 1H), 6.18-6.25 (m, 1H), 5.74-5.78(m, 1H), 2.58-2.78 (m, 4H), 2.50-2.59 (m, 8H), 2.07 (s, 3H).

Example 12: Preparation ofN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-morpholinophenyl)acrylamide

N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-morpholinophenyl)acrylamide(33.3 mg) was prepared as described forN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-phenylquinazolin-2-yl)amino)phenyl)acrylamide.LRMS (M+H⁺) m/z calculated 486.2, found 486.1. ¹H NMR (DMSO-d6, 400 MHz)δ 9.87 (s, 1H), 9.33 (s, 1H), 9.13 (s, 1H), 8.12 (s, 1H), 7.81-7.96 (m,4H), 7.66-7.68 (m, 1H), 7.44-7.65 (m, 3H), 7.03 (d, 1H), 6.62-6.70 (m,1H), 6.21-6.26 (m, 1H), 5.76-5.78 (m, 1H), 3.77-3.78 (m, 4H), 2.76-2.78(m, 4H).

Example 13: Preparation ofN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamide

To a solution of 2-(dimethylamino)ethanol (2.67 g, 0.03 mol, 3.0 eq.) inDMF (100 mL) was added NaH (1.32 g, 0.033 mol, 3.3 eq.) at 0° C. underN₂. After 0.5 h, 2-fluoro-5-nitroaniline (1.56 g, 0.01 mol, 1.0 eq.) wasadded to the mixture. The resulting mixture was stirred at r.t. for 0.5h, then poured into water and extracted with EA (100 mL×2). The combinedorganic layers were dried over Na₂SO₄ and concentrated to afford2-(2-(dimethylamino)ethoxy)-5-nitroaniline (2 g, 88.5% yield).

To a solution of 2-(2-(dimethylamino)ethoxy)-5-nitroaniline (2 g, 8.9mmol, 1 eq.) in DCM (100 mL) was added TEA (2.47 mL, 17.8 mmol, 2 eq.),followed by acryloyl chloride (0.7 mL, 8.9 mmol, 1 eq.) at 0° C. Theresulting mixture was stirred at r.t. for 1 h, then diluted with DCM (50mL), washed with brine, dried over anhydrous Na₂SO₄ and concentrated.The resulting residue was purified via column chromatography(DCM/MeOH=20:1, v/v) to affordN-(2-(2-(dimethylamino)ethoxy)-5-nitrophenyl)acrylamide as a yellowsolid (1.1 g, 45.8% yield).

To a solution of N-(2-(2-(dimethylamino)ethoxy)-5-nitrophenyl)acrylamide(1.1 g, 4 mmol, 1 eq.) and Fe (1.1 g, 20 mmol, 5 eq.) in EtOH/H₂O (20mL/4 mL) was added conc.HCl (0.4 mL, 4 mmol, 1 eq.) and the resultingmixture was stirred at 80° C. for 1 h. The mixture was filtered and thefiltrate was concentrated and the residue was recrystallized from EtOH(50 mL) to affordN-(5-amino-2-(2-(dimethylamino)ethoxy)phenyl)acrylamide as a brown solid(500 mg, 50.4% yield).

To a solution of N-(5-amino-2-(2-(dimethylamino)ethoxy)phenyl)acrylamide(100 mg, 0.40 mmol, 1.1 eq.) and 2-chloro-8-(3-chlorophenyl)quinazoline(100 mg, 0.36 mmol, 1 eq.) in n-BuOH (5 mL) was added TFA (0.5 mL), andthe resulting mixture was stirred at 110° C. for 24 h. The mixture wasconcentrated and the residue was dissolved in DCM, washed with Na₂CO₃solution, dried over anhydrous Na₂SO₄, then purified via silica column(DCM/MeOH=10/1, v/v) to affordN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamideas yellow solid (32.6 mg, 40% yield). LRMS (M+H⁺) m/z calculated 488.2,found 488.2. ¹H NMR (DMSO-d6, 400 MHz) δ 9.80-9.82 (m, 2H), 9.33 (s,1H), 8.19 (s, 1H), 7.93-7.95 (dd, 1H), 7.84-7.93 (d, 1H), 7.78 (s, 1H),7.68 (d, 1H), 7.42-7.51 (m, 3H), 6.92-6.94 (d, 1H), 6.61 (br, 1H),6.20-6.25 (m, 1H), 5.74-5.77 (m, 1H), 4.13 (t, 2H), 2.76 (br, 2H), 2.39(s, 6H).

Example 14: Preparation ofN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-((1-methylpiperidin-4-yl)oxy)phenyl)acrylamide

N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-((1-methylpiperidin-4-yl)oxy)phenyl)acrylamide(36.7 mg) was prepared as described forN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamide.LRMS (M+H⁺) m/z calculated 514.2, found 514.2. ¹H NMR (DMSO-d6, 400 MHz)δ 9.78 (s, 1H), 9.32 (s, 1H), 9.14 (s, 1H), 8.04 (s, 1H), 7.93-7.95 (m,4H), 7.66 (d, 1H), 7.42-7.50 (m, 3H), 6.92 (d, 1H), 6.62-6.69 (m, 1H),6.19-6.23 (m, 1H), 5.73 (d, 1H), 4.20-4.22 (m, 1H), 2.52-2.63 (m, 2H),2.07-2.16 (m, 5H), 1.86-1.89 (m, 2H), 1.67-1.74 (m, 2H).

Example 15: Preparation ofN-(5-((8-(2-chlorophenyl)quinazolin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamide

N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-((1-methylpiperidin-4-yl)oxy)phenyl)acrylamide(41 mg) was prepared as described forN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamide.LRMS (M+H⁺) m/z calculated 488.2, found 488.2. ¹H NMR (DMSO-d6, 400 MHz)δ 9.88 (s, 2H), 9.31 (s, 1H), 7.95-8.03 (m, 2H), 7.60-7.75 (m, 3H),7.42-7.47 (m, 4H), 6.74 (d, 1H), 6.42-6.46 (m, 1H), 6.22-6.26 (m, 1H),5.76 (d, 1H), 4.04 (t, 2H), 2.52 (t, 2H), 2.24 (s, 6H).

Example 16: Preparation ofN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(2-methoxyethoxy)phenyl)acrylamide

N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(2-methoxyethoxy)phenyl)acrylamide(12.5 mg) was prepared as described forN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamide.LRMS (M+H⁺) m/z calculated 475.1, found 475.1. ¹H NMR (CDCl₃, 400 MHz) δ9.14 (s, 1H), 8.40 (d, 2H), 8.06 (d, 1H), 7.75-7.84 (m, 3H), 7.58-7.60(m, 2H), 7.37-7.42 (m, 3H), 6.93 (d, 1H), 6.24-6.45 (m, 2H), 5.75 (d,1H), 4.16-4.18 (m, 2H), 3.69-3.71 (m, 2H), 3.47 (s, 3H).

Example 17: Preparation ofN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamide

To a suspension of 4-fluoro-2-methoxy-5-nitroaniline (7.44 g, 40 mmol,1.0 eq.) and 8-bromo-2-chloroquinazoline (9.68 g, 40 mmol, 1.0 eq.) in2-Pentanol (200 mL) was added TFA (15 mL, 200 mmol, 5 eq.) and theresulting mixture was stirred at 90° C. for 24 h. The mixture was thencooled to r.t. and the resulting precipitate was collected by filtrationand dried in vacuo to afford8-bromo-N-(4-fluoro-2-methoxy-5-nitrophenyl)quinazolin-2-amine as abrown solid (11.6 g, 73.8% yield).

To a solution of8-bromo-N-(4-fluoro-2-methoxy-5-nitrophenyl)quinazolin-2-amine (2.36 g,6 mmol, 1.0 eq.) and (3-fluorophenyl)boronic acid (1.01 g, 7.2 mmol, 1.2eq.) in dioxane/water (100 mL/10 mL) was added Na₂CO₃ (2.5 g, 24 mmol,4.0 eq.), followed by Pd(dppf)Cl₂.CH₂Cl₂ (240 mg, 0.3 mmol, 0.05 eq.)under N₂. The mixture was stirred at 90° C. for 12 h, then cooled tor.t. and concentrated. The resulting residue was purified via columnchromatography (DCM/MeOH=30/1, v/v) to affordN-(4-fluoro-2-methoxy-5-nitrophenyl)-8-(3-fluorophenyl)quinazolin-2-amine(1.1 g, 45% yield).

A mixture ofN-(4-fluoro-2-methoxy-5-nitrophenyl)-8-(3-fluorophenyl)quinazolin-2-amine(204 mg, 0.5 mmol, 1.0 eq.) and N¹,N¹,N²-trimethylethane-1,2-diamine(102 mg, 1 mmol, 2 eq.) in DMF (10 mL) was added DIEA (0.35 mL, 2 mmol,4.0 eq.), and the mixture was heated at 140° C. for 30 mins in amicrowave reactor, then cooled and poured into ice-water. The mixturewas extracted with EA (3×150 mL), the combined EA phase was dried overanhydrous Na₂SO₄ and concentrated. The resulting residue was purifiedvia column chromatography (DCM/MeOH/NH₃.H₂O=100/10:1, v/v/v) to affordN1-(2-(dimethylamino)ethyl)-N4-(8-(3-fluorophenyl)quinazolin-2-yl)-5-methoxy-N1-methyl-2-nitrobenzene-1,4-diamine(150 mg, 60% yield).

To a solution ofN-(2-(dimethylamino)ethyl)-N4-(8-(3-fluorophenyl)quinazolin-2-yl)-5-methoxy-N1-methyl-2-nitrobenzene-1,4-diamine(150 mg, 0.31 mmol, 1 eq.) and Fe (174 mg, 3.1 mmol, 10 eq.) in MeOH/H₂O(20 mL/5 mL) was added conc.HCl (0.03 mL, 0.31 mmol, 1 eq.) and theresulting mixture was stirred at 80° C. for 1 h. Fe was filtered and thefiltrate was concentrated. The residue was extracted with DCM (2×50 mL)to affordN1-(2-(dimethylamino)ethyl)-N4-(8-(3-fluorophenyl)quinazolin-2-yl)-5-methoxy-N1-methylbenzene-1,2,4-triamine(143 mg, quant. yield).

To a solution ofN-(2-(dimethylamino)ethyl)-N4-(8-(3-fluorophenyl)quinazolin-2-yl)-5-methoxy-N1-methylbenzene-1,2,4-triamine(143 mg, 0.31 mmol, 1 eq.) in DCM (10 mL) was added TEA (125 mg, 1.24mmol, 4 eq.), followed by acryloyl chloride (56 mg, 0.62 mmol, 2 eq.) at0° C. The resulting mixture was stirred at r.t. for 1 h, then washedwith brine, dried over anhydrous Na₂SO₄ and concentrated. The resultingresidue was purified via column chromatography(DCM/MeOH/NH₃.H₂O=100/10:1, v/v/v) to affordN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamideas a yellow solid (73.9 mg, 50% yield). LRMS (M+H⁺) m/z calculated515.2, found 514.9. ¹H NMR. (CDCl₃, 400 MHz) δ 9.15 (s, 2H), 9.05 (s,1H), 7.68-7.77 (m, 3H), 7.56 (d, 1H), 7.34-7.43 (m, 3H), 7.15-7.17 (m,1H), 6.99-7.04 (m, 1H), 6.65 (s, 1H), 6.35 (d, 1H), 5.74 (d, 1H), 3.88(s, 1H), 3.31 (t, 2H), 3.11 (t, 2H), 2.82 (s, 6H), 2.71 (s, 3H).

Example 18: Preparation ofN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide

N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide(48.9 mg) was prepared as described forN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamide.LRMS (M+H⁺) m/z calculated 531.2, found 530.9. ¹H NMR (CDCl₃, 400 MHz) δ10.10 (s, 1H), 9.16-9.19 (m, 2H), 7.63-7.80 (m, 5H), 7.36 (t, 1H), 7.29(t, 1H), 7.20 (d, 1H), 6.76 (s, 1H), 6.29-6.40 (m, 2H), 5.70 (d, 1H),3.85 (s, 1H), 2.86 (t, 2H), 2.69 (s, 3H), 2.30 (s, 8H).

Example 19: Preparation ofN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide

N-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide(47.7 mg) was prepared as described forN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamide.LRMS (M+H⁺) m/z calculated 502.2, found 501.9. ¹H NMR (CDCl₃, 400 MHz) δ10.29 (s, 1H), 9.18 (s, 1H), 8.78 (s, 1H), 8.62 (d, 1H), 8.42 (d, 1H),8.30 (s, 1H), 7.97 (d, 1H), 7.80-7.83 (m, 2H), 7.56 (s, 1H), 7.43 (t,1H), 7.21 (d, 1H), 6.27-6.46 (m, 2H), 5.73 (d, 1H), 2.86 (t, 2H), 2.71(s, 3H), 2.26-2.32 (m, 8H).

Example 20: Preparation ofN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)phenyl)acrylamide

N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)phenyl)acrylamide(32.7 mg) was prepared as described forN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamide.LRMS (M+H⁺) m/z calculated 486.2, found 485.9. ¹H NMR (CDCl₃, 400 MHz) δ10.29 (s, 1H), 9.16 (s, 1H), 8.72 (s, 1H), 8.49 (dd, 2H), 8.07 (d, 1H),7.81-7.89 (m, 3H), 7.41-7.48 (m, 2H), 7.15 (dd, 1H), 6.28-6.45 (m, 2H),5.72 (d, 1H), 2.83 (t, 2H), 2.71 (s, 3H), 2.21-2.37 (m, 8H).

Example 21: Preparation ofN-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide

To a solution of 1-methylpyrrolidin-3-ol (150 mg, 1.5 mmol, 3.0 eq.) inDMF (5 mL) was added NaH (66 mg, 1.65 mmol, 3.3 eq.) at 0° C. under N₂.After 0.5 h,N-(4-fluoro-2-methoxy-5-nitrophenyl)-8-(3-fluorophenyl)quinazolin-2-amine(204 mg, 0.5 mmol, 1.0 eq.) was added to the mixture. The resultingmixture was stirred at r.t. for 0.5 h, then poured into water andextracted with EA (2×100 mL). The combined organic layers were driedover Na₂SO₄ and concentrated to afford8-(3-fluorophenyl)-N-(2-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)-5-nitrophenyl)quinazolin-2-amine(210 mg, 86.1% yield).

To a solution of8-(3-fluorophenyl)-N-(2-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)-5-nitrophenyl)quinazolin-2-amine(210 mg, 0.43 mmol, 1 eq.) and Fe (120 mg, 2.15 mmol, 5 eq.) in MeOH/H₂O(10 mL/2 mL) was added conc.HCl (0.05 mL, 0.43 mmol, 1 eq.) and theresulting mixture was stirred at 80° C. for 1 h. The mixture wasfiltered and the filtrate was concentrated. The residue was extractedwith DCM (2×50 mL), dried over anhydrous Na₂SO₄, then purified viasilica column (DCM/MeOH/NH₃.H2O=100/10:1, v/v/v)) to affordN1-(8-(3-fluorophenyl)quinazolin-2-yl)-6-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)benzene-1,3-diamine(60 mg, 30.5% yield).

To a solution ofN-(8-(3-fluorophenyl)quinazolin-2-yl)-6-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)benzene-1,3-diamine(60 mg, 0.13 mmol, 1 eq.) in DCM (5 mL) was added TEA (65.6 mg, 0.65mmol, 5 eq.), followed by acryloyl chloride (18 mg, 0.20 mmol, 2 eq.) at0° C. The resulting mixture was stirred at r.t. for 1 h, washed withbrine, dried over anhydrous Na₂SO₄ and concentrated. The resultingresidue was purified via column chromatography(DCM/MeOH/NH₃.H₂O=100/10/1, v/v/v) to affordN-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide(18.9 mg, 28.3% yield). LRMS (M+H⁺) m/z calculated 514.2, found 513.9.¹H NMR. (CD₃OD, 400 MHz) δ 9.10 (s, 1H), 8.42 (s, 1H), 7.71-7.79 (m,2H), 7.25-7.44 (m, 3H), 6.90-6.94 (m, 1H), 6.69 (s, 1H), 6.29-6.48 (m,2H), 5.80-5.82 (d, 1H), 5.21 (s, 1H), 3.90 (s, 3H), 3.51-3.82 (m, 2H),3.23-3.44 (m, 2H), 2.92 (s, 3H), 2.23-2.24 (m, 2H).

Example 22: Preparation ofN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide

N-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide(17.8 mg) was prepared as described forN-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide.LRMS (M+H⁺) m/z calculated 530.2, found 529.8. ¹H NMR (CDCl₃, 400 MHz) δ9.11 (s, 1H), 8.72 (s, 1H), 7.65-7.75 (m, 5H), 7.30-7.40 (m, 3H),6.35-6.42 (m, 2H), 5.80 (m, 1H), 5.12 (s, 1H), 3.86-3.88 (m, 4H),3.31-3.52 (m, 3H), 2.86 (s, 3H), 2.20-2.51 (m, 2H).

Example 23: Preparation ofN-(2-(3-(dimethylamino)pyrrolidin-1-yl)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamide

N-(2-(3-(dimethylamino)pyrrolidin-1-yl)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamide(28.6 mg) was prepared as described forN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamide.LRMS (M+H⁺) m/z calculated 527.2, found 526.9. ¹H NMR (CDCl₃, 400 MHz) δ9.12 (s, 1H), 8.83 (s, 1H), 7.66-7.75 (m, 4H), 7.51-7.55 (m, 2H),7.32-7.37 (m, 2H), 6.98-7.00 (m, 1H), 6.62-6.63 (m, 1H), 6.31-6.33 (m,2H), 5.75 (dd, 1H), 3.87 (s, 3H), 3.15-3.21 (m, 4H), 2.82-2.85 (m, 1H),2.05 (s, 7H), 1.89-1.91 (m, 1H).

Example 24: Preparation ofN-(2-(3-(dimethylamino)pyrrolidin-1-yl)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)phenyl)acrylamide

N-(2-(3-(dimethylamino)pyrrolidin-1-yl)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)phenyl)acrylamide(77.9 mg) was prepared as described forN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamide.LRMS (M+H⁺) m/z calculated 497.2, found 496.9. ¹H NMR (CDCl₃, 400 MHz) δ9.13 (s, 1H), 8.62 (d, 1H), 8.27 (s, 1H), 8.08 (d, 1H), 7.74-7.81 (m,2H), 7.37-7.60 (m, 5H), 7.08-7.16 (m, 2H), 6.31-6.42 (m, 2H), 5.75 (d,1H), 3.04-3.11 (m, 4H), 2.90-2.93 (m, 1H), 2.31 (s, 6H), 2.16-2.21 (m,1H), 1.94-1.97 (m, 1H).

Example 25: Preparation ofN-(2-(3-(dimethylamino)azetidin-1-yl)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)phenyl)acrylamide

N-(2-(3-(dimethylamino)azetidin-1-yl)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)phenyl)acrylamide(53.1 mg) was prepared as described forN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamide.LRMS (M+H⁺) m/z calculated 483.2, found 482.9. ¹H NMR (CDCl₃, 400 MHz) δ9.12 (s, 1H), 8.06 (d, 1H), 7.35-7.91 (m, 9H), 7.14-7.17 (m, 1H), 6.81(d, 1H), 6.33-6.48 (m, 2H), 5.80 (d, 1H), 3.83-3.88 (m, 2H), 3.59-3.64(m, 2H), 3.12-3.16 (m, 1H), 2.23 (s, 6H).

Example 26:1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one

To a solution of 2,4-dichloro-5-nitropyrimidine (4.7 g, 24.0 mmol, 1.0eq.) and DIEA (8.0 mL, 48.0 mmol, 2.0 eq.) in THF (100 mL) at −78° C.was added tert-butyl 3-aminopyrrolidine-1-carboxylate (4.5 g, 24.0 mmol,1.0 eq.) dropwise. The mixture was stirred at −78° C. for 5 h, and thenconcentrated. The resulting residue was purified via columnchromatography (EA/PE=1:3, v/v) to afford tert-butyl3-((2-chloro-5-nitropyrimidin-4-yl)amino)pyrrolidine-1-carboxylate as ayellow solid (7.2 g, 79% yield).

A mixture of 2-(4-(4-amino-3-fluorophenyl)piperazin-1-yl)ethanol (340mg, 1.5 mmol, 1.0 eq.) and tert-butyl3-((2-chloro-5-nitropyrimidin-4-yl)amino)pyrrolidine-1-carboxylate (500mg, 1.5 mmol, 1.0 eq.) in dioxane (10 mL) was added DIEA. The mixturewas stirred at r.t. overnight. The organic phase was washed with brine,separated, dried over anhydrous Na₂SO₄, and concentrated. The resultingresidue was purified via column chromatography (DCM/MeOH=10:1, v/v) toafford tert-butyl3-((2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-nitropyrimidin-4-yl)amino)pyrrolidine-1-carboxylateas a yellow solid (500 mg, 62.8% yield).

To a mixture of tert-butyl3-((2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-nitropyrimidin-4-yl)amino)pyrrolidine-1-carboxylate(500 mg, 0.9 mmol, 1.0 eq.) in EtOH (30 mL) was added HCl (0.01 mL, 1.1eq) and Fe (308 mg, 5.5 mmol, 6.0 eq.). The mixture was stirred underreflux for 12 h, then cooled to r.t. and concentrated. The resultingresidue was purified via column chromatography (DCM/MeOH=30:1, v/v) toafford tert-butyl3-((5-amino-2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)pyrrolidine-1-carboxylateas a yellow solid (400 mg, 84.6% yield).

To a solution of tert-butyl3-((5-amino-2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)pyrrolidine-1-carboxylate(400 mg, 0.8 mmol, 1.0 eq.) in triethyl orthoformate (TEOF, 3 mL). Themixture was stirred at 100° C. for 12 h, then concentrated and dilutedwith EA (30.0 mL), washed with brine, dried over anhydrous Na₂SO₄, andconcentrated. The resulting residue was purified via columnchromatography (DCM/MeOH=30:1, v/v) to afford tert-butyl3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidine-1-carboxylateas a yellow solid (435 mg, 89.3% yield).

To a solution of tert-butyl3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidine-1-carboxylate(435 mg, 0.8 mmol, 1.0 eq) in DCM (10.0 mL) was added TFA (5 mL) andstirred at r.t. for 2 h, then concentrated. The resulting residue wasused in the next step directly without further purification.

A solution of2-(4-(3-fluoro-4-((9-(pyrrolidin-3-yl)-9H-purin-2-yl)amino)phenyl)piperazin-1-yl)ethanol(400 mg, 0.8 mmol, 1.0 eq.) in THF (5 mL) was cooled to −78° C. and wasadded TEA (2 mL), followed by acryloyl chloride (70 mg, 0.8 mmol, 1.0eq.). The resulting mixture was stirred at r.t. for 1 h, then dilutedwith EA (10 mL), washed with brine, dried over anhydrous Na₂SO₄ andconcentrated. The resulting residue was purified via columnchromatography (DCM/MeOH=10:1, v/v) to afford1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-oneas a yellow solid (50.0 mg, 15.0% yield over two steps). LRMS (M+H⁺) m/zcalculated 481.2, found 481.6. ¹H NMR. (CD₃OD, 400 MHz) δ 8.67 (s, 1H),8.15 (d, 1H), 7.74-7.78 (m, 1H), 6.73-6.80 (m, 2H), 6.53-6.65 (m, 1H),6.29-6.34 (m, 1H), 5.74-5.81 (m, 1H), 5.15-5.20 (m, 1H), 4.17-4.23 (m,1H), 4.05-4.10 (m, 1H), 3.95-4.05 (m, 2H), 3.64-3.80 (m, 3H), 3.19 (t,4H), 2.67 (t, 5H), 2.51-2.64 (m, 3H).

Example 27: Preparation of1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one

1-(3-(2-((4-(4-(2-Hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one(13.2 mg) was prepared as described for1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one.LRMS (M+H⁺) m/z calculated 463.2, found 463.6. ¹H NMR. (CD₃OD, 400 MHz)δ 8.66 (s, 1H), 8.11 (d, 1H), 7.54-7.59 (m, 2H), 6.92-6.97 (m, 2H),6.53-6.65 (m, 1H), 6.31-6.36 (m, 1H), 5.74-5.81 (m, 1H), 5.16-5.22 (m,1H), 4.11-4.23 (m, 2H), 3.95-4.05 (m, 1H), 3.64-3.80 (m, 4H), 3.15 (t,4H), 2.60-2.70 (m, 5H), 2.53-2.61 (m, 3H).

Example 28: Preparation of1-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one

1-(3-(2-((3-Fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one(25.2 mg) was prepared as described for1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one.LRMS (M+H⁺) m/z calculated 481.2, found 481.6. ¹H NMR. (CD₃OD, 400 MHz)δ 8.66 (s, 1H), 8.15 (d, 1H), 7.64 (dd, 1H), 7.35 (d, 1H), 6.94-6.99 (m,1H), 6.56-6.71 (m, 1H), 6.30-6.37 (m, 1H), 5.75-5.83 (m, 1H), 4.90-5.24(m, 1H), 4.11-4.23 (m, 2H), 3.67-4.05 (m, 2H), 3.64-3.80 (m, 3H), 3.07(t, 4H), 2.65-2.80 (m, 5H), 2.55-2.63 (m, 3H).

Example 29: Preparation of1-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one

1-(3-(2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one(34.9 mg) was prepared as described for1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one.LRMS (M+H⁺) m/z calculated 451.2, found 451.6. ¹H NMR. (CD₃OD, 400 MHz)δ 8.71 (s, 1H), 8.18 (d, 1H), 7.67 (d, 1H), 7.37 (d, 1H), 7.0 (t, 1H),6.57-6.72 (m, 1H), 6.29-6.35 (m, 1H), 5.73-5.83 (m, 1H), 5.23-5.28 (m,1H), 4.24-4.30 (m, 1H), 4.14 (d, 1H), 3.70-4.03 (m, 2H), 3.09 (t, 4H),2.55-2.85 (m, 7H), 2.39 (s, 3H).

Example 30: Preparation of1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one

1-(3-(2-((4-(4-Methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one(44.3 mg) was prepared as described for1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one.LRMS (M+H⁺) m/z calculated 433.2, found 433.6. ¹H NMR. (CDCl3, 400 MHz)δ 8.67 (s, 1H), 8.14 (d, 1H), 7.59 (d, 2H), 7.57 (d, 1H), 7.0 (d, 1H),6.56-6.68 (m, 1H), 6.29-6.36 (m, 1H), 5.73-5.83 (m, 1H), 5.21-5.26 (m,1H), 4.24-4.28 (m, 1H), 4.14 (d, 1H), 3.70-4.03 (m, 2H), 3.15 (t, 4H),2.55-2.80 (m, 7H), 2.36 (s, 3H).

Example 31: Preparation of1-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one

1-(3-(2-((2-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one(3.9 mg) was prepared as described for1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one.LRMS (M+H⁺) m/z calculated 451.2, found 451.6. ¹H NMR. (CD₃OD, 400 MHz)δ 8.67 (s, 1H), 8.15 (d, 1H), 7.76 (dd, 2H), 6.75-6.82 (m, 2H),6.57-6.75 (m, 1H), 6.32 (d, 1H), 5.75-5.81 (m, 1H), 5.14-5.21 (m, 1H),4.05-4.30 (m, 1H), 3.60-4.03 (m, 2H), 3.21 (t, 4H), 2.40-2.73 (m, 7H),2.39 (s, 3H).

Example 32: Preparation of1-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one

1-(3-(2-((2-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one(2.4 mg) was prepared as described for1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one.LRMS (M+H⁺) m/z calculated 465.2, found 465.5. ¹H NMR. (CD₃OD, 400 MHz)δ 8.67 (s, 1H), 8.20 (s, 1H), 7.76 (dd, 2H), 7.75-7.90 (m, 1H),6.65-6.86 (m, 3H), 6.15-6.27 (m, 1H), 5.60-5.80 (m, 1H), 4.48-4.87 (m,2H), 4.24 (dd, 1H), 3.62-3.68 (m, 1H), 3.20 (t, 4H), 2.86 (t, 1H), 2.62(t, 4H), 2.45 (t, 1H), 2.32 (s, 3H), 2.19-2.27 (m, 1H), 1.95-1.96 (m,1H), 1.64-1.74 (m, 1H).

Example 33: Preparation of1-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one

1-(3-(2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one(19.0 mg) was prepared as described for1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one.LRMS (M+H⁺) m/z calculated 465.2, found 465.7. ¹H NMR. (CD₃OD, 400 MHz)δ 8.71 (s, 1H), 8.21 (s, 1H), 7.76 (dd, 2H), 7.31-7.37 (m, 1H),6.70-7.03 (m, 2H), 6.17-6.29 (m, 1H), 5.60-5.81 (m, 1H), 4.39-4.80 (m,2H), 4.04 (dd, 1H), 3.50-3.72 (m, 1H), 3.07 (t, 4H), 2.94 (t, 1H), 2.54(t, 4H), 2.35 (t, 1H), 2.28 (s, 3H), 2.01 (t, 1H), 1.74-1.77 (m, 1H),1.68-1.71 (m, 1H).

Example 34: Preparation of1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one

1-(3-(2-((4-(4-Methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one(8.2 mg) was prepared as described for1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one.LRMS (M+H⁺) m/z calculated 447.3, found 447.7. ¹H NMR. (CD₃OD, 400 MHz)δ 8.71 (s, 1H), 7.76 (s, 1H), 7.48 (d, 2H), 7.20 (s, 1H), 6.89 (s, 2H),6.54-6.63 (m, 1H), 6.36 (t, 1H), 5.59-5.78 (m, 1H), 4.80-4.84 (m, 1H),4.67-4.70 (m, 1H), 3.44-3.54 (m, 1H), 3.16 (s, 4H), 2.61 (s, 4H),1.94-2.35 (m, 5H), 0.77-0.81 (m, 4H).

Example 35: Preparation of1-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one

1-(3-(2-((3-Fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one(22.8 mg) was prepared as described for1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one.LRMS (M+H⁺) m/z calculated 495.3, found 495.8. ¹H NMR. (CD₃OD, 400 MHz)δ 8.73 (s, 1H), 8.21 (s, 1H), 7.76 (dd, 2H), 7.32-7.37 (m, 1H),7.00-7.03 (m, 1H), 6.65-6.84 (m, 1H), 6.22-6.29 (m, 1H), 5.60-5.81 (m,1H), 4.39-4.85 (m, 2H), 4.34 (dd, 1H), 3.72-3.77 (m, 3H), 3.09 (t, 4H),2.94 (t, 1H), 2.74 (t, 4H), 2.62 (t, 2H), 2.60 (s, 1H), 2.30 (t, 1H),2.00-2.02 (m, 1H), 1.72-1.75 (m, 1H).

Example 36: Preparation of1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one

1-(3-(2-((2-Fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one(7.4 mg) was prepared as described for1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one.LRMS (M+H⁺) m/z calculated 495.3, found 495.7. ¹H NMR. (CD₃OD, 400 MHz)δ 8.67 (s, 1H), 8.13 (s, 1H), 7.82 (dd, 2H), 6.62-6.86 (m, 3H),6.14-6.27 (m, 1H), 5.60-5.80 (m, 1H), 4.47-4.76 (m, 2H), 4.24 (dd, 1H),3.72-3.74 (m, 2H), 3.35-3.67 (m, 2H), 3.25 (t, 4H), 2.82-2.89 (m, 1H),2.70 (t, 4H), 2.59 (t, 2H), 2.44 (t, 1H), 2.20-2.27 (m, 1H), 1.73-2.03(m, 1H), 1.58-1.70 (m, 1H).

Example 37: Preparation of1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one

1-(3-(2-((4-(4-(2-Hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one(23.7 mg) was prepared as described for1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one.LRMS (M+H⁺) m/z calculated 477.3, found 477.6. ¹H NMR. (CD₃OD, 400 MHz)δ 8.67 (s, 1H), 8.17 (s, 1H), 7.63 (t, 2H), 6.99 (t, 2H), 6.80-6.86 (m,2H), 6.67-6.74 (m, 1H), 6.12-6.28 (m, 1H), 5.58-5.80 (m, 1H), 4.50-4.79(m, 2H), 4.24 (dd, 1H), 3.76-3.79 (m, 2H), 3.42-3.70 (m, 2H), 3.21 (t,4H), 2.89 (t, 4H), 2.77 (t, 2H), 2.45-2.48 (m, 1H), 2.27 (t, 1H),1.97-2.01 (m, 1H), 1.66-1.76 (m, 1H), 1.24-1.30 (m, 1H).

Example 38: Preparation ofN-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide

N-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide(19.1 mg) was prepared as described for1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one.LRMS (M+H⁺) m/z calculated 455.2, found 455.7. ¹H NMR. (DMSO-d6, 400MHz) δ 10.66 (s, 1H), 9.54 (s, 1H), 8.89 (s, 1H), 8.57 (s, 1H), 8.40 (s,1H), 7.68 (d, 1H), 7.53-7.57 (m, 3H), 6.85 (d, 1H), 6.54-6.57 (m, 1H),6.33 (d, 1H), 5.84 (d, 1H), 3.15 (t, 4H), 2.90 (t, 4H), 2.51 (s, 3H).

Example 39: Preparation ofN-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide

N-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide(2.7 mg) was prepared as described for1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one.LRMS (M+H⁺) m/z calculated 473.2, found 473.6. ¹H NMR. (CD₃OD, 400 MHz)δ 8.80 (s, 1H), 8.49 (s, 1H), 8.44 (s, 1H), 7.82 (d, 1H), 7.55-7.79 (m,3H), 7.32 (d, 1H), 6.91-6.97 (m, 1H), 6.38-6.48 (m, 1H), 5.82 (d, 1H),3.05 (t, 4H), 2.69 (t, 4H), 2.40 (s, 3H).

Example 40: Preparation ofN-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide

N-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide(38.8 mg) was prepared as described for1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one.LRMS (M+H⁺) m/z calculated 473.2, found 473.5. ¹H NMR (DMSO-d6, 400 MHz)δ 10.43 (s, 1H), 8.90 (s, 1H), 8.83 (s, 1H), 8.54 (s, 1H), 8.22 (s, 1H),7.65 (d, 1H), 7.48-7.55 (m, 3H), 6.77 (d, 1H), 6.65 (d, 1H), 6.47-6.54(m, 1H), 6.33 (d, 1H), 5.84 (d, 1H), 3.08 (t, 4H), 2.44 (t, 4H), 2.22(s, 3H).

Example 41: Preparation ofN-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide

N-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide(48.5 mg) was prepared as described for1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one.LRMS (M+H⁺) m/z calculated 485.2, found 485.5. ¹H NMR (DMSO-d6, 400 MHz)δ 10.47 (s, 1H), 9.49 (s, 1H), 8.88 (s, 1H), 8.57 (s, 1H), 8.37 (s, 1H),7.64 (d, 3H), 7.52-7.57 (m, 2H), 6.80 (d, 1H), 6.49-6.52 (m, 1H), 6.34(d, 1H), 5.83 (d, 1H), 4.43 (t, 2H), 3.51-3.55 (m, 2H), 3.00 (t, 4H),2.44 (t, 4H), 2.41 (t, 2H).

Example 42: Preparation ofN-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide

N-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide(26.7 mg) was prepared as described for1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one.LRMS (M+H⁺) m/z calculated 503.2, found 503.5. ¹H NMR. (CD₃OD, 400 MHz)δ 8.72 (s, 1H), 8.41 (s, 2H), 7.75 (dd, 1H), 7.48-7.59 (m, 3H), 6.87 (t,1H), 6.41-6.46 (m, 1H), 5.80 (dd, 1H), 5.49 (s, 1H), 3.72 (t, 2H), 3.02(s, 4H), 2.70 (s, 4H), 2.62 (t, 2H).

Example 43: Preparation ofN-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide

N-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide(34.7 mg) was prepared as described for1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one.LRMS (M+H⁺) m/z calculated 503.2, found 503.5. ¹H NMR (CD₃OD, 400 MHz) δ8.75 (s, 1H), 8.46 (s, 1H), 8.38 (s, 1H), 7.96 (t, 1H), 7.51-7.55 (m,3H), 6.80 (d, 1H), 6.76 (d, 1H), 6.44-6.48 (m, 1H), 5.84 (dd, 1H), 3.77(t, 2H), 3.32 (t, 4H), 2.86 (t, 4H), 2.76 (t, 2H).

Example 44: Preparation ofN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide

N-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide(26.1 mg) was prepared as described for1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one.LRMS (M+H⁺) m/z calculated 521.2, found 521.6. ¹H NMR. (CD₃OD, 400 MHz)δ 8.70 (s, 1H), 8.41 (s, 1H), 8.38 (s, 1H), 7.44-7.52 (m, 3H), 6.63 (t,1H), 6.42-6.46 (m, 2H), 5.82 (dd, 1H), 3.74 (t, 2H), 3.06 (t, 4H), 2.76(t, 4H), 2.67 (t, 2H).

Example 45:1-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one

To a mixture of tert-butyl3-((2-chloro-5-nitropyrimidin-4-yl)amino)pyrrolidine-1-carboxylate (860mg, 2.5 mmol, 1.0 eq.) in EtOH (30 mL) was added HCl (0.2 mL, 1.1 eq.)and Fe (840 mg, 15.0 mmol, 6.0 eq.). The mixture was stirred at refluxfor 12 h, then cooled to r.t. and concentrated. The resulting residuewas purified via column chromatography (DCM/MeOH=30:1, v/v) to affordtert-butyl3-((5-amino-2-chloropyrimidin-4-yl)amino)pyrrolidine-1-carboxylate (500mg, 63.7% yield).

A solution of tert-butyl3-((5-amino-2-chloropyrimidin-4-yl)amino)pyrrolidine-1-carboxylate (500mg, 1.6 mmol, 1.0 eq.) in TEOF (3.0 mL) was stirred at 100° C. for 12 h,then concentrated and diluted with EA (30 mL), washed with brine, driedover anhydrous Na₂SO₄, and concentrated. The resulting residue waspurified via column chromatography (DCM/MeOH=30:1, v/v) to affordtert-butyl 3-(2-chloro-9H-purin-9-yl)pyrrolidine-1-carboxylate as ayellow solid (180.0 mg, 34.9% yield).

To a solution of tert-butyl3-(2-chloro-9H-purin-9-yl)pyrrolidine-1-carboxylate (180 mg, 0.6 mmol,1.0 eq.) and 2,3-difluoro-4-(4-methylpiperazin-1-yl)aniline (125 mg, 0.6mmol, 1.0 eq.) in DMF (3 mL) was added BINAP (75 mg, 0.1 mmol, 0.2 eq.),Cs₂CO₃ (450 mg, 1.4 mmol, 2.5 eq.) and Pd₂(dba)₃ (55 mg, 0.06 mmol, 0.1eq.). The mixture was stirred at 100° C. under N₂ for 12 h, then cooledand concentrated. The residue was diluted with EA (30.0 mL), washed withbrine, dried over anhydrous Na₂SO₄, and concentrated. The resultingresidue was purified via column chromatography (DCM/MeOH=30:1, v/v) toafford tert-butyl3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidine-1-carboxylate(60 mg, 20.9% yield).

To a solution of tert-butyl3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidine-1-carboxylate(60 mg, 0.1 mmol, 1.0 eq.) in DCM (10 mL) was added TFA (5 mL) andstirred at r.t. for 2 h, then concentrated. The residue was used in nextstep directly.

A solution of2-(4-(3-fluoro-4-((9-(pyrrolidin-3-yl)-9H-purin-2-yl)amino)phenyl)piperazin-1-yl)ethanol(55 mg, 0.1 mmol, 1.0 eq.) in THF (5 mL) was cooled to −78° C. and wasadded TEA (0.5 mL), followed by acryloyl chloride (20 mg, 0.1 mmol, 1.0eq.). The resulting mixture was stirred at r.t. for 1 h, then dilutedwith EA (10 mL), washed with brine, dried over anhydrous Na₂SO₄, andconcentrated. The resulting residue was purified via columnchromatography (DCM/MeOH=10:1, v/v) to afford1-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-oneas a yellow solid (33.5 mg, 61.2% yield for two steps). LRMS (M+H⁺) m/zcalculated 469.2, found 469.6. ¹H NMR. (CD₃OD, 400 MHz) δ 8.68 (s, 1H),8.17 (d, 1H), 7.65-7.69 (m, 1H), 6.74-6.79 (m, 1H), 6.52-6.63 (m, 1H),6.28-6.34 (m, 1H), 5.73-5.81 (m, 1H), 5.18-5.21 (m, 1H), 4.14-4.24 (m,2H), 3.81-4.09 (m, 2H), 3.13 (t, 4H), 2.57-2.69 (m, 7H), 2.36 (s, 3H).

Example 46: Preparation of1-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one

1-(3-(2-((2,3-Difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one(18.5 mg) was prepared as described for1-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one.LRMS (M+H⁺) m/z calculated 499.2, found 499.6. ¹H NMR. (CD₃OD, 400 MHz)δ 8.69 (s, 1H), 8.19 (d, 1H), 7.62-7.70 (m, 1H), 6.76-6.80 (m, 1H),6.53-6.67 (m, 1H), 6.28-6.34 (m, 1H), 5.74-5.81 (m, 1H), 5.17-5.24 (m,1H), 4.11-4.26 (m, 2H), 3.67-4.05 (m, 1H), 3.62-3.80 (m, 4H), 3.11 (t,4H), 2.65-2.75 (m, 4H), 2.50-2.63 (m, 4H).

Example 47: Preparation ofN-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide

N-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamide(31.0 mg) was prepared as described for1-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one.LRMS (M+H⁺) m/z calculated 491.2, found 491.6. ¹H NMR. (DMSO-d6, 400MHz) δ 9.25 (s, 1H), 8.89 (s, 1H), 8.59 (s, 1H), 8.23 (s, 1H), 7.66 (d,1H), 7.49-7.57 (m, 3H), 6.73 (t, 1H), 6.47-6.54 (m, 1H), 6.32 (d, 1H),5.84 (d, 1H), 3.35 (t, 4H), 2.98 (t, 4H), 2.23 (s, 3H).

Example 48: Preparation of1-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one

1-(3-(2-((2,3-Difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one(39.6 mg) was prepared as described for1-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one.LRMS (M+H⁺) m/z calculated 483.2, found 483.1. ¹H NMR (CD₃OD, 400 MHz) δ8.68 (s, 1H), 8.23 (s, 1H), 7.80 (dt, 1H), 6.63-6.86 (m, 2H), 6.20 (dd,1H), 5.70 (dd, 1H), 4.60-4.84 (m, 2H), 4.25 (dd, 1H), 3.35-3.67 (m, 1H),3.20-3.28 (m, 1H), 3.23 (s, 4H), 2.96 (s, 4H), 2.60 (s, 3H), 2.37-2.47(m, 1H), 2.24-2.27 (m, 1H), 1.95-1.98 (m, 1H), 1.68-1.70 (m, 1H).

Example 49: Preparation of1-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one

1-(3-(2-((2,3-Difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one(33.1 mg) was prepared as described for1-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one.LRMS (M+H⁺) m/z calculated 513.2, found 513.7. ¹H NMR (CD₃OD, 400 MHz) δ8.67 (s, 1H), 8.21 (s, 1H), 7.72 (dt, 1H), 6.63-6.86 (m, 2H), 6.22 (dd,1H), 5.69 (dd, 1H), 4.45-4.83 (m, 2H), 4.10-4.38 (m, 1H), 3.73 (t, 2H),3.36-3.65 (m, 1H), 2.81-3.27 (m, 1H), 3.09 (s, 4H), 2.72 (s, 4H), 2.61(t, 2H), 2.37-2.45 (m, 1H), 2.39-2.40 (m, 1H), 1.94-2.00 (m, 1H),1.67-1.70 (m, 1H).

Example 50: Inhibitory Activity Against BTK, EGFR, EGFR Mutants

Inhibitory activities of compounds against BTK, EGFR and EGFR mutants(EGFR L858R/T790M) were measured by Invitrogen using Z′-LYTE® Method asbriefly described in the following.

Test Compounds are screened in 1% DMSO (final) in the well. For 10 pointtitrations, 3-fold serial dilutions are conducted from the startingconcentration. All ATP Solutions are diluted to a 4× workingconcentration in Kinase Buffer (50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mMMgCl₂, 1 mM EGTA). Peptide/Kinase Mixtures are diluted to a 2× workingconcentration in the appropriate Kinase Buffers as described below.

(i) Peptide/Kinase Mixtures for Measurement of EGFR (ErbB1):

The 2×EGFR (ErbB1)/Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5,0.01% BRIJ-35, 10 mM MgCl₂, 4 mM MnCl₂, 1 mM EGTA, 2 mMDTT. The final 10μL Kinase Reaction consists of 1.1-5.25 ng EGFR (ErbB1) and 2 μM Tyr 04in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl₂, 2 mM MnCl₂, 1 mMEGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a1:64 dilution of Development Reagent B is added.

(ii) Peptide/Kinase Mixtures for Measurement of EGFR (ErbB1) L858R:

The 2×EGFR (ErbB1) L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH7.5, 0.01% BRIJ-35, 10 mM MgCl₂, 4 mM MnCl₂, 1 mM EGTA, 2 mM DTT. Thefinal 10 μL Kinase Reaction consists of 0.2-1.68 ng EGFR (ErbB1) L858Rand 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl₂, 2 mMMnCl₂, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation,5 μL of a 1:64 dilution of Development Reagent B is added.

(iii) Peptide/Kinase Mixtures for Measurement of EGFR (ErbB1) T790M:

The 2×EGFR (ErbB1) T790M/Tyr 04 mixture is prepared in 50 mM HEPES pH6.5, 0.01% BRIJ-35, 10 mM MgCl₂, 1 mM EGTA, 0.02% NaN₃. The final 10 μLKinase Reaction consists of 3.9-30.2 ng EGFR (ErbB1) T790M and 2 μM Tyr04 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl₂, 1 mM EGTA, 0.01%NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64dilution of Development Reagent B is added.

(iv) Peptide/Kinase Mixtures for Measurement of EGFR (ErbB1) T790ML858R:

The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPESpH 6.5, 0.01% BRIJ-35, 10 mM MgCl₂, 1 mM EGTA, 0.02% NaN₃. The final 10μL Kinase Reaction consists of 0.38-4.22 ng EGFR (ErbB1) T790M L858R and2 μM Tyr 04 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl₂, 1 mMEGTA, 0.01% NaN₃. After the 1 hour Kinase Reaction incubation, 5 μL of a1:64 dilution of Development Reagent B is added.

(v) Peptide/Kinase Mixtures for Measurement of BTK:

The 2×BTK/Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01%BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reactionconsists of 1.04-10.4 ng BTK and 2 μM Tyr 01 in 50 mM HEPES pH 7.5,0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reactionincubation, 5 μL of a 1:256 dilution of Development Reagent B is added.

Reaction starts by 30-second shaking of mixture consisting of 2.5 μL 4×test compound, 5 L 2× kinase reaction mixture and 2.5 μL 4×ATP Solutionon Bar-coded Corning, low volume NBS, black 384-well plate (Corning Cat.#3676). Then the mixture is incubated for 60-minute at room temperaturefor the kinase reaction, followed by addition of 5 μL of a 1:1024dilution of development reagent A and 30-second plate shake. The mixtureis then incubated for another 60-minute at room temperature fordevelopment reaction. Finally fluorescence is read by plate reader.Table 2 shows % inhibition against EGFR L858R/T790M, EGFR and BTK ofseveral compounds at 10 μM of ATP. Table 3 shows % inhibition with ATPconcentration at Km. The scale utilized in Tables 2 and 3 is as follows:++ more than 50% inhibition and + less than 50% inhibition.

TABLE 2 Biological activity of illustrative compounds against BTK, EGFRand EGFR L5858R/T790M EGFR EGFR L858R/T790M BTK (Compound at (Compoundat (Compound at Compound No. 41 nM) 13.7 nM) 41 nM) C001 + C003 +C007 + + ++ C008 + ++ ++ C009 + ++ ++ C010 + + ++ C011 + + C012 + ++C013 + ++ C014 + + C015 + + C016 + +

TABLE 3 Biological activity of illustrative compounds against BTK, EGFRand EGFR L5858R/T790M, [ATP] = Km. EGFR BTK L858R/T790M EGFR (Compoundat (Compound at (Compound at Compound No. 100 nM) 100 nM) 100 nM) A001++ A002 ++ A003 + A004 ++ A005 ++ A006 ++ A007 ++ A008 + A009 ++ A010 ++A011 + + + A012 ++ + + A013 ++ + + A014 + + + A015 ++ + + A016 + + +A017 + + + A018 + + + A019 + + + A020 ++ ++ + A021 + + + A022 + + +A023 + + + A024 + + + C003 + + C004 ++ ++ ++ C005 ++ ++ ++ C006 ++ ++ ++C007 ++ + + C008 ++ + + C009 ++ + + C010 ++ + + C011 ++ + + C012 ++ + +C013 ++ + + C014 ++ + + C015 + + + C016 + + + C017 ++ ++ ++ C018 ++ ++++ C019 ++ ++ ++ C020 ++ ++ ++ C021 ++ ++ + C022 ++ ++ + C023 ++ C024 ++C025 ++

To determine IC₅₀ of a compound against EGFR or EGFR mutants, a seriesof concentrations of the compound were tested for the inhibition. IC₅₀was calculated by plotting the concentration of compound vs thepercentage of inhibition in treated wells using GraphPad Prism 5. Table4 shows IC₅₀ values of several compounds of the invention against BTK,EGFR and EGFR L858R/T790M. The scale utilized in Table 4 is as follows:++ less than 100 nM and + greater than 100 nM.

TABLE 4 IC₅₀ of several illustrative compounds against BTK, EGFR andEGFR mutant EGFR EGFR L858R/T790M BTK Compound No. (nM) (nM) (nM)C002 + + + C004 + ++ ++ C005 + ++ C006 ++ ++ A002 + + ++ A009 + + ++A010 + + ++

Example 51: Inhibition of Human Cancer Cell Growth by Compounds UsingMTT Assay

Inhibition of cell growth by compounds was measured using MTT assay(Mosmann, T., Journal of Immunological Methods, 1983, 65, 55-63). Tumorcell lines were purchased from ATCC (American Type Culture Collection,Manassas, Va.). All cell lines were maintained in RPMI 1640 (Hyclone)supplemented with 10% fetal bovine serum (FBS, Hyclone), glutamine (2mM, Hyclone), and antibiotics (penicillin 100 U/mL and streptomycin 50g/mL) at 37° C. in a humidified atmosphere of 5% CO₂ in air. Taxol (as apositive control, Sigma) and compounds were dissolved in DMSO (Sigma),and the final concentration of DMSO in the medium was 1%. Tumor cellswere plated in 96-well plates at densities of about 4000 cells/well of a96-well plate and allowed to adhere/grow for 24 h. They were thentreated with various concentrations of drug for 72 h.3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT,Sigma) was used to determine the number of viable cells at the time ofcompound addition and the number of cells remaining after 72 h compoundexposure. The number of cells remaining after 72 h was compared to thenumber of viable cells at the time of compound addition by measuring theabsorbance at 570 nm, allowing for the calculation of growth inhibition.

All concentrations of compounds were tested in triplicate and controlswere averaged over 4 wells. IC₅₀ was calculated by plotting theconcentration of compound vs the percentage of inhibition in treatedwells using GraphPad Prism 5. Data for representative compounds areshown below.

Tables 5 show IC₅₀ values of several compounds of the invention in A549,A431, H1299, and H1975 human cancer cells. A549 cells have a mutation onKRAS, H3255 cells have L858R mutation, and H1975 cells have double EGFRmutations (L858R/T790M). The scale utilized in Table 5 is as follows:+++ less than 100 nM; ++ between 100 nM and 500 nM; and + greater than500 nM.

TABLE 5 IC₅₀ of several illustrative compounds in A549, A431, H3255 andH1975 cells Compound No. A549 A431 H3255 H1975 C001 +++ C002 + ++ +++C003 + ++ +++ C004 +++ +++ +++ +++ C005 ++ +++ +++ +++ C006 +++ +++ ++++++ C007 +++ C008 ++ ++ C009 +++ C010 ++ C011 +++ C012 +++ C013 ++ C014+++ C015 + C016 +++ C017 ++ +++ C018 ++ +++ C019 ++ +++ C020 ++ +++ C021+++ C022 ++ +++ +++ C023 + +++ +++ C024 ++ +++ +++ C025 ++ +++ +++

While some embodiments have been shown and described, variousmodifications and substitutions may be made thereto without departingfrom the spirit and scope of the invention. For example, for claimconstruction purposes, it is not intended that the claims set forthhereinafter be construed in any way narrower than the literal languagethereof, and it is thus not intended that exemplary embodiments from thespecification be read into the claims. Accordingly, it is to beunderstood that the present invention has been described by way ofillustration and not limitations on the scope of the claims.

What is claimed is:
 1. A compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein

is aryl or heteroaryl;

 is selected from a group consisting of:

wherein;

a is point of attachment for L and

b is point of attachment for G; X₃ is C—R₃, or N; X₄ is C—R₄, or N; X₅is C—R₅, or N; X₆ is C—R₁₉, or N; X₇ is C—R₂₀, or N; X₈ is C—R₂₁, or N;Y is O, S, or N—R₂₂; L is —[(CR₃₀R₃₁)_(x)—O—(CR₃₂R₃₃)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)]_(z)—, —[(CR₃₀R₃₁)—S—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—NR₂₉—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CO—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—SO₂—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CO₂—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)—CONR₂₉—(CR₃₀R₃₁)_(y)]_(z)—, or—[(CR₃₀R₃₁)_(x)—SO₂NR₂₉—(CR₃₀R₃₁)_(y)]_(z)—; each of R₃, R₄, R₅, R₆,R₁₄, R₁₅, R₁₆, R₁₉, R₂₀, R₂₁, R₃₀, R₃₁, R₃₂, R₃₃, and G is independentlyhydrogen, cyano, halo, hydroxy, azido, nitro, carboxy, oxo, sulfinyl,sulfanyl, sulfonyl, optionally substituted alkoxy, optionallysubstituted cycloalkyloxy, optionally substituted aryloxy, optionallysubstituted heteroaryloxy, optionally substituted heterocycloalkyloxy,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted aryl, optionally substituted heteroaryl,optionally substituted heterocycloalkyl, optionally substituted amino,optionally substituted acyl, optionally substituted alkoxycarbonyl,optionally substituted aminocarbonyl, optionally substitutedaminosulfonyl, or optionally substituted carbamimidoyl; R₁₇, R₁₈, R₂₂,and R₂₉ are independently is independently hydrogen, sulfonyl,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted aryl, optionally substituted heteroaryl,optionally substituted heterocycloalkyl, optionally substituted acyl,optionally substituted alkoxycarbonyl, optionally substitutedaminocarbonyl, optionally substituted aminosulfonyl, or optionallysubstituted carbamimidoyl; or R₃ and R₄, R₄ and R₅, R₁₅ and R₁₆, R₁₅ andR₁₇, R₂₀ and R₂₁, R₂₀ and R₂₂, or R₂₁ and R₂₂ may optionally be joinedtogether with any intervening atoms to form an optionally substitutedaryl, heteroaryl, cycloalkyl, or heterocycloalkyl ring; each Z isindependently hydrogen, cyano, halo, hydroxy, azido, nitro, carboxy,oxo, sulfinyl, sulfanyl, sulfonyl, optionally substituted alkoxy,optionally substituted cycloalkyloxy, optionally substituted aryloxy,optionally substituted heteroaryloxy, optionally substitutedheterocycloalkyloxy, optionally substituted alkyl, optionallysubstituted cycloalkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted aryl, optionally substitutedheteroaryl, optionally substituted heterocycloalkyl, optionallysubstituted amino, optionally substituted acyl, optionally substitutedalkoxycarbonyl, optionally substituted aminocarbonyl, optionallysubstituted aminosulfonyl, optionally substituted carbamimidoyl, or E;wherein E is an electrophilic group capable of forming a covalent bondwith a nucleophile; n is 0, 1, 2, 3, 4 or 5; and x, y, or z isindependently 0, 1, 2, 3, or 4; provided that when

G is

 wherein

 is aryl, heteroaryl, or heterocycloalkyl; m is 0, 1, 2, 3, 4, or 5 andeach Q is independently hydrogen, cyano, halo, hydroxy, azido, nitro,carboxy, oxo, sulfinyl, sulfanyl, sulfonyl, optionally substitutedalkoxy, optionally substituted cycloalkyloxy, optionally substitutedaryloxy, optionally substituted heteroaryloxy, optionally substitutedheterocycloalkyloxy, optionally substituted alkyl, optionallysubstituted cycloalkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted aryl, optionally substitutedheteroaryl, optionally substituted heterocycloalkyl, optionallysubstituted amino, optionally substituted acyl, optionally substitutedalkoxycarbonyl, optionally substituted aminocarbonyl, optionallysubstituted aminosulfonyl, optionally substituted carbamimidoyl, or E;and L is —NH—; then n is 12, 3, 4, or 5, and at least one Z is E.
 2. Thecompound or pharmaceutically acceptable salt of any one of claim 1,wherein G iscyano, halo, optionally substituted alkoxy, optionallysubstituted cycloalkyloxy, optionally substituted aryloxy, optionallysubstituted heteroaryloxy, optionally substituted heterocycloalkyloxy,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted aryl, optionally substituted heteroaryl,optionally substituted heterocycloalkyl, optionally substituted amino,optionally substituted acyl, optionally substituted alkoxycarbonyl,optionally substituted aminocarbonyl, optionally substitutedaminosulfonyl.
 3. The compound or pharmaceutically acceptable salt ofclaim 2, wherein G is halo or optionally substituted alkoxy.
 4. Thecompound or pharmaceutically acceptable salt of claim 2, wherein G isoptionally substituted aryl, optionally substituted heteroaryl, oroptionally substituted heterocycloalkyl.
 5. The compound orpharmaceutically acceptable salt of any one of claims 1-4, wherein

is selected from the group consisting of: pyrrolyl, furanyl, thienyl,imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,1,2,3-triazolyl, 1,2,4-triazolyl, furazanyl, 1,2,3-oxadiazolyl,1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, thiadiazolyl,dithiazolyl, tetrazolyl, pyridinyl, pyranyl, thiopyranyl, diazinyl,pyrazinyl, pyrimidinyl, pyridazinyl, oxazinyl, thiazinyl, dioxinyl,dithiinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl,tetrazinyl, and phenyl.
 6. The compound or pharmaceutically acceptablesalt of claim 5, wherein

is selected from the group consisting of: phenyl, pyridinyl,pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl, pyrazolyl,isoxazolyl, and thienyl.
 7. The compound or pharmaceutically acceptablesalt of claim 6, wherein

is phenyl or pyridinyl.
 8. The compound or pharmaceutically acceptablesalt of claim 6, wherein

is phenyl.
 9. The compound or pharmaceutically acceptable salt of anyone of claims 1-8, wherein L is—[(CR₃₀R₃₁)_(x)—NR₂₉—(CR₃₀R₃₁)_(y)]_(z)—.
 10. The compound orpharmaceutically acceptable salt of claim 9, wherein L is —O—, —CH₂—,—NH—, —S—, —CO—, —CO₂—, —CONH—, SO₂—, or —SO₂NH—.
 11. The compound orpharmaceutically acceptable salt of claim 10, wherein L is —NH—.
 12. Thecompound or pharmaceutically acceptable salt of any one of claims 1-11,wherein each Z is independently hydrogen, cyano, halo, optionallysubstituted amino, optionally substituted alkoxy, optionally substitutedcycloalkyloxy, optionally substituted aryloxy, optionally substitutedheteroaryloxy, optionally substituted heterocycloalkyloxy, optionallysubstituted alkyl, optionally substituted cycloalkyl, optionallysubstituted aryloxy, optionally substituted heterocycloalkyl, optionallysubstituted aminocarbonyl, or E.
 13. The compound or pharmaceuticallyacceptable salt of claim 12, wherein each Z is independently hydrogen,cyano, halo, optionally substituted alkoxy, optionally substitutedheterocycloalkyloxy, optionally substituted heterocycloalkyl, oroptionally substituted amino, optionally substituted aminocarbonyl, orE.
 14. The compound or pharmaceutically acceptable salt of claim 13,wherein n is 1, 2, 3, 4, or 5; and at least one Z is cyano, fluoro,chloro, methoxy, —CONH₂, 2-methoxyethoxy, 2-(dimethylamino)ethoxy,(1-methylpyrrolidin-3-yl)oxy, (1-methylpiperidin-4-yl)oxy,(1-methylpiperidin-3-yl)oxy, (1-methylazetidin-3-yl)oxy(2-(dimethylamino)ethyl)(methyl)amino, dimethylamino,methyl(1-methylazetidin-3-yl)amino,methyl(1-methylpyrrolidin-3-yl)amino,methyl(1-methylpiperidin-4-yl)amino, optionally substituted morpholinyl,optionally substituted piperazinyl, optionally substituted pyrrolidinyl,optionally substituted piperidinyl, optionally substituted azetidinyl.15. The compound or pharmaceutically acceptable salt of claim 13,wherein n is 1, 2, 3, 4, or 5; and at least one Z is E.
 16. The compoundor pharmaceutically acceptable salt of claim 15, wherein each E isindependently an electrophilic group capable of forming a covalent bondwith a cysteine residue of a protein.
 17. The compound orpharmaceutically acceptable salt of claim 16, wherein each E isindependently selected from a group consisting of


18. The compound or pharmaceutically acceptable salt of claim 17,wherein at least one E is


19. The compound or pharmaceutically acceptable salt of claim 17,wherein at least one E is


20. The compound or pharmaceutically acceptable salt of claim 1, wherein

is

X₁₀ is C—R₃₅, or N; and R₃₄, R₃₅, R₃₆, R₃₇, and R₃₈ are independentlyhydrogen, cyano, halo, hydroxy, azido, nitro, carboxy, sulfinyl,sulfanyl, sulfonyl, optionally substituted alkoxy, optionallysubstituted cycloalkyloxy, optionally substituted aryloxy, optionallysubstituted heteroaryloxy, optionally substituted heterocycloalkyloxy,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted aryl, optionally substituted heteroaryl,optionally substituted heterocycloalkyl, optionally substituted amino,optionally substituted acyl, optionally substituted alkoxycarbonyl,optionally substituted aminocarbonyl, optionally substitutedaminosulfonyl, optionally substituted carbamimidoyl, or E.
 21. Thecompound or pharmaceutically acceptable salt of claim 20, wherein R₃₄,R₃₅, R₃₆, R₃₇, and R₃₈ are independently hydrogen, cyano, halo,optionally substituted alkoxy, optionally substitutedheterocycloalkyloxy, optionally substituted heterocycloalkyl, optionallysubstituted amino, optionally substituted aminocarbonyl, or E.
 22. Thecompound or pharmaceutically acceptable salt of claim 21, wherein R₃₅ orR₃₇ is E.
 23. The compound or pharmaceutically acceptable salt of claim20, wherein R₃₄, R₃₅, R₃₇, and R₃₈ are independently hydrogen, cyano,fluoro, chloro, methoxy, or —CONH₂, and R₃₆ is optionally substitutedmorpholinyl, optionally substituted piperazinyl, optionally substitutedpyrrolidinyl, optionally substituted piperidinyl, optionally substitutedazetidinyl, or substituted amino.
 24. The compound or pharmaceuticallyacceptable salt of claim 22, wherein R₃₆ is

wherein R₂₈ is hydrogen, sulfonyl, optionally substituted alkyl,optionally substituted cycloalkyl, optionally substituted alkenyl,optionally substituted alkynyl, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted heterocycloalkyl,optionally substituted amino, optionally substituted acyl, optionallysubstituted alkoxycarbonyl, optionally substituted aminocarbonyl,optionally substituted aminosulfonyl, or optionally substitutedcarbamimidoyl.
 25. The compound or pharmaceutically acceptable salt ofclaim 24, wherein R₂₈ is —C(O)C₁-C₄ alkyl or C₁-C₆ alkyl optionallysubstituted with —OH, halo, C₁-C₄ alkyl, or —OC₁-C₄ alkyl.
 26. Thecompound or pharmaceutically acceptable salt of claim 25, wherein R₂₈ is—CH₃, —COCH₃, —CH₂CH₂OH, —CH₂CH₂F, —CH₂CH₂OMe, —CH₂C(CH₃)₂OH, or—CH₂CH(CH₃)OH.
 27. The compound or pharmaceutically acceptable saltthereof of claim 1, having the Formula Ia:

wherein

is optionally substituted aryl, optionally substituted heteroaryl, oroptionally substituted heterocycloalkyl; each Q is independentlyhydrogen, cyano, halo, hydroxy, azido, nitro, carboxy, oxo, sulfinyl,sulfanyl, sulfonyl, optionally substituted alkoxy, optionallysubstituted cycloalkyloxy, optionally substituted aryloxy, optionallysubstituted heteroaryloxy, optionally substituted heterocycloalkyloxy,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted aryl, optionally substituted heteroaryl,optionally substituted heterocycloalkyl, optionally substituted amino,optionally substituted acyl, optionally substituted alkoxycarbonyl,optionally substituted aminocarbonyl, optionally substitutedaminosulfonyl, optionally substituted carbamimidoyl, or E; wherein eachE is independently an electrophilic group capable of forming a covalentbond with a nucleophile; and m is 0, 1, 2, 3, 4, or
 5. 28. The compoundor pharmaceutically acceptable salt of claim 27, wherein

is selected from the group consisting of: phenyl, pyridinyl,pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl, pyrazolyl,isoxazolyl, and thienyl.
 29. The compound or pharmaceutically acceptablesalt of claim 28, wherein

is phenyl or pyridinyl.
 30. The compound or pharmaceutically acceptablesalt of claim 27, wherein

is selected from the group consisting of: piperazinyl, morpholinyl,piperidinyl, thiomorpholinyl, pyrrolidinyl, tetrahydrofuranyl,diazepanyl, azetidinyl, oxetanyl, oxiranyl, and aziridinyl.
 31. Thecompound or pharmaceutically acceptable salt of claim 30, wherein

is selected from the group consisting of: piperazinyl, morpholinyl,piperidinyl, pyrrolidinyl, tetrahydrofuranyl, and diazepanyl.
 32. Thecompound or pharmaceutically acceptable salt of claim 31, wherein

is selected from the group consisting of: piperazinyl, morpholinyl,piperidinyl, and pyrrolidinyl.
 33. The compound or pharmaceuticallyacceptable salt of any one of claims 26 to 31, wherein m is 1, 2, or 3;and at least one Q is E.
 34. The compound or pharmaceutically acceptablesalt of claim 33, wherein each E is independently an electrophilic groupcapable of forming a covalent bond with a cysteine residue of a protein.35. The compound or pharmaceutically acceptable salt of claim 34,wherein each E is independently selected from a group consisting of


36. The compound or pharmaceutically acceptable salt of claim 35,wherein at least one E is


37. The compound or pharmaceutically acceptable salt of claim 35,wherein at least one E is


38. The compound or pharmaceutically acceptable salt of claim 27,wherein

is

X₁₁ is C—R₂₇, or N; and R₂₃, R₂₄, R₂₅, R₂₆, and R₂₇ are independently,hydrogen, cyano, halo, hydroxy, azido, nitro, carboxy, oxo, sulfinyl,sulfanyl, sulfonyl, optionally substituted alkoxy, optionallysubstituted cycloalkyloxy, optionally substituted aryloxy, optionallysubstituted heteroaryloxy, optionally substituted heterocycloalkyloxy,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted aryl, optionally substituted heteroaryl,optionally substituted heterocycloalkyl, optionally substituted amino,optionally substituted acyl, optionally substituted alkoxycarbonyl,optionally substituted aminocarbonyl, optionally substitutedaminosulfonyl, or optionally substituted carbamimidoyl or E;
 39. Thecompound or pharmaceutically acceptable salt of claim 38, wherein R₂₃,R₂₄, R₂₅, R₂₆, and R₂₇ are independently hydrogen, cyano, halo,optionally substituted alkoxy, optionally substituted amino, optionallysubstituted aminocarbonyl, or E.
 40. The compound or pharmaceuticallyacceptable salt of claim 39, wherein R₂₄, R₂₅, or R₂₆ is E.
 41. Thecompound or pharmaceutically acceptable salt of claim 1, having theFormula Ib:


42. The compound or pharmaceutically acceptable salt of claim 41,wherein X₃, X₄ and X₅ are respectively C—R₃, C—R₄, and C—R₅.
 43. Thecompound or pharmaceutically acceptable salt of claim 41, wherein X₅, X₄and X₃ are respectively N, C—R₄, and C—R₃.
 44. The compound orpharmaceutically acceptable salt of claim 41, wherein X₅, X₄ and X₃ arerespectively C—R₅, N, and C—R₃.
 45. The compound or pharmaceuticallyacceptable salt of claim 41, wherein X₅, X₄ and X₃ are respectivelyC—R₅, C—R₄, and N.
 46. The compound or pharmaceutically acceptable saltof claim 41, wherein X₅, X₄ and X₃ are respectively N, C—R₄, and N. 47.The compound or pharmaceutically acceptable salt of claim 41, wherein nis 1, 2, 3, 4, or 5; and at least one Z is E.
 48. The compound orpharmaceutically acceptable salt of claim 41, having the Formula Ic:


49. The compound or pharmaceutically acceptable salt of claim 48,wherein R₃, R₄, R₆ and R₅ are independently hydrogen, cyano, halo,optionally substituted alkoxy, optionally substitutedheterocycloalkyloxy, optionally substituted heterocycloalkyl, optionallysubstituted amino, or optionally substituted aminocarbonyl.
 50. Thecompound or pharmaceutically acceptable salt of claim 49, wherein R₃,R₄, R₆ and R₅ are independently hydrogen, cyano, fluoro, chloro, methyl,hydroxymethyl, —CH₂F, —CONH₂, or methoxy.
 51. The compound orpharmaceutically acceptable salt of claim 49, wherein R₃, R₄, R₆ and R₅are independently hydrogen, fluoro, or chloro.
 52. The compound orpharmaceutically acceptable salt of any one of claims 48 to 51, whereinG is halo or optionally substituted alkoxy, optionally substituted aryl,optionally substituted heteroaryl, or optionally substitutedheterocycloalkyl.
 53. The compound or pharmaceutically acceptable saltof claim 52, wherein G is optionally substituted aryl.
 54. The compoundor pharmaceutically acceptable salt of claim 53, wherein G is halosubstituted aryl.
 55. The compound or pharmaceutically acceptable saltof claim 53, wherein G is optionally substituted phenyl or pyridinyl.56. The compound or pharmaceutically acceptable salt of claim 55,wherein G is halo substituted phenyl or pyridinyl.
 57. The compound orpharmaceutically acceptable salt of claim 52, wherein G is halo oroptionally substituted alkoxy.
 58. The compound or pharmaceuticallyacceptable salt of any one of claims 48 to 57, wherein R₃₄, R₃₇, and R₃₈are independently hydrogen, cyano, halo, optionally substituted alkoxy,optionally substituted heterocycloalkyloxy, optionally substitutedheterocycloalkyl, optionally substituted amino, or optionallysubstituted aminocarbonyl.
 59. The compound or pharmaceuticallyacceptable salt of claim 58, wherein R₃₄, R₃₇, and R₃₈ are independentlyhydrogen, cyano, fluoro, chloro, methoxy, or —CONH₂.
 60. The compound orpharmaceutically acceptable salt of any one of claims 48 to 59, whereinR₃₆ is optionally substituted alkoxy, optionally substitutedheterocycloalkyloxy, optionally substituted heterocycloalkyl, oroptionally substituted amino.
 61. The compound or pharmaceuticallyacceptable salt of claim 60, wherein R₃₆ is methoxy, 2-methoxyethoxy,2-(dimethylamino)ethoxy, (1-methylpyrrolidin-3-yl)oxy,(1-methylpiperidin-4-yl)oxy, (1-methylpiperidin-3-yl)oxy,(1-methylazetidin-3-yl)oxy, (2-(dimethylamino)ethyl)(methyl)amino,dimethylamino, methyl(1-methylazetidin-3-yl)amino,methyl(1-methylpyrrolidin-3-yl)amino,methyl(1-methylpiperidin-4-yl)amino, optionally substituted morpholinyl,optionally substituted piperazinyl, optionally substituted pyrrolidinyl,optionally substituted piperidinyl, or optionally substitutedazetidinyl.
 62. The compound or pharmaceutically acceptable salt of anyone of claims 48 to 61, wherein E is


63. The compound or pharmaceutically acceptable salt of any one ofclaims 48 to 61, wherein E is


64. The compound or pharmaceutically acceptable salt of claim 1, havingthe Formula Id:


65. The compound or pharmaceutically acceptable salt of claim 64,wherein X₁₀ is C—R₂₅, or N.
 66. The compound or pharmaceuticallyacceptable salt of claim 64, wherein X₁₁ is C—R₂₇, or N.
 67. Thecompound or pharmaceutically acceptable salt of claim 64, wherein R₃₄,R₃₇, and R₃₈ are independently hydrogen, cyano, fluoro, chloro, methoxy,or —CONH₂, and R₃₆ is optionally substituted morpholinyl, optionallysubstituted piperazinyl, optionally substituted pyrrolidinyl, optionallysubstituted piperidinyl, optionally substituted azetidinyl, orsubstituted amino.
 68. The compound or pharmaceutically acceptable saltof claim 67, wherein R₃₆ is

wherein R₂₈ is hydrogen, sulfonyl, optionally substituted alkyl,optionally substituted cycloalkyl, optionally substituted alkenyl,optionally substituted alkynyl, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted heterocycloalkyl,optionally substituted amino, optionally substituted acyl, optionallysubstituted alkoxycarbonyl, optionally substituted aminocarbonyl,optionally substituted aminosulfonyl, or optionally substitutedcarbamimidoyl.
 69. The compound or pharmaceutically acceptable salt ofclaim 68, wherein R₂₈ is —C(O)C₁-C₄ alkyl or C₁-C₆ alkyl optionallysubstituted with —OH, halo, C₁-C₄ alkyl, or —OC₁-C₄ alkyl.
 70. Thecompound or pharmaceutically acceptable salt of claim 69, wherein R₂₈ is—CH₃, —COCH₃, —CH₂CH₂OH, —CH₂CH₂F, —CH₂CH₂OMe, —CH₂C(CH₃)₂OH, or—CH₂CH(CH₃)OH.
 71. The compound or pharmaceutically acceptable salt ofany one of claims 64-70, wherein E is selected from a group consistingof


72. The compound or pharmaceutically acceptable salt of claim 71,wherein E is


73. The compound or pharmaceutically acceptable salt of claim 71,wherein E is


74. A compound of Formula Ie:

or a pharmaceutically acceptable salt thereof, wherein:

is aryl or heteroaryl;

is selected from a group consisting of:

wherein

a is point of attachment for L and

b is point of attachment for

X₆ is C—R₁₉, or N; X₇ is C—R₂₀, or N; X₈ is C—R₂₁, or N; Y is O, S, orN—R₂₂; L is —[(CR₃₀R₃₁)_(x)—O—(CR₃₂R₃₃)_(y)]_(z)—, —[CR₃₀R₃₁)_(x)]_(z)—,—[CR₃₀R₃₁)_(x)—S—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—NR₂₉—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CO—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—SO₂—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CO₂—(CR₃₀R₃₁)_(y)]_(z)—,—[(CR₃₀R₃₁)_(x)—CONR₂₉—(CR₃₀R₃₁)_(y)]_(z)—, or—[(CR₃₀R₃₁)_(x)—SO₂NR₂₉—(CR₃₀R₃₁)_(y)]_(z)—; each of R₆, R₁₉, R₂₀, R₂₁,R₃₀, R₃₁, R₃₂, R₃₃ is independently hydrogen, cyano, halo, hydroxy,azido, nitro, carboxy, oxo, sulfinyl, sulfanyl, sulfonyl, optionallysubstituted alkoxy, optionally substituted cycloalkyloxy, optionallysubstituted aryloxy, optionally substituted heteroaryloxy, optionallysubstituted heterocycloalkyloxy, optionally substituted alkyl,optionally substituted cycloalkyl, optionally substituted alkenyl,optionally substituted alkynyl, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted heterocycloalkyl,optionally substituted amino, optionally substituted acyl, optionallysubstituted alkoxycarbonyl, optionally substituted aminocarbonyl,optionally substituted aminosulfonyl, or optionally substitutedcarbamimidoyl; R₂₂ and R₂₉ are independently hydrogen, sulfonyl,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted aryl, optionally substituted heteroaryl,optionally substituted heterocycloalkyl, optionally substituted acyl,optionally substituted alkoxycarbonyl, optionally substitutedaminocarbonyl, optionally substituted aminosulfonyl, or optionallysubstituted carbamimidoyl; or R₂₀ and R₂₁, R₂₀ and R₂₂, or R₂₁ and R₂₂may optionally be joined together with any intervening atoms to form anoptionally substituted aryl, heteroaryl, cycloalkyl, or heterocycloalkylring; each Z is independently hydrogen, cyano, halo, hydroxy, azido,nitro, carboxy, oxo, sulfinyl, sulfanyl, sulfonyl, optionallysubstituted alkoxy, optionally substituted cycloalkyloxy, optionallysubstituted aryloxy, optionally substituted heteroaryloxy, optionallysubstituted heterocycloalkyloxy, optionally substituted alkyl,optionally substituted cycloalkyl, optionally substituted alkenyl,optionally substituted alkynyl, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted heterocycloalkyl,optionally substituted amino, optionally substituted acyl, optionallysubstituted alkoxycarbonyl, optionally substituted aminocarbonyl,optionally substituted aminosulfonyl, optionally substitutedcarbamimidoyl, or E; wherein E is an electrophilic group capable offorming a covalent bond with a nucleophile;

is optionally substituted aryl, optionally substituted heteroaryl, oroptionally substituted heterocycloalkyl; each Q is independentlyhydrogen, cyano, halo, hydroxy, azido, nitro, carboxy, oxo, sulfinyl,sulfanyl, sulfonyl, optionally substituted alkoxy, optionallysubstituted cycloalkyloxy, optionally substituted aryloxy, optionallysubstituted heteroaryloxy, optionally substituted heterocycloalkyloxy,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted aryl, optionally substituted heteroaryl,optionally substituted heterocycloalkyl, optionally substituted amino,optionally substituted acyl, optionally substituted alkoxycarbonyl,optionally substituted aminocarbonyl, optionally substitutedaminosulfonyl, optionally substituted carbamimidoyl, or E; wherein Eeach is independently an electrophilic group capable of forming acovalent bond with a nucleophile; m is 0, 1, 2, 3, 4, or 5; n is 0, 1,2, 3, 4 or 5; and each of x, y, or z is independently 0, 1, 2, 3, or 4.75. The compound or pharmaceutically acceptable salt of claim 74,wherein

is:


76. The compound or pharmaceutically acceptable salt of claim 74 or 75,having a Formula If:


77. The compound or pharmaceutically acceptable salt of any one ofclaims 74-76, wherein L is NH.
 78. The compound or pharmaceuticallyacceptable salt of any one of claims 74-77, wherein

wherein X₁₀ is C—R₃₅, or N; and R₃₄, R₃₅, R₃₆, R₃₇, and R₃₈ areindependently hydrogen, cyano, halo, hydroxy, azido, nitro, carboxy,sulfinyl, sulfanyl, sulfonyl, optionally substituted alkoxy, optionallysubstituted cycloalkyloxy, optionally substituted aryloxy, optionallysubstituted heteroaryloxy, optionally substituted heterocycloalkyloxy,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted aryl, optionally substituted heteroaryl,optionally substituted heterocycloalkyl, optionally substituted amino,optionally substituted acyl, optionally substituted alkoxycarbonyl,optionally substituted aminocarbonyl, optionally substitutedaminosulfonyl, optionally substituted carbamimidoyl, or E.
 79. Thecompound or pharmaceutically acceptable salt of any one of claims 74-77,wherein


80. The compound or pharmaceutically acceptable salt of any one ofclaims 74-79, having a Formula Ig:


81. The compound or pharmaceutically acceptable salt of any one ofclaims 78-80, wherein R₃₄, R₃₅, R₃₆, R₃₇, and R₃₈ are independentlyhydrogen, cyano, halo, optionally substituted alkoxy, optionallysubstituted heterocycloalkyloxy, optionally substitutedheterocycloalkyl, optionally substituted amino, optionally substitutedaminocarbonyl, or E.
 82. The compound or pharmaceutically acceptablesalt of any one of claims 78-81, wherein R₃ or R₃₇ is E.
 83. Thecompound or pharmaceutically acceptable salt of any one of claims 78-81,wherein R₃ or R₃₇ is


84. The compound or pharmaceutically acceptable salt of any one ofclaims 78-81, wherein, R₃₅ or R₃₇ is


85. The compound or pharmaceutically acceptable salt of any one ofclaims 78-80, wherein R₃₄, R₃₅, R₃₇, and R₃₈ are independently hydrogen,cyano, fluoro, chloro, methoxy, or —CONH₂, and R₃₆ is optionallysubstituted morpholinyl, optionally substituted piperazinyl, optionallysubstituted pyrrolidinyl, optionally substituted piperidinyl, optionallysubstituted azetidinyl, or substituted amino.
 86. The compound orpharmaceutically acceptable salt of anyone of claims 78-80, wherein R₃₆is

wherein R₂₈ is hydrogen, sulfonyl, optionally substituted alkyl,optionally substituted cycloalkyl, optionally substituted alkenyl,optionally substituted alkynyl, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted heterocycloalkyl,optionally substituted amino, optionally substituted acyl, optionallysubstituted alkoxycarbonyl, optionally substituted aminocarbonyl,optionally substituted aminosulfonyl, or optionally substitutedcarbamimidoyl.
 87. The compound or pharmaceutically acceptable salt ofclaim 86, wherein R₂₈ is —C(O)C₁-C₄ alkyl or C₁-C₆ alkyl optionallysubstituted with —OH, halo, C₁-C₄ alkyl, or —OC₁-C₄ alkyl.
 88. Thecompound or pharmaceutically acceptable salt of claim 86, wherein R₂₈ is—CH₃, —COCH₃, —CH₂CH₂OH, —CH₂CH₂F, —CH₂CH₂OMe, —CH₂C(CH₃)₂OH, or—CH₂CH(CH₃)OH.
 89. The compound or pharmaceutically acceptable salt ofany one of claims 78-80, wherein X₁₀ is C—R₃₅.
 90. The compound orpharmaceutically acceptable salt of any one of claims 78-89, wherein R₃₅is hydrogen, cyano, halo, optionally substituted alkyl, optionallysubstituted cycloalkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted aryl, optionally substitutedheteroaryl, or optionally substituted heterocycloalkyl.
 91. The compoundor pharmaceutically acceptable salt of any one of claims 78-90, whereinR₃₅ is hydrogen or halo.
 92. The compound or pharmaceutically acceptablesalt of any one of claims 78-80, wherein X₁₀ is N
 93. The compound orpharmaceutically acceptable salt of any one of claims 74-92, wherein mis 1, 2, 3, 4 or 5 and at least one Q is E.
 94. The compound orpharmaceutically acceptable salt of any one of claims 74-93, whereineach E is independently selected from a group consisting of:


95. The compound or pharmaceutically acceptable salt of any one ofclaims 74-94, wherein

is selected from the group consisting of:

wherein each W is independently selected from the group consisting ofhydrogen, cyano, halo, hydroxy, azido, nitro, carboxy, oxo, sulfinyl,sulfanyl, sulfonyl, optionally substituted alkoxy, optionallysubstituted cycloalkyloxy, optionally substituted aryloxy, optionallysubstituted heteroaryloxy, optionally substituted heterocycloalkyloxy,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted aryloxy, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted heterocycloalkyl,optionally substituted amino, optionally substituted acyl, optionallysubstituted alkoxycarbonyl, optionally substituted aminocarbonyl,optionally substituted aminosulfonyl, optionally substitutedcarbamimidoyl, or E; wherein each E is independently an electrophilicgroup capable of forming a covalent bond with a nucleophile.
 96. Thecompound or pharmaceutically acceptable salt of claim 95, wherein W isselected from the group consisting of H, optionally substituted alkyl,and


97. The compound or pharmaceutically acceptable salt of claim 95 or 96,wherein W is selected from the group consisting of H, C₁-C₄ alkyl, and


98. The compound or pharmaceutically acceptable salt of any one ofclaims 74-92, wherein

X₁₁ is C—R₂₇, or N; and R₂₃, R₂₄, R₂₅, R₂₆, and R₂₇ are independently,hydrogen, cyano, halo, hydroxy, azido, nitro, carboxy, oxo, sulfinyl,sulfanyl, sulfonyl, optionally substituted alkoxy, optionallysubstituted cycloalkyloxy, optionally substituted aryloxy, optionallysubstituted heteroaryloxy, optionally substituted heterocycloalkyloxy,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted aryl, optionally substituted heteroaryl,optionally substituted heterocycloalkyl, optionally substituted amino,optionally substituted acyl, optionally substituted alkoxycarbonyl,optionally substituted aminocarbonyl, optionally substitutedaminosulfonyl, or optionally substituted carbamimidoyl, or E.
 99. Thecompound or pharmaceutically acceptable salt of claim 98, wherein R₂₃,R₂₄, R₂₅, R₂₆, and R₂₇ are independently hydrogen, cyano, halo,optionally substituted alkoxy, optionally substituted amino, optionallysubstituted aminocarbonyl, or E.
 100. The compound or pharmaceuticallyacceptable salt of claim 98 or 99, wherein, R₂₄, R₂₅, or R₂₆ is E. 101.The compound or pharmaceutically acceptable salt of any one of claims98-100, wherein R₂₄, R₂₅, or R₂₆ is


102. The compound or pharmaceutically acceptable salt of any one ofclaims 98-100, R₂₄, R₂₅, or R₂₆ is


103. The compound or pharmaceutically acceptable salt of claim 98,wherein R₂₃, R₂₅, R₂₆, and R₂₇ are independently hydrogen, cyano, halo,optionally substituted alkoxy, optionally substituted amino, optionallysubstituted aminocarbonyl, and R₂₄ is E.
 104. The compound orpharmaceutically acceptable salt of claim 98, wherein R₂₃, R₂₅, R₂₆, andR₂₇ are independently hydrogen, cyano, halo, methoxy, or —CONH₂, and R₂₄is E.
 105. The compound or pharmaceutically acceptable salt of claim 98,wherein R₂₃, R₂₄, R₂₆, and R₂₇ are independently hydrogen, cyano, halo,optionally substituted alkoxy, optionally substituted amino, optionallysubstituted aminocarbonyl, and R₂₅ is E.
 106. The compound orpharmaceutically acceptable salt of claim 98, R₂₃, R₂₄, R₂₆, and R₂₇ areindependently hydrogen, cyano, halo, methoxy, or —CONH₂, and R₂₅ is E.107. A compound or pharmaceutically acceptable salt thereof, wherein thecompound is chosen from the group consisting of:N-(3-(7-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2,3-difluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide(R)—N-(3-(7-((2,3-difluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide(S)—N-(3-(7-((2,3-difluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2,3-difluoro-4-(4-(2-fluoroethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((4-(4-ethylpiperazin-1-yl)-2,3-difluorophenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((4-(4-acetylpiperazin-1-yl)-2,3-difluorophenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2,3-difluoro-4-(piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2,3-difluoro-4-morpholinophenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((3,5-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2,5-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2,6-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((3,5-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2,5-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2,6-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((3,5-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2,5-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2,6-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((3,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2-fluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide(R)—N-(3-(7-((2-fluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide(S)—N-(3-(7-((2-fluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2-fluoro-4-(4-(2-fluoroethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((4-(4-ethylpiperazin-1-yl)-2-fluorophenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((4-(4-acetylpiperazin-1-yl)-2-fluorophenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2-fluoro-4-(piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2-fluoro-4-morpholinophenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((3-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((3-fluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide(R)—N-(3-(7-((3-fluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide(S)—N-(3-(7-((3-fluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((3-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((3-fluoro-4-(4-(2-fluoroethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((4-(4-ethylpiperazin-1-yl)-3-fluorophenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((4-(4-acetylpiperazin-1-yl)-3-fluorophenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((3-fluoro-4-(piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((3-fluoro-4-morpholinophenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2,3-difluoro-4-((1-methylpiperidin-4-yl)amino)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2-fluoro-4-((1-methylpiperidin-4-yl)amino)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((3-fluoro-4-((1-methylpiperidin-4-yl)amino)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((4-((1-methylpiperidin-4-yl)amino)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide(R)—N-(3-(7-((4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide(S)—N-(3-(7-((4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((4-(4-(2-fluoroethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((4-(4-ethylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((4-(4-acetylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(4-oxo-7-((4-(piperazin-1-yl)phenyl)amino)pyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((4-morpholinophenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2-chloro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2-cyano-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methoxyphenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)-2-(hydroxymethyl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide2-((8-(3-acrylamidophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-5-(4-(2-hydroxyethyl)piperazin-1-yl)benzamideN-(3-(7-((3-chloro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)-3-methoxyphenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)-3-(hydroxymethyl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide5-((8-(3-acrylamidophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-2-(4-(2-hydroxyethyl)piperazin-1-yl)benzamideN-(3-(7-((2-chloro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2-cyano-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2-(hydroxymethyl)-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide2-((8-(3-acrylamidophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-5-(4-methylpiperazin-1-yl)benzamideN-(3-(7-((3-chloro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((3-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((3-(hydroxymethyl)-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide5-((8-(3-acrylamidophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-2-(4-methylpiperazin-1-yl)benzamideN-(3-(7-((6-(4-(2-hydroxyethyl)piperazin-1-yl)pyridin-3-yl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((5-(4-(2-hydroxyethyl)piperazin-1-yl)pyridin-2-yl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((6-(4-methylpiperazin-1-yl)pyridin-3-yl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(6-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamideN-(4-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamideN-(5-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-3-yl)acrylamideN-(2-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-4-yl)acrylamideN-(3-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)-4-fluorophenyl)acrylamideN-(3-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)-2-fluorophenyl)acrylamideN-(5-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)-2-fluorophenyl)acrylamideN-(3-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)-5-fluorophenyl)acrylamideN-(6-(7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamideN-(4-(7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamideN-(5-(7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-3-yl)acrylamideN-(2-(7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-4-yl)acrylamideN-(4-fluoro-3-(7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(2-fluoro-3-(7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(2-fluoro-5-(7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-fluoro-5-(7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(6-(7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamideN-(4-(7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamideN-(5-(7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-3-yl)acrylamideN-(2-(7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-4-yl)acrylamideN-(4-fluoro-3-(7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(2-fluoro-3-(7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(2-fluoro-5-(7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-fluoro-5-(7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(6-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamideN-(4-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamideN-(5-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-3-yl)acrylamideN-(2-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-4-yl)acrylamideN-(4-fluoro-3-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(2-fluoro-3-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(2-fluoro-5-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-fluoro-5-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(6-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamideN-(4-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamideN-(5-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-3-yl)acrylamideN-(2-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-4-yl)acrylamideN-(3-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)-4-fluorophenyl)acrylamideN-(3-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)-2-fluorophenyl)acrylamideN-(5-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)-2-fluorophenyl)acrylamideN-(3-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)-5-fluorophenyl)acrylamideN-(6-(7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamideN-(4-(7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamideN-(5-(7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-3-yl)acrylamideN-(2-(7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-4-yl)acrylamideN-(4-fluoro-3-(7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(2-fluoro-3-(7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(2-fluoro-5-(7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-fluoro-5-(7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(6-(7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamideN-(4-(7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamideN-(5-(7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-3-yl)acrylamideN-(2-(7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-4-yl)acrylamideN-(4-fluoro-3-(7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(2-fluoro-3-(7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(2-fluoro-5-(7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-fluoro-5-(7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(6-(7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamideN-(4-(7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-2-yl)acrylamideN-(5-(7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-3-yl)acrylamideN-(2-(7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)pyridin-4-yl)acrylamideN-(4-fluoro-3-(7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(2-fluoro-3-(7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(2-fluoro-5-(7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-fluoro-5-(7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-2-methyl-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-2-(hydroxymethyl)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide1-(3-acrylamidophenyl)-7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxo-1,4-dihydropyrimido[4,5-d]pyrimidine-2-carboxamideN-(3-(2-cyano-7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-2-methyl-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-2-(hydroxymethyl)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide1-(3-acrylamidophenyl)-7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxo-1,4-dihydropyrimido[4,5-d]pyrimidine-2-carboxamideN-(3-(2-cyano-7-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-2-methyl-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-2-(hydroxymethyl)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide1-(3-acrylamidophenyl)-7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxo-1,4-dihydropyrimido[4,5-d]pyrimidine-2-carboxamideN-(3-(2-cyano-7-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-2-methyl-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-2-(hydroxymethyl)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide1-(3-acrylamidophenyl)-7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxo-1,4-dihydropyrimido[4,5-d]pyrimidine-2-carboxamideN-(3-(2-cyano-7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-2-methyl-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-2-(hydroxymethyl)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide1-(3-acrylamidophenyl)-7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxo-1,4-dihydropyrimido[4,5-d]pyrimidine-2-carboxamideN-(3-(2-cyano-7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-2-methyl-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-2-(hydroxymethyl)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide1-(3-acrylamidophenyl)-7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxo-1,4-dihydropyrimido[4,5-d]pyrimidine-2-carboxamideN-(3-(2-cyano-7-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-2-methyl-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-2-(hydroxymethyl)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide1-(3-acrylamidophenyl)-7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxo-1,4-dihydropyrimido[4,5-d]pyrimidine-2-carboxamideN-(3-(2-cyano-7-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(2-methyl-7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(2-(hydroxymethyl)-7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamide1-(3-acrylamidophenyl)-7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxo-1,4-dihydropyrimido[4,5-d]pyrimidine-2-carboxamideN-(3-(2-cyano-7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4-oxopyrimido[4,5-d]pyrimidin-1(4H)-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-fluoroethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((4-(4-ethylpiperazin-1-yl)-2,3-difluorophenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((4-(4-acetylpiperazin-1-yl)-2,3-difluorophenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-fluoroethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((4-(4-ethylpiperazin-1-yl)-2-fluorophenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((4-(4-acetylpiperazin-1-yl)-2-fluorophenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-morpholinophenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-fluoroethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((4-(4-ethylpiperazin-1-yl)-3-fluorophenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((4-(4-acetylpiperazin-1-yl)-3-fluorophenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-morpholinophenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-((1-methylpiperidin-4-yl)amino)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-((1-methylpiperidin-4-yl)amino)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-((1-methylpiperidin-4-yl)amino)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((4-((1-methylpiperidin-4-yl)amino)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide(R)—N-(3-(2-((4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide(S)—N-(3-(2-((4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-fluoroethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((4-(4-ethylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((4-(4-acetylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(5-oxo-2-((4-(piperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((4-morpholinophenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2-chloro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2-cyano-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methoxyphenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((3-chloro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)-3-methoxyphenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2-chloro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2-cyano-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((3-chloro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((3-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)pyridin-3-yl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((5-(4-(2-hydroxyethyl)piperazin-1-yl)pyridin-2-yl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((6-(4-methylpiperazin-1-yl)pyridin-3-yl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(6-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamideN-(4-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamideN-(5-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-3-yl)acrylamideN-(2-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-4-yl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)-4-fluorophenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)-2-fluorophenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)-5-fluorophenyl)acrylamideN-(6-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamideN-(4-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamideN-(5-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-3-yl)acrylamideN-(2-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-4-yl)acrylamideN-(4-fluoro-3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(2-fluoro-3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-fluoro-5-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(6-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamideN-(4-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamideN-(5-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-3-yl)acrylamideN-(2-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-4-yl)acrylamideN-(4-fluoro-3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(2-fluoro-3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-fluoro-5-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(6-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamideN-(4-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamideN-(5-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-3-yl)acrylamideN-(2-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-4-yl)acrylamideN-(4-fluoro-3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(2-fluoro-3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-fluoro-5-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(6-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamideN-(4-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamideN-(5-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-3-yl)acrylamideN-(2-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-4-yl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)-4-fluorophenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)-2-fluorophenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)-5-fluorophenyl)acrylamideN-(6-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamideN-(4-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamideN-(5-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-3-yl)acrylamideN-(2-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-4-yl)acrylamideN-(4-fluoro-3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(2-fluoro-3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-fluoro-5-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(6-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamideN-(4-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamideN-(5-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-3-yl)acrylamideN-(2-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-4-yl)acrylamideN-(4-fluoro-3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(2-fluoro-3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-fluoro-5-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(6-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamideN-(4-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-2-yl)acrylamideN-(5-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-3-yl)acrylamideN-(2-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)pyridin-4-yl)acrylamideN-(4-fluoro-3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(2-fluoro-3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-fluoro-5-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-(hydroxymethyl)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide8-(3-acrylamidophenyl)-2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-7-carboxamideN-(3-(7-cyano-2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-(hydroxymethyl)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide8-(3-acrylamidophenyl)-2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-7-carboxamideN-(3-(7-cyano-2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-(hydroxymethyl)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide8-(3-acrylamidophenyl)-2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-7-carboxamideN-(3-(7-cyano-2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-(hydroxymethyl)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide8-(3-acrylamidophenyl)-2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-7-carboxamideN-(3-(7-cyano-2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-(hydroxymethyl)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide8-(3-acrylamidophenyl)-2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-7-carboxamideN-(3-(7-cyano-2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-(hydroxymethyl)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide8-(3-acrylamidophenyl)-2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-7-carboxamideN-(3-(7-cyano-2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-(hydroxymethyl)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide8-(3-acrylamidophenyl)-2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-7-carboxamideN-(3-(7-cyano-2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(7-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(7-(hydroxymethyl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide8-(3-acrylamidophenyl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-7-carboxamideN-(3-(7-cyano-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-6-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-6-(hydroxymethyl)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-6,7-dimethyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamide8-(3-acrylamidophenyl)-2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamideN-(3-(6-cyano-2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(6-cyano-2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(7-cyano-2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-6-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-6-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-6-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-6-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-6-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-6-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-6-methyl-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(6-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((4-(4-acetylpiperazin-1-yl)-2,3-difluorophenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((4-(4-acetylpiperazin-1-yl)-2-fluorophenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-morpholinophenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-hydroxypropyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((4-(4-acetylpiperazin-1-yl)-3-fluorophenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-morpholinophenyl)amino)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-morpholinophenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-morpholinophenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(7-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((4-morpholinophenyl)amino)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-morpholinophenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-morpholinophenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)-9H-purin-9-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-morpholinophenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(5-((2-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2-fluoro-4-morpholinophenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2-fluoro-4-morpholinophenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-morpholinophenyl)amino)-9H-purin-9-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((2-fluoro-4-morpholinophenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-morpholinophenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(5-((3-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((3-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((3-fluoro-4-morpholinophenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((3-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((3-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((3-fluoro-4-morpholinophenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-morpholinophenyl)amino)-9H-purin-9-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((3-fluoro-4-morpholinophenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((4-morpholinophenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(5-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((4-morpholinophenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((4-(4-methylpiperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((4-morpholinophenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamideN-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)phenyl)acrylamideN-(3-(2-((4-morpholinophenyl)amino)-9H-purin-9-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(2-((4-morpholinophenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-morpholinophenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-morpholinophenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)acrylamideN-(3-(6-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamideN-(3-(6-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamideN-(3-(6-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamideN-(3-(6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamideN-(3-(6-((4-morpholinophenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamideN-(3-(6-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)acrylamideN-(3-(6-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)acrylamideN-(3-(6-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)acrylamideN-(3-(6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)acrylamideN-(3-(6-((4-morpholinophenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)acrylamideN-(3-(6-((3-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamideN-(3-(6-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamideN-(3-(6-((3-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamideN-(3-(6-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamideN-(3-(6-((3-fluoro-4-morpholinophenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamideN-(3-(6-((2-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamideN-(3-(6-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamideN-(3-(6-((2-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamideN-(3-(6-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamideN-(3-(6-((2-fluoro-4-morpholinophenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-morpholinophenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2-fluoro-4-morpholinophenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((3-fluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((3-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((3-fluoro-4-morpholinophenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((4-(4-methylpiperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((4-morpholinophenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(3-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)phenyl)acrylamideN-(3-(3-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)phenyl)acrylamideN-(3-(3-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)phenyl)acrylamideN-(3-(3-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)phenyl)acrylamideN-(3-(3-((2,3-difluoro-4-morpholinophenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[1,2-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,2-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,2-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,2-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-morpholinophenyl)amino)imidazo[1,2-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,5-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-morpholinophenyl)amino)imidazo[1,5-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((2,3-difluoro-4-morpholinophenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((2,3-difluoro-4-morpholinophenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(3-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)phenyl)acrylamideN-(3-(3-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)phenyl)acrylamideN-(3-(3-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)phenyl)acrylamideN-(3-(3-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)phenyl)acrylamideN-(3-(3-((2,3-difluoro-4-morpholinophenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)phenyl)acrylamideN-(3-(7-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)phenyl)acrylamideN-(3-(7-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)phenyl)acrylamideN-(3-(7-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)phenyl)acrylamideN-(3-(7-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)phenyl)acrylamideN-(3-(7-((2,3-difluoro-4-morpholinophenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-morpholinophenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((2,3-difluoro-4-morpholinophenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((4-morpholinophenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((4-morpholinophenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(2-((4-morpholinophenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)phenyl)acrylamideN-(3-(3-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)phenyl)acrylamideN-(3-(3-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)phenyl)acrylamideN-(3-(3-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)phenyl)acrylamideN-(3-(3-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)phenyl)acrylamideN-(3-(3-((4-morpholinophenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)phenyl)acrylamideN-(3-(6-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[1,2-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,2-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,2-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,2-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((4-morpholinophenyl)amino)imidazo[1,2-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,5-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((4-morpholinophenyl)amino)imidazo[1,5-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(6-((4-morpholinophenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((4-morpholinophenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((4-morpholinophenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(2-((4-morpholinophenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)phenyl)acrylamideN-(3-(3-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)phenyl)acrylamideN-(3-(3-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)phenyl)acrylamideN-(3-(3-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)phenyl)acrylamideN-(3-(3-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)phenyl)acrylamideN-(3-(3-((4-morpholinophenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)phenyl)acrylamideN-(3-(7-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)phenyl)acrylamideN-(3-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)phenyl)acrylamideN-(3-(7-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)phenyl)acrylamideN-(3-(7-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)phenyl)acrylamideN-(3-(7-((4-morpholinophenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)phenyl)acrylamideN-(3-(5-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((4-morpholinophenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((4-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)phenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((4-(4-methylpiperazin-1-yl)phenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamideN-(3-(5-((4-morpholinophenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpiperidin-4-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpiperidin-4-yl)amino)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpiperidin-4-yl)amino)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpiperidin-4-yl)amino)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamideN-(2-(3-(dimethylamino)pyrrolidin-1-yl)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(3-(dimethylamino)azetidin-1-yl)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(3-(dimethylamino)pyrrolidin-1-yl)-4-methoxyphenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(3-(dimethylamino)azetidin-1-yl)-4-methoxyphenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-(3-(dimethylamino)pyrrolidin-1-yl)-4-methoxyphenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-(3-(dimethylamino)azetidin-1-yl)-4-methoxyphenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamideN-(2-(3-(dimethylamino)pyrrolidin-1-yl)-5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(3-(dimethylamino)azetidin-1-yl)-5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)-4-methoxyphenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylpiperidin-4-yl)oxy)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylpiperidin-4-yl)oxy)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylpiperidin-4-yl)oxy)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylpiperidin-4-yl)oxy)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)-4-methoxyphenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)-4-methoxyphenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)-4-methoxyphenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-2-(methyl(1-methylpiperidin-4-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(methyl(1-methylpiperidin-4-yl)amino)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-(methyl(1-methylpiperidin-4-yl)amino)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-2-(methyl(1-methylpiperidin-4-yl)amino)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-2-(4-methylpiperazin-1-yl)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-2-morpholinophenyl)acrylamideN-(2-(3-(dimethylamino)pyrrolidin-1-yl)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)phenyl)acrylamideN-(2-(3-(dimethylamino)azetidin-1-yl)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(4-methylpiperazin-1-yl)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-morpholinophenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(3-(dimethylamino)pyrrolidin-1-yl)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(3-(dimethylamino)azetidin-1-yl)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-(4-methylpiperazin-1-yl)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-morpholinophenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-(3-(dimethylamino)pyrrolidin-1-yl)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-(3-(dimethylamino)azetidin-1-yl)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-2-(4-methylpiperazin-1-yl)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-2-morpholinophenyl)acrylamideN-(2-(3-(dimethylamino)pyrrolidin-1-yl)-5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)phenyl)acrylamideN-(2-(3-(dimethylamino)azetidin-1-yl)-5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylazetidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-2-((1-methylpiperidin-4-yl)oxy)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-((1-methylpiperidin-4-yl)oxy)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-((1-methylpiperidin-4-yl)oxy)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-2-((1-methylpiperidin-4-yl)oxy)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)quinazolin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)quinazolin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)quinazolin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(5-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(5-((8-(5-fluoropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(5-chloropyridin-3-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-2-((1-methylazetidin-3-yl)oxy)phenyl)acrylamideN-(5-((7-(3-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)isoxazolo[4,5-d]pyrimidin-5-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((9-(3-fluorophenyl)-9H-purin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((7-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((1-(3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)isoxazolo[4,3-d]pyrimidin-5-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrrolo[1,2-a][1,3,5]triazin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)imidazo[1,5-a][1,3,5]triazin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)-[1,2,3]triazolo[1,5-c]pyrimidin-5-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((7-(3-fluorophenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((7-(3-fluorophenyl)imidazo[2,1-f][1,2,4]triazin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((7-(3-fluorophenyl)imidazo[5,1-f][1,2,4]triazin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)-[1,2,4]triazolo[4,3-a]pyrazin-6-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-5-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)isoxazolo[5,4-c]pyridin-5-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((1-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((1-(3-fluorophenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((1-(3-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)isoxazolo[3,4-c]pyridin-5-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((5-(3-fluorophenyl)pyrrolo[1,2-c]pyrimidin-3-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((1-(3-fluorophenyl)imidazo[1,5-c]pyrimidin-7-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)pyrazolo[1,5-c]pyrimidin-5-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((6-(3-fluorophenyl)pyrrolo[1,2-a]pyrazin-3-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)imidazo[1,2-a]pyrazin-6-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)imidazo[1,5-a]pyrazin-6-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((7-(3-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)isoxazolo[4,5-d]pyrimidin-5-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((9-(3-fluorophenyl)-9H-purin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((7-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((1-(3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)isoxazolo[4,3-d]pyrimidin-5-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)pyrrolo[1,2-a][1,3,5]triazin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)imidazo[1,5-a][1,3,5]triazin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)-[1,2,3]triazolo[1,5-c]pyrimidin-5-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((7-(3-fluorophenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((7-(3-fluorophenyl)imidazo[2,1-f][1,2,4]triazin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((7-(3-fluorophenyl)imidazo[5,1-f][1,2,4]triazin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)-[1,2,4]triazolo[4,3-a]pyrazin-6-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-5-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)isoxazolo[5,4-c]pyridin-5-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((1-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((1-(3-fluorophenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((1-(3-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)isoxazolo[3,4-c]pyridin-5-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((5-(3-fluorophenyl)pyrrolo[1,2-c]pyrimidin-3-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((1-(3-fluorophenyl)imidazo[1,5-c]pyrimidin-7-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)pyrazolo[1,5-c]pyrimidin-5-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((6-(3-fluorophenyl)pyrrolo[1,2-a]pyrazin-3-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)imidazo[1,2-a]pyrazin-6-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)imidazo[1,5-a]pyrazin-6-yl)amino)-4-methoxyphenyl)acrylamideN-(5-((7-(3-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)isoxazolo[4,5-d]pyrimidin-5-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((9-(3-fluorophenyl)-9H-purin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((7-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((1-(3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)isoxazolo[4,3-d]pyrimidin-5-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrrolo[1,2-a][1,3,5]triazin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)imidazo[1,5-a][1,3,5]triazin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)-[1,2,3]triazolo[1,5-c]pyrimidin-5-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((7-(3-fluorophenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((7-(3-fluorophenyl)imidazo[2,1-f][1,2,4]triazin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((7-(3-fluorophenyl)imidazo[5,1-f][1,2,4]triazin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)-[1,2,4]triazolo[4,3-a]pyrazin-6-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-5-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)isoxazolo[5,4-c]pyridin-5-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((1-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((1-(3-fluorophenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((1-(3-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)isoxazolo[3,4-c]pyridin-5-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((5-(3-fluorophenyl)pyrrolo[1,2-c]pyrimidin-3-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((1-(3-fluorophenyl)imidazo[1,5-c]pyrimidin-7-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)pyrazolo[1,5-c]pyrimidin-5-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((6-(3-fluorophenyl)pyrrolo[1,2-a]pyrazin-3-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)imidazo[1,2-a]pyrazin-6-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)imidazo[1,5-a]pyrazin-6-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((7-(3-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)isoxazolo[4,5-d]pyrimidin-5-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((9-(3-fluorophenyl)-9H-purin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((7-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((1-(3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)isoxazolo[4,3-d]pyrimidin-5-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)pyrrolo[1,2-a][1,3,5]triazin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)imidazo[1,5-a][1,3,5]triazin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)-[1,2,3]triazolo[1,5-c]pyrimidin-5-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((7-(3-fluorophenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((7-(3-fluorophenyl)imidazo[2,1-f][1,2,4]triazin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((7-(3-fluorophenyl)imidazo[5,1-f][1,2,4]triazin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)-[1,2,4]triazolo[4,3-a]pyrazin-6-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-5-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)isoxazolo[5,4-c]pyridin-5-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((1-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((1-(3-fluorophenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((1-(3-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)isoxazolo[3,4-c]pyridin-5-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((5-(3-fluorophenyl)pyrrolo[1,2-c]pyrimidin-3-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((1-(3-fluorophenyl)imidazo[1,5-c]pyrimidin-7-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)pyrazolo[1,5-c]pyrimidin-5-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((6-(3-fluorophenyl)pyrrolo[1,2-a]pyrazin-3-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)imidazo[1,2-a]pyrazin-6-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)imidazo[1,5-a]pyrazin-6-yl)amino)-4-methoxyphenyl)acrylamideN-(5-((7-(3-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)isoxazolo[4,5-d]pyrimidin-5-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((9-(3-fluorophenyl)-9H-purin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((7-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((1-(3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)isoxazolo[4,3-d]pyrimidin-5-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrrolo[1,2-a][1,3,5]triazin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)imidazo[1,5-a][1,3,5]triazin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)-[1,2,3]triazolo[1,5-c]pyrimidin-5-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((7-(3-fluorophenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((7-(3-fluorophenyl)imidazo[2,1-f][1,2,4]triazin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((7-(3-fluorophenyl)imidazo[5,1-f][1,2,4]triazin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)-[1,2,4]triazolo[4,3-a]pyrazin-6-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-5-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)isoxazolo[5,4-c]pyridin-5-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((1-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((1-(3-fluorophenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((1-(3-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)isoxazolo[3,4-c]pyridin-5-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((5-(3-fluorophenyl)pyrrolo[1,2-c]pyrimidin-3-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((1-(3-fluorophenyl)imidazo[1,5-c]pyrimidin-7-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)pyrazolo[1,5-c]pyrimidin-5-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((6-(3-fluorophenyl)pyrrolo[1,2-a]pyrazin-3-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)imidazo[1,2-a]pyrazin-6-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)imidazo[1,5-a]pyrazin-6-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((7-(3-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)isoxazolo[4,5-d]pyrimidin-5-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((9-(3-fluorophenyl)-9H-purin-2-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((7-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((1-(3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)isoxazolo[4,3-d]pyrimidin-5-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)pyrrolo[1,2-a][1,3,5]triazin-2-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)imidazo[1,5-a][1,3,5]triazin-2-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)-[1,2,3]triazolo[1,5-c]pyrimidin-5-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((7-(3-fluorophenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((7-(3-fluorophenyl)imidazo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((7-(3-fluorophenyl)imidazo[5,1-f][1,2,4]triazin-2-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)-[1,2,4]triazolo[4,3-a]pyrazin-6-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-5-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)isoxazolo[5,4-c]pyridin-5-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((1-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((1-(3-fluorophenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((1-(3-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)isoxazolo[3,4-c]pyridin-5-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((5-(3-fluorophenyl)pyrrolo[1,2-c]pyrimidin-3-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((1-(3-fluorophenyl)imidazo[1,5-c]pyrimidin-7-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)pyrazolo[1,5-c]pyrimidin-5-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((6-(3-fluorophenyl)pyrrolo[1,2-a]pyrazin-3-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)imidazo[1,2-a]pyrazin-6-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((3-(3-fluorophenyl)imidazo[1,5-a]pyrazin-6-yl)amino)phenyl)acrylamideN-(5-((7-(3-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)isoxazolo[4,5-d]pyrimidin-5-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((9-(3-fluorophenyl)-9H-purin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((7-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((1-(3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)isoxazolo[4,3-d]pyrimidin-5-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrrolo[1,2-a][1,3,5]triazin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)imidazo[1,5-a][1,3,5]triazin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)-[1,2,3]triazolo[1,5-c]pyrimidin-5-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((7-(3-fluorophenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((7-(3-fluorophenyl)imidazo[2,1-f][1,2,4]triazin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((7-(3-fluorophenyl)imidazo[5,1-f][1,2,4]triazin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)-[1,2,4]triazolo[4,3-a]pyrazin-6-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-5-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)isoxazolo[5,4-c]pyridin-5-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((1-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((1-(3-fluorophenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((1-(3-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)isoxazolo[3,4-c]pyridin-5-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((5-(3-fluorophenyl)pyrrolo[1,2-c]pyrimidin-3-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((1-(3-fluorophenyl)imidazo[1,5-c]pyrimidin-7-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)pyrazolo[1,5-c]pyrimidin-5-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((6-(3-fluorophenyl)pyrrolo[1,2-a]pyrazin-3-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)imidazo[1,2-a]pyrazin-6-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((3-(3-fluorophenyl)imidazo[1,5-a]pyrazin-6-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((7-(3-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)isoxazolo[4,5-d]pyrimidin-5-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((9-(3-fluorophenyl)-9H-purin-2-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((7-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((1-(3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)isoxazolo[4,3-d]pyrimidin-5-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)pyrrolo[1,2-a][1,3,5]triazin-2-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)imidazo[1,5-a][1,3,5]triazin-2-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)-[1,2,3]triazolo[1,5-c]pyrimidin-5-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((7-(3-fluorophenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((7-(3-fluorophenyl)imidazo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((7-(3-fluorophenyl)imidazo[5,1-f][1,2,4]triazin-2-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)-[1,2,4]triazolo[4,3-a]pyrazin-6-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-5-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)isoxazolo[5,4-c]pyridin-5-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((1-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((1-(3-fluorophenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((1-(3-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)isoxazolo[3,4-c]pyridin-5-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((5-(3-fluorophenyl)pyrrolo[1,2-c]pyrimidin-3-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((1-(3-fluorophenyl)imidazo[1,5-c]pyrimidin-7-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)pyrazolo[1,5-c]pyrimidin-5-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((6-(3-fluorophenyl)pyrrolo[1,2-a]pyrazin-3-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)imidazo[1,2-a]pyrazin-6-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((3-(3-fluorophenyl)imidazo[1,5-a]pyrazin-6-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-6-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-6-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(3-fluorophenyl)-6-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxy-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-6-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamideN-(5-((8-(3-fluorophenyl)-6-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-6-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(3-fluorophenyl)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-6-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(5-((8-(3-fluorophenyl)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-6-methyl-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrimido[4,5-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-7-methyl-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-5-methyl-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(2-(2-(dimethylamino)ethoxy)-5-((8-(3-fluorophenyl)-6-oxo-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl)amino)phenyl)acrylamideN-(5-((8-bromoquinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamideN-(5-((8-chloroquinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-methoxyquinazolin-2-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-phenylquinazolin-2-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(pyridin-4-yl)quinazolin-2-yl)amino)phenyl)acrylamideN-(5-((8-(2-chlorophenyl)quinazolin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(2-fluorophenyl)quinazolin-2-yl)amino)phenyl)acrylamideN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((8-(pyridin-3-yl)quinazolin-2-yl)amino)phenyl)acrylamideN-(5-((8-(2-chlorophenyl)quinazolin-2-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamideN-(5-((8-(3-chlorophenyl)quinazolin-2-yl)amino)-2-(2-methoxyethoxy)phenyl)acrylamideN-(5-((3-(3-chlorophenyl)imidazo[1,5-a]pyrazin-6-yl)amino)-2-(2-(dimethylamino)ethoxy)phenyl)acrylamide1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(6-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(5-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(5-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(5-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(6-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(6-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a]pyrazin-3-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(6-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,2-a]pyrazin-3-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(3-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(5-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(3-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(5-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)piperidin-1-yl)prop-2-en-1-one1-(1-acryloylpiperidin-3-yl)-7-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrimido[4,5-d]pyrimidin-4(1H)-one8-(1-acryloylpiperidin-3-yl)-2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-5(8H)-one8-(1-acryloylpiperidin-3-yl)-2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrido[3,2-d]pyrimidin-6(5H)-one8-(1-acryloylpiperidin-3-yl)-2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-methylpyrido[3,2-d]pyrimidin-6(5H)-one1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(5-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(5-((4-(4-methylpiperazin-1-yl)phenyl)amino)isoxazolo[4,5-d]pyrimidin-3-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(5-((4-(4-methylpiperazin-1-yl)phenyl)amino)isoxazolo[4,3-d]pyrimidin-3-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(6-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,5-a]pyrazin-3-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(6-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,2-a]pyrazin-3-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(3-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[1,2-a]pyrazin-6-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[5,1-f][1,2,4]triazin-7-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[2,1-f][1,2,4]triazin-7-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(5-((4-(4-methylpiperazin-1-yl)phenyl)amino)-[1,2,3]triazolo[1,5-c]pyrimidin-3-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(7-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,5-c]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(3-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[1,2-c]pyrimidin-5-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(5-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrazolo[1,5-c]pyrimidin-3-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)imidazo[1,5-a][1,3,5]triazin-8-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrrolo[1,2-a][1,3,5]triazin-8-yl)piperidin-1-yl)prop-2-en-1-one1-(1-acryloylpiperidin-3-yl)-7-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimido[4,5-d]pyrimidin-4(1H)-one8-(1-acryloylpiperidin-3-yl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-5(8H)-one8-(1-acryloylpiperidin-3-yl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[3,2-d]pyrimidin-6(5H)-one8-(1-acryloylpiperidin-3-yl)-5-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[3,2-d]pyrimidin-6(5H)-one1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one1-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one1-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one1-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one1-(3-(2-((3-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(2-((2-fluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one1-(3-(2-((2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one1-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)pyrrolidin-1-yl)prop-2-en-1-one1-(3-(2-((2,3-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-oneand1-(3-(2-((2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-9H-purin-9-yl)piperidin-1-yl)prop-2-en-1-one.108. A pharmaceutically acceptable salt of the compound according to anyone of claims 1-107.
 109. The pharmaceutically acceptable salt of claim108, wherein the salt is a chloride, carbonate, gluconate, benzoate,acetate, lactate, citrate, propionate, hydrogenphosphate, fumarate,succinate, or TRIS (hydroxymethyl-aminomethane), maleate, malonate,tartrate, oxalate, pamoate, or stearate salt.
 110. The pharmaceuticallyacceptable salt of claim 109, wherein the salt is a chloride, fumarate,malonate, maleate, acetate, lactate, citrate, succinate, or tartratesalt.
 111. The pharmaceutically acceptable salt of claim 110, whereinthe salt is a chloride, fumarate, malonate, maleate, or tartrate salt.112. A pharmaceutical composition comprising a pharmaceuticallyacceptable carrier and a compound or pharmaceutically acceptable salt ofany one of claims 1 to
 111. 113. A pharmaceutical composition of claim112, wherein the composition is formulated in a form chosen from thegroup consisting of tablets, capsules, powders, liquids, suspensions,suppositories, and aerosols.
 114. The packaged pharmaceuticalcomposition comprising a pharmaceutical composition of claim 112 or 113and instructions for using the composition to treat a subject sufferingfrom cancer.
 115. A method of treating cancer in a subject whichcomprises administering to a subject in need thereof a therapeuticallyeffective amount of the compound or pharmaceutically acceptable salt ofany one of claims 1 to
 111. 116. The method of claim 115, wherein thecancer is colon carcinoma, pancreatic cancer, breast cancer, ovariancancer, prostate cancer, thyroid cancer, fibrosarcoma, myxosarcoma,liposarcoma, chondrosarcoma, osteogenic sarcoma, chondroma,angiosarcoma, endotheliosarcoma, lymphangiosarcoma,lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor,leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cellcarcinoma, adenocarcinoma, sweat gland carcinoma, thyroid cancer,sebaceous gland carcinoma, papillary carcinoma, papillaryadenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogeniccarcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma,choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervicalcancer, testicular tumor, lung carcinoma, small cell lung carcinoma,non-small cell lung cancer, bladder carcinoma, epithelial carcinoma,glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma,pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma,meningioma, melanoma, neuroblastoma, retinoblastoma, leukemia, acutelymphocytic leukemia and acute myelocytic leukemia (myeloblastic,promyelocytic, myelomonocytic, monocytic and erythroleukemia); chronicleukemia (chronic myelocytic (granulocytic) leukemia and chroniclymphocytic leukemia); and polycythemia vera, lymphoma (Hodgkin'sdisease and non-Hodgkin's disease), multiple myeloma, Waldenstrom'smacroglobulinemia, or heavy chain disease.
 117. The method of claim 116,wherein the cancer is non-small cell lung cancer, breast cancer, coloncancer, thyroid cancer, or ovarian cancer.
 118. A method of treating adisorder mediated by EGFR in a subject in need thereof, comprisingadministering to the subject a therapeutically effective amount of thecompound or pharmaceutically acceptable salt of any one of claims 1 to111.
 119. A method of treating a disorder in a subject in need thereof,comprising: a) determining the presence or absence of a EGFR mutation ina biological sample isolated from the subject; and b) if a EGFR mutationor double mutations are determined to be present in the subject,administering to the subject a therapeutically effective amount of thecompound or pharmaceutically acceptable salt of any one of claims 1 to111.
 120. The method of claim 119, wherein the EGFR mutation is in codon790.
 121. The method of claim 119, wherein the EGFR mutation is delE746-A750, del E747-E749/A750P, del E747-S752/P753S, delE747-T751/Sins/A750P, del S752-I759, G719S, G719C, L861Q, L858R, T790M,or L858R/T790M.
 122. The method of claim 119, wherein determining thepresence or absence of the EGFR mutation comprises amplifying EGFRnucleic acid from the biological sample and sequencing the amplifiednucleic acid.
 123. The method of claim 119, wherein determining thepresence or absence of the EGFR mutation comprises detecting a mutantEGFR polypeptide in the biological sample using a binding agent to amutant EGFR polypeptide.
 124. The method of claim 123, wherein thebinding agent is an antibody.
 125. The method of claim 119, wherein thebiological sample is isolated from a tumor of the subject.
 126. A methodof treating a disorder mediated by BTK in a subject in need thereof,comprising administering to the subject a therapeutically effectiveamount of the compound or pharmaceutically acceptable salt of any one ofclaims 1 to
 111. 127. The method of any one of claims 118-126, whereinthe disorder is cancer.
 128. The method of claim 127, wherein the canceris colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer,prostate cancer, thyroid cancer, fibrosarcoma, myxosarcoma, liposarcoma,chondrosarcoma, osteogenic sarcoma, chondroma, angiosarcoma,endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma,synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma,rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma,adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma,papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma,medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma,hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonalcarcinoma, Wilms' tumor, cervical cancer, testicular tumor, lungcarcinoma, small cell lung carcinoma, non-small cell lung cancer,bladder carcinoma, epithelial carcinoma, glioma, astrocytoma,medulloblastoma, craniopharyngioma, ependymoma, pinealoma,hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma,melanoma, neuroblastoma, retinoblastoma, leukemia, acute lymphocyticleukemia and acute myelocytic leukemia (myeloblastic, promyelocytic,myelomonocytic, monocytic and erythroleukemia); chronic leukemia(chronic myelocytic (granulocytic) leukemia and chronic lymphocyticleukemia); and polycythemia vera, lymphoma (Hodgkin's disease andnon-Hodgkin's disease), multiple myeloma, Waldenstrom'smacroglobulinemia, or heavy chain disease.
 129. The method of claim 127,wherein the cancer is non-small cell lung cancer, colon cancer, thyroidcancer, or ovarian cancer.
 130. The method of any one of claims 115-129,further comprising administering an additional anti-cancer and/orcytotoxic agent.
 131. The compound or pharmaceutically acceptable saltof anyone of claims 48 to 57, wherein E is selected from a groupconsisting of: